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ABSTRACT

Diabetes mellitus is a highly prevalent condition, afflicting an estimated 6% of
the United States adult population . It is also a complex condition to manage.
Dietary, exercise, and drug therapies are essential for reducing the risk of
various neurologic and vascular diseases related to disease progression.
Tight control of blood glucose as achieved through intensive pharmacologic
therapy has been shown to decrease the risk of developing several types of
diabetic complications. Success in achieving tight blood glucose control is
contingent upon adherence to the prescribed hypoglycemic drug regimen , a
behavior known to often be sub-optimal.

The objectives of this study were a) to describe hypoglycemic drug utilization,
and compare drug regimens prescribed and costs among age groups,
insurance plans, and by gender; b) to assess adherence to prescribed
hypoglycemic therapies, and to explore the association between
nonadherence and change in the strength or type of hypoglycemic medication
prescribed; and c) to identify the frequency of nonadherence among patients
who are prescribed monotherapy with a sulfonylurea or metformin, as
compared to the frequency of nonadherence in patients who are prescribed
dual therapy with both medications.

Analyses were performed using retail pharmacy data . The data provided
included over one-quarter-million dispensings to 5056 diabetic patients. From
this population , 2901 patients that received at least 2 dispensings for a
hypoglycemic medication during a 12-month period were selected for study.

Sulfonylureas were the mainstay of treatment for those receiving oral therapy:
82% of patients received a sulfonylurea as monotherapy or in combination
with another hypoglycemic medication . The most frequently observed drug
regimen was sulfonylurea monotherapy (40.3%); followed by insulin use only
(24.9%); dual therapy with sulfonylurea plus metformin (13.9%); and
metformin monotherapy (6.96%). Differences in the drug regimen utilized
were found among age groups and between genders. Most notably,
sulfonylurea monotherapy was prescribed most frequently for patients 65
years of age and older (age 65 years or older: 48.4%; age 50-64: 43.6%; age
under 50: 30.8% , p < 0.0001 ). The 12-month cost of hypoglycemic medication
dispensed was lowest among patients 65 years of age or older.

The medication possession ratio (MPR) was used as an estimate of
adherence. Possession of medication was found to be associated with a
change in the strength or type of hypoglycemic medication dispensed.
Sulfonylurea users who failed to possess medication for at least 80% of days
during a four-month period were 41.7% more likely to receive a dispensing for
a different strength of medication in subsequent months, as compared with

those possessing medication for at least 80% of days (OR 1.42, 95% Cl 1.02 1.96). Additionally, among patients receiving either monotherapy with a
sulfonylurea or metformin, those possessing medication for at least 80% of
days were 36.4% more likely than those possessing at least enough
medication for 80% of days to receive a dispensing for a different strength of
medication (OR 1.36, 95% Cl 1.019 - 1.83), or for a different strength or type
of hypoglycemic medication (OR 1.39, 95% Cl 1.03 - 1.87). This finding was
not statistically significant in the smaller sample of patients receiving
monotherapy with metformin.

Medication possession was also found to be associated with the number of
hypoglycemic drugs prescribed . Patients who were prescribed a regimen of
dual therapy with a sulfonylurea plus metformin were found to be less likely to
possess medication for 80% or 90% of days, as compared with those
prescribed monotherapy with either a sulfonylurea or metformin . In
multivariate analyses controlling for age and the total number of dispensings,
patients receiving dual therapy were more than 3 times more likely to fail to
possess medication for at least eighty percent of days (OR 3.14, 95% Cl 2.42
- 4.08), or 90% of days (OR 3.20, 95% Cl 2.49 - 4.11 ).

The findings of this pharmacoepidemiologic research provide insight into the
drug utilization patterns of diabetic patients. Among patients in this study, the
type of drug regimen prescribed differed in frequency among age groups and

between genders. The strength and type of hypoglycemic medication utilized
was found to change frequently, particularly among patients that were
classified as nonadherent. Overall, a substantial percentage of patients were
found to be nonadherent with hypoglycemic drug therapy. Patients least
frequently adherent to drug therapy included those under 65 years of age and
those prescribed dual therapy with a sulfonylurea plus metformin. Presuming
that lack of medication possession results in poor glucose control, patients
who do not possess medication are at increased risk for diabetic
complications.
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PREFACE

This dissertation is organized using the manuscript format. Part 1 consists of
three studies that form the main body of the dissertation. Part 2 contains the
appendices which provide details required by the University but are not usually
presented in a published paper.
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Study 2: Changes in Oral Hypoglycemic Therapy: Influence of
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Study 3: Adherence to Hypoglycemic Therapy among Patients
Prescribed Monotherapy with a Sulfonylurea or Metformin , and Dual
Therapy with Both Agents
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Part 1 includes the following manuscripts:

Study 1: Hypoglycemic Drug Utilization in a Diabetic Population : A
Pharmacoepidemiologic Study Using Retail Pharmacy Data

Study 2: Changes in Oral Hypoglycemic Therapy: Influence of
Nonadherence as Determined by Medication Possession
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Prescribed Monotherapy with a Sulfonylurea or Metformin , and Dual
Therapy with Both Agents

Hypoglycemic Drug Utilization in a Diabetic Population: A
Pharmacoepidemiologic Study Using Retail Pharmacy Data

ABSTRACT

Background

For most diabetic patients, pharmacologic therapy is an

essential component of disease management. Several classes of
hypoglycemic medications are available for prescribing , with no single class of
hypoglycemic drugs has been proven superior in reducing diabetic
complications.

Objective

To describe hypoglycemic drug utilization patterns among

diabetic patients ; and to determine if such patterns differ by patient
characteristics.

Methods

Cross-sectional descriptive study of hypoglycemic medication

dispensings to 2901 diabetic patients. Drug utilization was classified into
categories representing 10 various hypoglycemic drug regimens. The
frequency of drug regimen utilization was compared by age group, insurance
plan , and between genders. The total cost of hypoglycemic dispensings
during a 12-month period was also determined , and compared within each age
group and insurance plan , and between genders.
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Results

The most frequent hypoglycemic drug regimen utilized was

monotherapy with a sulfonylurea (n

= 1168; 40 .26%).

Use of insulin and no

oral hypoglycemic medication was the second most frequently utilized regimen
(n

=723; 24.92%).

Dual therapy with both a sulfonylurea and metformin was

utilized by 13.93% of patients (n = 404). No other regimen was observed at a
frequency greater than 5 percent. A substantial percentage of patients
received a dispensing for troglitazone (16.04% of all patients over 40 years of
age), mostly in combination with other medications. Patients 65 years of age
and older more frequently received dispensings for a sulfonylurea only (age 65
years or older: 48.4%; age 50-64: 43.6%; age under 50: 30.8%, p < 0.0001 ),
but not for dispensings for a sulfonylurea and metformin (age 65 years or
older: 14.4%; age 50-64: 15.2%; age under 50: 15.6%, p < 0.8275). Older
patients also less frequently received dispensings for only metformin (age 65
years or older: 4.8%; age 50-64: 7.9%; age under 50: 7.2%, p < 0.0.476), and
for troglitazone (age 65 years or older: 10.28%; age 50-64: 17.6%; age under
40-49: 20.3%, p < 0.0001 ). Female patients more frequently received
dispensings for only insulin (28.1 % versus 22.2%, p =0002). Male patients
received only a sulfonylurea more frequently than female patients (44.1 %
versus 35.8% , p< 0.0001 ). The hypoglycemic drug regimen utilized did not
differ significantly by insurance plan for the most frequently utilized regimens
and between the two main insurers included in this study. The 12-month cost
of hypoglycemic drug utilization was lowest among patients 65 years of age or
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older (age 65 years or older: $470 .38; age 50-64: $593.23; age under 50 :
$580.80, Pr> F less than 0.0001 ).

Conclusions

We found sulfonylureas to be the mainstay of treatment

for the majority of patients receiving oral therapy. Patients 65 years of age
and older were less frequently dispended troglitazone, or metformin in monotherapy, and were most frequently prescribed sulfonylureas as the only
hypoglycemic medication . For patients 65 years of age or older, the 12-month
cost of hypoglycemic medications dispensed was roughly 20% less than the
average hypoglycemic drug utilization cost for younger diabetic patients.
Differences in drug utilization among senior patients may reflect differences in
co-morbidities that influence drug selection, differences in insurance coverage
and associated out-of-pocket costs, or perhaps reluctance of prescribers to
utilize newer therapies in older diabetic patients. Further research is needed
to determine if older patients are less frequently prescribed newer therapies,
and if diabetes control and progression is impacted.
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INTRODUCTION

Diabetes mellitus has been identified as an epidemic throughout the world (115). Approximately 16 million Americans are afflicted with the condition, a
prevalence rate that exceeds 6% of the United States population (16). The
number of Americans living with diabetes has increased steadily. Based upon
data from the US National Health Interview Surveys, the prevalence of
diabetes has grown in a near-linear manner, rising from under 1% in 1958 to
approximately 7% in 1993 (17). Recently, Mokdad et al reported that the
prevalence rate of diabetes increased 33% from 1990 to1998 (4.9 to 6.5%)
(18). The number of Americans living with diabetes is expected to double by
2020, and the disease is expected to become more prevalent in younger age
groups (19).

Positive family history (20-22), older age (23-26), and obesity (27-29) are
associated with an increased risk of developing diabetes. The rise in diabetes
prevalence reflects the growing number of older adults in the US population,
and is compounded by an increased rate of the disease in this population (17).
An increasing prevalence of obesity among Americans of all adult ages has
also contributed to the rise in diabetes prevalence (30). Diabetes has a major
impact on the health of those afflicted with the condition. Diabetes is the
seventh leading cause of death among U.S. citizens (31 ), and co ntributes
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significantly to other leading causes of death such as cardiovascular disease
(32 , 33), stroke (34), and kidney failure (35-37).

Type 2 diabetes, formerly termed adult-onset or non-insulin dependent
diabetes mellitus, accounts for roughly 90% of all cases of diabetes (17).
Patients with type 2 diabetes mellitus generally develop the condition after the
age of thirty (20), and are usually managed with oral hypoglycemic
medications when dietary therapy and exercise fail to control blood glucose
levels. Sulfonylureas, discovered in 1942 by Janborn (38), have long been the
mainstay of type 2 diabetes treatment. During the past several years newer
oral therapies have become available, which exert a hypoglycemic effect
through differing biological mechanisms. These agents have been approved
for use in combination with other medications (39-45) or, for some drugs, for
use as mono-therapy (40, 43 - 45).

The choice of oral hypoglycemic medication may reflect patient characteristics.
For example, metformin has been shown to be particularly efficacious in
patients with obesity (46), and sulfonylureas may cause rash in some patients
(47). However, despite the several classes of hypoglycemic medications to
choose from , specific guidelines or algorithms for selection of drug therapy in
type 2 diabetic patients are lacking . For example, the American Diabetes
Association 's 2001 Clinical Practice Recommendations (48) include specific
goals of pharmacologic therapy; including reduction of glycated hemoglobin

6

(HbA 1c) to below 7%. However, the choice of hypoglycemic agent is left to
the prescriber. Thus , the choice of anti-diabetic agent utilized can be largely
determined by prescriber preferences and experiences. Further, despite the
availability of numerous studies assessing the glycemic control achieved with
various hypoglycemic drugs, there is scant comparative data describing
primary outcomes among diabetic patients prescribed alternative
hypoglycemic drug classes.

We examined hypoglycemic drug utilization in a large diabetic population ,
using data obtained from retail pharmacies during a 24-month period. We
determined the frequency of dispensing of medications, and the characteristics
of patients receiving dispensings for specific hypoglycemic agents. Changes
in hypoglycemic drug regimen during a 12-month period were determined,
including the number of patients switching to a different drug or combination of
drugs. The average cost of hypoglycemic medications dispensed during a 12month period was calculated, and compared between age groups, gender,
and insurance types .
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METHODS

Data source and study population

Consumer Value Stores (CVS). Inc provided data from 198 retail pharmacies
throughout Pennsylvania . The data included all pharmacy claims for 5056
diabetic patients from April, 1997 - May, 1999. The total number of pharmacy
dispensings for these patients during the 2-year period was 288, 171.

All patients were enrolled in a comprehensive diabetes management program
through one of two health insurance plans. Pharmacy services for these
patients were provided by CVS pharmacies. and patients were not reimbursed
for prescriptions filled by other pharmacies. Thus, the data represents
patients' utilization of hypoglycemic drugs, though some patients may have
filled prescriptions elsewhere using a different third party plan for drug
reimbursement, or by paying cash.

To create a standard basis of comparison, we included only patients who were
dispensed at least 2 prescriptions over a time period spanning at least 12
months. This was accomplished by determining the number of days between
the first and last dispensing of any hypog lycemic medication during the twoyea r period for which data was available. Of the 5056 patients in the
population, 2901 patients (57.4%) met this criteria . For these patients. a
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sample was created that included only the first 12-months of hypoglycemic
drug dispensings. This sample was used for all analyses.

Hypoglycemic medications were categorized by therapeutic class , or by
generic name if the drug was the only available product of its class. The
following categories were created: insulin , sulfonylurea , metformin, alphaglucosidase inhibitor, meglitinide , glimepramide, and troglitazone (Rezulin®),
the first available drug from the thiazoladinedionne class. The study period
preceded the withdrawal of troglitazone from the U.S. market, and also
preceded the introduction of two newer thiazoladinedionne agents to the US
market: pioglitazone (Actos®) and rosiglitazone (Avandia®).

Patients were categorized as receiving one of ten hypoglycemic drug
regimens, based upon the class(es) of hypoglycemic agent prescribed during
the first 90 days of the 12-month period. These drug regimens are presented
in Figure 1. For comparison , we also categorized drug regimens based upon
hypoglycemic agents dispensed during the last 90 days of the 12-month
period.

For all patients, we determined the age , gender, and insurance plan
associated with prescription dispensings . Age was categorized into three
groups: less than 50; 50-65; and 65 years or older. To enhance the focus on
drug regimens used by type 2 diabetics, some analyses were performed
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restricting the population to those 40 years of age or older, to exclude patients
likely to be type 1 diabetics. The two major insurers included in this study
were classified as health plan A and health plan B. Patients were categorized
as enrollees of health plan A or health plan B if any prescription dispensed
during the 12-month period was associated with a reimbursement claim to
either of these insurers. In instances where both insurances were used during
the 12 month period , the insurance type associated with first hypoglycemic
drug dispensing was used . A smaller number of patients used other
insurances for their prescription drug coverage. These patients were included
in a third category consisting of all 'other insurances'. A fourth category
included patients that paid cash for their hypoglycemic medication
prescriptions during the 12-month period .

For dispensings of sulfonylureas, we also categorized agents as first
generation sulfonylureas (chlorpropamide, tolazamide, and tolbutamide) or
second-generation sulfonylureas (glyburide or glipizide), and into groups of
brand name and generic products. The use of these agents among different
age categories was determined .

We calculated the total cost of all hypoglycemic medication dispensed during
the 12-month period , and compared this cost between genders, age
categories, and insurance types. Cost was calculated as the average
wholesale price (AWP) of medication dispensed minus 10 percent. Generally,
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drug purchasers pay AWP minus a discount rate for drugs , which can be
influenced by factors such as the quantity of medication purchased (49). We
considered AWP-10 % to be a relatively conservative estimate of the cost of
drug dispensed , representing the highest amount a drug purchaser would
typically pay (50-52).

Statistical analyses

Descriptive statistics were used to determine and present gender, age
category, and insurance type. Drug regimens utilized and changes in drug
regimen were presented as frequencies and percentages. Non-parametric
(chi-square) analyses were used to determine if the frequency of drug regimen
utilized differed in statistical significance by the gender, age category, and
insurance type of subjects. Chi-square tests were also to determine
differences in dispensing of brand name products and first generation
sulfonylureas among age groups, gender, and insurance types; and to
determine differences in the frequency of troglitazone dispensing in the three
age groups.

Analysis of variance procedures using Tu key's test were used to determine if
differences in 12-month hypoglycemic drug utilization costs among age groups
and insurance types were statistically significantly different. We used the
student's t-test for independent samples to determine if hypoglycemic drug
spending differed by gender.
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Statistical analyses were performed using SAS for windows version 8.01 .
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RESULTS

Descriptive statistics

A total of 2901 patients received hypoglycemic drugs spanning at least a 12month time period . Of these patients, 1002 (34 .54%) were under 50 years of
age; 1259 (43.4%) were between 50 and 65 years of age; and 640 (22.06%)
were 65 years old or older. Slightly more patients were male (n = 1552;
53 .5%). One-third of patients (n =967) were insured by health plan A, and
53.84% of patients (n = 1562) were enrollees in health plan 8 . A smaller
percentage of patients (8.62%) used other insurance plans for their
prescription coverage, and 4.21 % of patients paid for their prescriptions by
cash . Nearly one-third of the population were insulin users (n = 890; 30.86%).
These statistics are presented in table 1.

Drug regimen prescribed

Patients were categorized as receiving one of nine potential drug regimens . A
tenth regimen category represented miscellaneous combination therapies not
captured by the first nine regimen categories. The number and percentage of
patients receiving each regimen during the first 90 days of the 12-month
period is presented in Table 2a. A comparison of the frequency and percent
utilization of drug regimens identified using the first and last 90-days of the 12month period is presented in Table 2b.
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Based upon dispensings during th e first 90 days of the 12-month period , the
most frequently prescribed hypoglycemic drug regimen was mono-therapy
with a sulfonylurea (n = 1168; 40.26%). The 723 patients receiving insulin as
their only hypoglycemic medication accounted for next most frequently
observed regimen (24.92%). Combination therapy with sulfonylurea and
metformin was the only other regimen observed in more than 10% of patients
(13.93%; n = 404 ). Metformin mono-therapy was the fourth most frequently
observed hypoglycemic regimen (6 .96%; n =202). The prevalence of the
other five prescribed regimens ranged from 1.17 to 3.14% . Less than 2
percent of patients received a combination of drugs that was not characterized
by any of drug regimen categories 1-9.

Drug regimen classification based upon the last 90 days of the 12-month
period produced similar results , though some differences were observed . The
order of the top four frequentl y utilized regimens was the same for drug
regimens classified using the first and last 90 days . However, the percent of
patients utilizing other regimens differed notably. The percentage of patients
receiving a sulfonylurea plus anoth er oral agent other than metformin (regimen
6) more than doubled (6.17% versus 2. 65%). Correspondingly, the
percentage of patients receiving sulfonylurea mono-therapy during the last 90
days of the 12-month period declined from 40.26% to 31.51 %. Also , during
the last 90-days , a greater number of patients received a regimen other than
one of the 9 identified regimen categories (6.27% versus 1.72%). Utilization of
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the other less frequently observed regimens remained similar: the difference in
percentage observed ranged from 0.14% - 1.14%.

We determined the number of patients remaining on the same regimen during
the two 90-day periods. For patients not utilizing the same hypoglycemic drug
regimen in each 90-day period , we identified which regimen patients switched
to. These results are presented in Tables 3a (frequencies) and 3b
(percentages). Insulin-only users as identified during the first 90-day period
were most likely to be classified as utilizing the same regimen in each 90-day
period (82%). The regimens with the lowest percentage of patients utilizing the
same hypoglycemic regimen in each 90-day period were regimen 2 (insulin +
troglitazone (56%)) and regimen 3 (insulin+ non-troglitazone agent (30%)),
though the total number of patients receivi ng these regimens was small.

Three-quarters of patients receiving a sulfonylurea. glimepramide, or
metformin mono-therapy utilized these same regimens in each 90-day period.
Patients receiving mono-therapy with a sulfonylurea, glimepramide, or
metformin remained on the same regimen more frequently than patients
receiving combination therapy of a sulfonylurea plus another oral agent
(remained on mono-therapy with either sulfonylurea, glimepramide, or
metformin: 74-75%; remained on sulfonylurea plus metformin: 70%, or
remained on sulfonylurea plus non-metformin oral agent: 65%). Half of
patients categorized as receiving mono-therapy with troglitazone during the
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first 90-days of the 12-month period were utilizing this regimen during the last
90-day period . Of the patients categorized as utilizing an uncategorized
combination of hypoglycemic agents (regimen 10) during the first 90-day
period , 68% remained in this category when examining the last 90 days of
drug dispensings. A greater number of patients utilized an uncategorized drug
regimen during the last 90 days as compared to the first 90 days of the 12month period (232 versus 50).

As compared with male patients, females were more frequently dispensed
prescriptions for insulin (28.12% versus 22.2%; p

=0.0002) and dispensings

for insulin and troglitazone (3.9% versus 2.5%; p

=0.0386).

Diabetic males

were more frequently prescribed sulfonylureas as mono-therapy (44.1 %
versus 35.8%; p < 0.0001 ). There was no statistically significant difference in
the percentage of male and female patients that received combination therapy
that included a sulfonylurea. The percentage of male and female patients
receiving mono-therapy with metformin , troglitazone, or glimepramide also did
not differ significantly. These findings are summarized in Table 4.

Table 5a presents regimen categories stratified by age group. A higher
percentage of patients under 50 years of age received insulin as their only
hypoglycemic agent, as compared to patients aged 50-64 or 65 or older
(36.9% versus 18.4% and 19.1% respectively, p < 0.0001). Conversely, the
percentage of patients that received only a sulfonylurea was significantly less
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for patients under 50 years of age as compared to patients aged 50-64 or 65
or older (30.8% versus 43.6% and 48.4%, p < 0.0001 ).

To focus on drug prescribing in type 2 diabetic patients, we identified drug
regimens prescribed for patients over 40 years of age (Table 5b). When
patients under 40 years of age were excluded from the analysis, the
percentage of patients using insulin as their sole hypoglycemic agent was no
longer statistically significantly different among age groups. However,
subjects in the 40-49 age group were more frequent users of insulin plus
troglitazone combination therapy (5.0% versus 3.3% and 1.4%; p

=0.0013),

though there was a relatively small number or total patients receiving this
regimen (91 /2901 ; 3.14%). The youngest age group remained the least
frequent users of a sulfonylurea mono-therapy regimen (39.6% versus 43.6%
and 48.4% ; p

=0.0067).

Diabetics 40-49 years of age were also more likely

to be prescribed metformin compared to patients over 65 years of age (9.1 %
versus 4.8%; p

=0.0107).

We also examined the relation between insurance type and drug regimen
utilized. Table 6 presents percentages of patients receiving each drug
regimen , stratified by four categories of payment: Plan A , Plan B, other
insurance, and cash payment. There was no statically significant difference in
the percentage of patients utilizing regimens of insulin only, insulin plus an oral
agent, sulfonylurea mono-therapy, or sulfonylurea plus a non-metformin oral
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agent. Patients not utilizing insurance (paying cash) were less frequently
dispensed regimens that included metformin (metformin mono-therapy: cash
2.5%, plan A: 6.5%, plan B: 4.0%, other insurance types: 8.4%; p

=0.0107;

metformin plus sulfonylurea: cash 9.8%, plan A 11.8%, plan B 15.8%, all other
insurance types: 12.8%; p =0.0187. Also , a lesser percentage of Plan B
patients received mono-therapy with glimepramide (plan A: 4.3%, plan B:
1.3%, all other insurances: 2.8% , cash: 5.7%; p< 0.001)

The percentage of patients receiving a brand name sulfonylurea did not differ
in statistical significance among age groups or gender (Table 7). Patients with
insurance plan A received brand name products more frequently that patients
enrolled in plan B (64.0% versus 41 .8%; p < 0.001 ). The percentage of brand
name sulfonylureas dispensed was highest among patients paying cash for
their prescription (64.6%), although the frequency was only slightly higher than
that found for plan A (64.0%). Of patients with insurance other than plan A or
plan B, 55.2% of sulfonylurea-using patients received brand name products.

Of the 1575 patients receiving a sulfonylurea, 17 (1 .08%) received a first
generation product. The frequency of first-generation sulfonylurea utilization
did not differ in statistical significance among age groups, gender, or insurance
type.
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Patients 40-49 years of age were most frequently dispensed troglitazone
(20.3%), while those 65 years of age or older were least frequently prescribed
this drug (10 .1%). The difference in frequency of troglitazone utilization
between these age groups was statistically significant (p < 0.0001 ).

Table 9 presents the average cost of all hypoglycemic medications dispensed
during the 12-month period for each age category, gender, and insurance
type. The average 12-month cost of hypoglycemic medication utilized by
patients 65 years of age and older was significantly less than the cost of
hypoglycemic medications utilized by younger patients (age 65 and older:
$470.37, age 50-65: $593.23, age under 50: $580 .80; Pr> F: < 0.0001 ). The
average 12-month hypoglycemic drug utilization cost did not differ significantly
between men and women. Average costs were similar among insurance
types, but not among patients paying cash. (plan A: $521.63, plan B: $587.82,
all other insurances: $523 .01, cash: $385 .37).
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DISCUSSION

Pharmacy data is a useful and often available information source for
pharmacoepidemiologic investigations of drug utilization patterns. Pharmacy
data can be used to identify trends in prescribing patterns (53), assess the
impact of regulatory changes (54), and to determine drug expenditures (55).
Though the lack of information related to patient diagnoses can be limiting
(56), pharmacy data can be superior to the medical record for determining if
and when prescriptions are actually filled by patients; an action necessary for
adherence to therapy. Pharmacy data is an excellent source for describing
drug use in populations, and for comparing patterns of use between
populations.

In this study, pharmacy data was used to describe the utilization of
hypoglycemic drugs in a population of diabetic patients. We created nine
categories of drug regimens utilized, based upon the types of hypoglycemic
drugs dispensed to patients. We compared the frequency of regimen
utilization among age groups, gender, and payment type. Identification of
regimen utilized was based upon hypoglycemic drugs dispensed during the
first 90 days of a 12-month period , and was compared with the frequency of
regimens utilized in the last 90-days of the 12-month period. We identified
which patients changed medication regimen , and which different regimen was
utilized.
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Frequency of regimen category utilized

Sulfonylureas, a staple of therapy for type 2 diabetes for several decades,
were the most frequently prescribed oral hypoglycemic agent in this
population. Factors contributing to the popularity of these agents include a
long history of use (38), relatively low expense (57), high tolerability (58), and
prescriber familiarity. Metformin was also prescribed frequently in this
population, either as mono-therapy or in combination with other oral agents,
usually a sulfonylurea. Several oral hypoglycemic agents became available
just before or during the study period: troglitazone, acarbose, repaglinide , and
glimepramide. Despite the availability of these newer agents, the majority of
patients receiving oral hypoglycemic therapy were receiving a sulfonylurea ,
metformin, or both together. However, the impact of the new
thiazoladinedionne drug class was apparent. Troglitazone , the first
thiazoladinedionne available in the US market, was the only
thiazoladinedionne available for prescribing during the study period.
Consistent with its approved indications, troglitazone was utilized as monotherapy or in combination with insulin or oral hypoglycemic agents.
Troglitazone was discontinued in 1999 after awareness of an association with
hepatic failure and death among patients prescribed this agent (59-62). The
increased risk for liver toxicity in those treated with troglitazone was
recognized while the drug was available for prescribing (63), potentially
explaining why troglitazone was prescribed less frequently for older patients in
this population (Table 7).
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Despite the effective treatment of diabetes with sulfonylurea, metformin , or
insulin , glycemic control is known to become poorer as diabetes progresses
(64-66). Failure of sulfonylurea mono-therapy to control blood glucose levels
generally occurs within 5 years (67 , 68). In this population, patients changed
medication regimens with high frequency; perhaps reflecting increased
medication needs to achieve blood glucose control. Though it was the most
frequently observed oral hypoglycemic regimen , mono-therapy with a
sulfonylurea was the regimen having the largest percentage change during the
12-month observation period (sulfonylurea mono-therapy in first 90 days:
40.26% ; in last 90 days: 31.51 %). Slightly greater than 10% of patients
utilizing sulfonylurea mono-therapy added metformin to their regimen during
the 12-month period {Table 3a). Another 5% of patients added an agent other
than metformin, and 6% of these patients changed therapy to a combination
regimen that did not include a sulfonylurea. These findings suggest that many
type 2 diabetic patients do not remain stable on their medication regimens,
and that medication requirements increase over time. Indeed, 26.68% of
patients (774/2127) were categorized as utilizing a different drug regimen
during the last and first 90 day periods of the 12-month period. The finding
that one of four patients changed regimen during the 12-month study period is
consistent with what is known about diabetes: the condition progresses, it can
be unstable, and medication needs increase over time (20).
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As compared to utilization based upon the first 90 days of the 12-month
period, the utilization of sulfonylurea mono-therapy was less, and the
utilization of combination therapies was greater during the last 90-days of the
12-month period . The decrease in sulfonylurea mono-therapy and increase in
use of oral combination therapies may be related to several factors . First, it is
possible that the increase in utilization of combination regimens is partly the
resu lt of increased medication needs associated with disease progression
over time. Second , the increased use of combination therapy may reflect the
availability of newer hypoglycemic agents approved for use in combination
therapies during the 12-month period, such as repaglinide, glimepramide,
acarbose, and troglitazone. A third possible influencing factor is the increased
awareness and popularity of combination therapy as a means to achieve
improved glycemic control.

Of patients categorized as users of insulin as their sole hypoglycemic
medication during the first 90 days of the 12-month period, 5% added
troglitazone to their regimen during the following 9 months. Anoth er 5% of
insulin users added an oral agent other than troglitazone to their regimen .

Differences in hypoglycemic drug utilization between the two 90 day periods
may be partly attributed to patient behavior, and may not necessarily represent
changes in hypoglycemic drugs prescribed. Non-adherence to prescribed
drug regimens is a recognized problem (69-71 ), and may have caused
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misclassification of regimens , since patients must have filled a prescription to
be identified as being prescribed the drug . It is also possible that patients may
have received medication from another pharmacy, though the data includes all
designated pharmacies for patients in health plans A and B. A third possible
factor contributing to misclassification of regimens is the possibility that
patients received several month-supply of medication shortly before the 90day categorization period . Such stockpiling would be most likely among cash
paying subjects, since health plans A and B allowed only a one-month supply
of medication per dispensing. A frequency analysis of days supply dispensed
confirmed that one or two month supplies of medications were dispensed to a
great majority of patients.

Frequency of drug regimen utilization by gender, age group, and
insurance type

We compared the frequency of drug regimen utilization among female and
male subjects. Women were more frequently prescribed insulin as a sole
hypoglycemic therapy (p

=0.0002), and women were more frequently

dispensed insulin in combination with troglitazone (p

=0.0386).

This finding ,

in addition to the less frequent utilization of sulfonylurea mono-therapy
regimens, may indicate a greater frequency of type I diabetes among female
subjects in this population. Howeve r, there was no statistically significant
difference in the utilization of other oral hypoglycemic drug regimens between
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men and women. Additionally, the frequency of metformin use did not differ in
statistical significance among men and women. In sum, women were more
frequently dispensed insulin and less frequently dispensed only sulfonylureas;
yet the frequency of utilization of other oral regimens did not differ significantly.
This observation is not readily explainable.

Those in the under-50 age group were the most frequent users of insulin, likely
due to a higher prevalence of type 1 diabetics in this age strata. There was no
significant difference in the frequency of insulin-only therapy among age
categories when patients under 40 years of age were removed from the
analysis. This finding suggested that the proportion of type 1 diabetics in each
age group was similar when including only patients 40 years of age or older.
Thus, when comparing drug regimens utilized among age groups, differences
in the regimen utilized was presumed not to reflect differences in the
proportion of type 1 and type 2 diabetics.

We found differences in the frequency of drug regimen utilized by patients 65
years of age or older. First, though there was no statistically significant
difference in insulin prescribing among age groups, seniors were less
frequently prescribed troglitazone in combination with insulin. Though
removed from the US market in 2000 due to risk of life-threatening hepatic
injury, troglitazone, the first available thiazoladinedionne, was recommended
as a useful agent in the management of diabetes (72-74). Prescribers may
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have avoided prescribing troglitazone in older patients due to concern that
older patients may be at greater risk for troglitazone-induced hepatic toxicity.
Though prescription drug coverage was available to older patients in this
population, it is also possible that prescribers avoided prescribing this product
in older patients due to financial considerations. The retail price for a 30-day
supply of troglitazone exceeded the average one-month cost of a generic
sulfonylurea, a regimen utilized with increased frequency among older
subjects. Since the cost of the dispensing to the patient (co-payment) was
not available, the influence of cost on drug regimen utilization cannot be
directly assessed . However, it is interesting that seniors were most frequentl y
prescribed mono-therapy with a sulfonylurea, the oldest and most inexpensive
oral hypoglycemic drug regimen available. Additionally, seniors utilized
metformin as mono-therapy less frequently, but were not less frequent users
of regimens of sulfonylurea plus metformin . Thus metformin was used more
frequently as an adjunct to sulfonylurea therapy in seniors. Contrastingly,
younger patients were prescribed mono-therapy with metformin more
frequently than older patients (p

=0.0107).

Metformin has been shown to be

particularly useful in obese diabetic patients (65). The less frequent use of
metformin mono-therapy among seniors may reflect a lower prevalence of
obesity among those 65 years of age and older in this population .

We also examined the frequen cy of drug regimen prescribed for each insurer
type. We did not find the frequency of drug regimens prescribed to differ
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significantly between the two main insurance plans included in this study. One
exception was the use of glimepramide as mono-therapy, which was less
frequently prescribed for patients insured by plan B. However, only a small
percentage of patients were prescribed this drug as mono-therapy (2.6%;
76/2901 ). Of the patients that paid cash for their prescription , one-half were
prescribed sulfonylurea mono-therapy.

Additional analyses

We found a low prevalence of first generation sulfonylurea utilization (1 .1%;
17/1168), and older persons were not more frequently dispensed these
agents. The infrequent use of these products reflects an awareness of the
increased potential for hypoglycemia associated with chlorpropamide (58), and
the lower likelihood for adverse effects such as hyponatremia and disulfiramtype reactions (75-77). Use of first-generation sulfonylureas did not differ by
age group or by gender. We did not expect to find a difference in dispensings
for brand-name sulfonylurea products among age groups or by gender.
However, although patients covered by health plan B utilized brand name
sulfonylureas less frequently, the average 12-month cost of hypoglycemic
drugs dispensed to patients in plan B was the highest of all insurance types.
Thus, it appears that factors other than dispensing of generic products were
important determinants of drug utilization costs; and may include factors such
as the frequency of use of combination therapies, disease severity, or a more
frequent use of newer drugs for which generic products are not available.
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Average total 12-month cost of hypoglycemic drugs dispensed

A major finding of this research was that of all age groups, expenditures for
hypoglycemic medications were lowest among patients age 65 or older. The
mean 12-month expenditure of $470.38 for seniors differed by more than $100
compared with patients aged 50-64 ($593.23) and less than 50 yea rs of age
($580.80). This finding is consistent with other observations in this study.
First, seniors were less frequently prescribed troglitazone in combination with
other medications , and were less frequent users of metformin as monotherapy. Both troglitazone and metformin are higher priced products. Second ,
seniors were more frequently prescribed mono-therapy with sulfonylureas, a
drug class available as generic products that are less expensive than
metformin or troglitazone. Though seniors were less frequently prescribed
brand name sulfonylurea products (Table 8), the relative difference among
groups was small and did not differ in statistical significance. Thus, though the
proportion of patients in each age category prescribed generic sulfonylureas
was similar, more seniors received generic sulfonylureas as their only
hypoglycemic agent.

Study limitations

Several limitations of this study can be described. First, this study categorizes
drug regimen prescribed based upon medications dispensed during a 90-day
period. It is possible that medications were prescribed by the physician but not
dispensed by the pharmacy during the 90 day period. For example,
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medications received as samples or through special programs were not
identified . Further, it may be argued that drugs dispensed during the 90 day
period may not accurately reflect hypoglycemic drug utilization during a 12month period. We felt that using the first and last 90 days of the 12-month
period to identify the regimen afforded the opportunity to compare regimens
utilized at the start and end of the study period . Using a 12-month period to
categorize regimens would have resulted in identification of a large number of
miscellaneous regimens : Patients switching regimens during the year would
have been considered users of all hypoglycemic drug types dispensed during
the 12-month period. Another limitation relates to the use of other
pharmacies. Prescriptions filled by non-designated pharmacies would not have
been captured in this sampling , potentially resulting in the false indication of a
drug regimen change (i.e. change from combination therapy to mono-therapy).

It is also important to note that drug expenditures were calculated using AWP10%. We selected this figure mainly to provide a common metric for
assessing costs of hypoglycemic drug utilization. The dollar totals do not
include the cost of syringes or blood glucose monitoring devices or supplies,
or medications used for reasons and conditions other than blood glucose
control.

Though various insurance types are represented , a majority of study patients
were enrolled in a diabetes management program through one of two health
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plans. Generalizability to other populations is impaired by a lack of knowledge
of race and socio-economic status, and the absence of diagnostic information
such as diabetes type and co-morbidities.
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CONCLUSION

Retail pharmacy data were used to describe hypoglycemic drug utilization and
associated costs in a large population of ambulatory diabetic patients. Several
important findings are reported here. First, sulfonylureas continue to be the
mainstay of treatment in patients with type 2 diabetes. Second, many patients
changed medication regimens during a 12-month period, not including
changes in medication dosage. Third , patients 65 years of age and older were
less frequently prescribed troglitazone, or metformin in mono-therapy, and
were most frequently prescribed sulfonylureas as their only hypoglycemic
agent. The difference in hypoglycemic drug type utilization among seniors
was reflected in the average 12-month cost of hypoglycemic medications
dispensed . For seniors, this cost was roughly 20% less than average
hypoglycemic drug utilization costs for middle-aged and younger-aged diabetic
patients.

Perhaps the recent attention directed towards tight glycemic control and
enhanced control of post-prandial blood glucose will generate an increase in
the use of combination drug therapies that includes newer hypoglycemic
agents . However, though glycemic control may be enhanced through the use
of some of the newer agents, there is no evidence to suggest that
sulfonylureas are less effective than newer agents at preventing death and
disability due to diabetes. In this population, sulfonylureas were by far the
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most frequently used agents, particularly in older patients. Older patients were
also less frequently dispensed prescriptions for troglitazone, and metformin in
combination with a sulfonylurea. These findings may or may not suggest a
difference in the standard of care delivered to seniors, but we believe it
indicates a difference in the type of care received .
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Figure 1. Drug Regimen Categories

Regimen
1
2
3
4
5
6
7
8
9
10

Insulin only
Insulin + troglitazone
Insulin + non-troglitazone agent
Sulfonylurea mono-therapy
Sulfonylurea + metformin
Sulfonylurea + non-metformin agent
Troglitazone mono-therapy
Glimepramide mono-therapy
Metformin mono-therapy
Other regimen not classified above
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Table 1. Population Characteristics

N

%

Total population

2901

Age
Under 50
50-64
65 and older

1002
1259
640

34.5
43.4
22 .1

Gender
Female
Male

1349
1552

46 .5
53 .5

Insurance type
Plan A
Plan B
Other insurer
Cash

967
1562
250
122

33 .3
53.8
8.6
4.2

Insulin use

890

30.7

Oral hypoglycemic use

2010

69.3
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Table 2a. Frequency and Percentage of Drug Regimens Utilized , Based
Upon Dispensings During First 90 Days of the 12-Month Period

1
2
3
4
5
6
7
8
9
10

Regimen
Insulin only
Insulin + Troglitazone
Insulin + non-troglitazone agent
Sulfonylurea mono-therapy
Sulfonylurea + metformin
Sulfonylurea + non-metformin agent
Troglitazone mono-therapy
Glimepramide mono-therapy
Metformin mono-therapy
Other regimen not classified above
TOTAL

n
723
91
76
1168
404
77
34
76
202

35

%
24.92
3.14
2.62
40 .26
13.93
2.65
1.17
2 .62
6.96

fill

ill

2901

100.00

Table 2b. Comparison of Drug Regimen Utilization During First and Last
90 Days of the 12-Month Period.

Regimen

First 90
days
n

Insulin only
2

Insulin + Troglitazone

3

Insul in + non-troglitazone

4

Sulfonylurea mono-therapy

%

Last 90
days
n

%

Change

%

n

24.92

641

22 .10

-82

2.83

91

3.14

110

3.79

+19

0.65

76

2.62

87

3.76

+11

1.14

1168

40.26

914

31 .51

-254

8.76

723

5

Sulfonylurea + metformin

404

13.93

426

14.68

+22

0.76

6

Sulfonylurea + non-metformin

77

2.65

179

6.17

+102

3.52

7

Troglitazone mono-therapy

34

1.17

48

1.65

+14

0.48

8

Glimepramide mono-therapy

9

Metformin mono-therapy

10

Other regimen not classified

76

2.62

66

2.28

-10

0.34

202

6.96

198

6.83

-4

0.14

50

1.72

232

8.00

+182

6.27
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Table 3a. Frequency of Change in Hypoglycemic Drug Regimen Utilized During 12-Month Period
Patients remai ning on same drug regimen or switching to
different regimen during 12-month period
REGIMEN CATEGORY: LAST 90 DAYS

azone

Insulin
+nontroglitazone

Sultonylurea
monotherapy

Su Ifonylurea
+metform in

Sulfonylurea+
non met
-form in

Troglitazone
monoth erapy

Glimep
-ramide
monotherapy

therapy

not
classified

1

2

3

4

5

6

7

8

9

10

723

593

39

35

2

1

2

4

0

4

43

91

15

51

11

0

0

2

3

1

0

8

76

19

13

23

7

2

8

0

1

0

3

1168

4

3

7

869

121

58

11

2

24

69

Insulin
only
REGIMEN CATEGORY:
N
FIRST 90 DAYS

w

-.J

1
2

Insulin only
Insulin+
Troglitazone
3 Insulin+ nontroglitazone
4 Sulfonylurea
mono-therapy
5 Sulfonylurea +
metformin
6 Sulfonylurea +
non-metformin
7 Troglitazone
mono-therapy
8 Glimepramide
mono-therapy
9 Metformin
mono-therapy
10
Other not
classified
Total

Insulin+
Troglit-

Mellormin
mono-

Other
regimen

404

5

0

7

19

282

49

4

0

14

24

77

2

0

0

9

3

50

1

2

1

9

34

1

2

2

1

0

4

17

·o

0

7

76

0

0

0

1

0

2

1

57

2

13

202

1

0

1

5

14

1

5

2

151

22

50

1

2

1

1

3

3

2

1

2

34

2901

641

110

87

914

426

179

48

66

198

232

~

Table 3b. Percent of Change in Hypoglycemic Drug Regimen Utilized During 12-Month Period
Patients remaining on same drug regimen or switching to
different regimen during 12-month period
REG IMEN CATEGORY: LAST 90 DAYS

REG IMEN CATEGORY:
FI RST 90 DAYS
N
w
00

Insulin only
Insulin+
Troglitazone
3 Insulin+ nontroglitazone
4 Sulfonylurea
mono-therapy
5 Sulfonylurea +
metform in
6 Sulfonylurea +
non-metformin
7 Troglitazone
mono-therapy
8 Glimepram ide
mono-therapy
9 Metformin
mono-therapy
10
Other not
classified
1

Insulin
only

Insulin
+
Troglitazone

Insulin
+ nontroglitazone

Sulfonylurea
monotherapy

Sulfonylurea+
metform in

Sulfonylurea+non
metformin

Trog litazone
monotherapy

Glimep
-ramide
monotherapy

Metfor-

therapy

Other
regimen
not
clas sified

1

2

3

4

5

6

7

8

9

10

min
mono-

723

82%

5%

5%

0%

0%

0%

1%

0%

1%

6%

91

16%

56%

12%

0%

0%

2%

3%

1%

0%

9%

76

25%

17%

30%

9%

3%

11 %

0%

1%

0%

4%

1168

0%

0%

1%

74%

10%

5%

1%

0%

2%

6%

404

1%

0%

2%

5%

70%

12%

1%

0%

3%

6%

77

3%

0%

0%

12%

4%

65%

1%

3%

1%

12%

34

3%

6%

6%

3%

0%

12%

50%

0%

0%

21 %

76

0%

0%

0%

1%

0%

3%

1%

75%

3%

17%

75%

11 %

4%

68%

2

202

0%

0%

0%

2%

7%

0%

2%

1%

50

2%

4%

2%

2%

6%

6%

4%

2%

Table 4. Percentage of Patients Prescribed Each Drug Regimen;
Stratified By Gender

REGIMEN CATEGORY

2

3
4

5

N

Female

Male

Insulin only

723

28 .1%

22.2%

p = 0.0002

Insulin
+ Troglitazone

91

3.9%

2.5%

p = 0.0386

Insulin + nontroglitazone agent

76

2.4%

2.8%

p = 0.4362

1168

35.8%

44 .1%

p < 0.0001

404

14.0%

13.9%

p = 0.9029

Sulfonylurea
mono-therapy
Sulfonylurea
+ metformin

6

Sulfonylurea +
non-metformin

77

2.5%

2.8%

p = 0.6758

7

Troglitazone
mono-therapy

34

1.2%

1.2%

p = 0.9477

8

Glimepramide
mono-therapy

76

3.1%

2.2%

p=0.1207

9

Metformin
mono-therapy

202

7.5%

6.5%

p = 0.3013

Other regimen

§Q

1.5%

1.8%

2901

100%

100%

10

Total

39

Table 5a. Percentage of Patients Prescribed Each Drug Regimen ; Stratified By
Age

AGE

REGIMEN CATEGORY

N

Under
50

50-64

65 or
older

Insulin only

723

36.9%

18.4%

19.1%

p < 0.0001

Insulin
+ Troglitazone

91

4.1%

3.3%

1.4%

p = 0.0092

3

Insulin + nontroglitazone agent

76

2.4%

2.5%

3.1%

p = 0.6478

4

Sulfonylurea
mono-therapy

1168

30.8%

43 .6%

48.4%

p < 0.0001

Sulfonylurea
+ metformin

404

12.1%

15.2%

14.4%

p=0.1004

Sulfonylurea +
non-metformin

77

1.8%

3.4%

2.5%

p = 0.0568

Trog litazone
mono-therapy

34

1. 1%

1.4%

1.0%

p = 0.7058

Glimepramide
mono-therapy

76

2.1%

2.7%

3.3%

p = 0.3315

Mettormin
mono-therapy

202

7.2%

7.9%

4.8%

p = 0.0476

§Q

1.5%

1.9%

2.0%

100%

100%

100%

2

5

6

7

8

9

10

Other regimen

2901
Total

40

Table 5b. Percentage of Patients Prescribed Each Drug Regimen ;
Stratified By Age , Patients Under 40 Years of Age Excluded
AGE

REGIMEN CATEGORY

n

40-49

50-64

65 or older

Insulin only

723

20.1%

18.4%

19.1%

p

=0.6506

Insulin
+ Troglitazone

91

5.0%

3.3%

1.4%

p

=0.0013

Insulin + nontroglitazone agent

76

2.8%

2.5%

3.1%

p

=0.7627

Sulfonylurea
mono-therapy

1168

39.6%

43 .6%

48.4%

p

=0.0067

Sulfonylurea
+ metformin

404

15.6%

15.2%

14.4%

p

=0.8275

Sulfonylurea +
non-metformin

77

2.4%

3.4%

2.5%

p

=0.3715

Troglitazone
mono-therapy

34

1.0%

1.4%

1.0%

p

=0.6493

8

Glimepramide
mono-therapy

76

2.8%

2.7%

3.3%

p

=0.7612

9

Metformin
mono-therapy

202

9.1%

7.9%

4.8%

p

=0.0107

2

3

4

5
6
7

10

Other regimen
Total

50

1.6%

1.9%

2.0%

2901

100%

100%

100%
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Table 6. Percentage of Patients Prescribed Each Drug Regimen ; Stratified By Insurance Type

N

Plan A

Plan B

Other
Insurance

Cash

Insulin only

723

24.1%

25.3%

27.2%

22.1%

2

Insulin + Troglitazone

91

3.8%

3.1%

2.0%

0

3

Insulin +nontroglitazone agent

76

3.4%

2.1%

2.8%

3.3%

p = 0.2019

4

Sulfonylurea monotherapy

1168

39 .3%

40 .6%

37.2%

50.1%

p=0.1010

Sulfonylurea
+ metformin

404

11 .8%

15.8%

12.8%

9.8%

p = 0.0187

Sulfonylurea + nonmetformin

77

3.4%

2.1%

2.8%

3.3%

p = 0.2477

Troglitazone monotherapy

34

0.8%

1.2%

2.4%

0.8%

Glimepramide monotherapy

76

4.3%

1.3%

2.8%

5.7%

p < 0.001

Metformin
mono-therapy

202

6.5%

4.0%

8.4%

2.5%

p = 0.0107

Other regimen

50

2.6%

4.5%

1.6%

2.4%

2901

100%

100%

100%

100%

REGIMEN CATEGORY

...
N

5

6
7

8
9

10

Total

• X2 not reported due to cells with less than 5 subjects

p = 0.6444

Table 7. Prescriptions for Brand Name Sulfonylurea Products and Age ,
Gender, and Insurance Type

n

Percentage of Patients
Dispensed Brand Name
Product

Age
under 50
50-64
65 and older

430
740
402

54.2%
50.1%
48.3%

p =0.2079

Gender
Female
Male

672
900

48.4%
52.6%

p

Insurance Type
Plan A
Plan B
Other Insurance
Cash

316
368
69
45

64.0%
41.8%
55 .2%
64.6%

p < 0.001

Table 8. Troglitazone Prescribing and Age Category

Age
40-49
50-64
65 +
Total

N
616
1259
640
2515

Number
prescribed
troglitazone
125
222
65
412

*p < 0.0001

43

=0.1000

% prescribed
Troglitazone*
20.3%
17.6%
10.2%
16.4%

Table 9. Prescriptions for Hypoglycemic Drugs : 12-Month Expenditure

n

12-month expend iture
(mean )

Pr> F

Age
under 50
50-64
65 and older

1002
1259
640

$580.80
$593.23
$470.38

< 0.0001 •

Gender
Fema le
Male

1349
1552

$538.83
$531 .72

0.1172b

Insurance Type
Plan A
Plan B
Other Insura nce
Cash

967
1562
250
122

$521 .63
$587.82
$526.01
$385.37

0.0002•

a. Analysis of Variance , Tukey's test
b. Student's I-test for independent samples
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Changes in Oral Hypoglycemic Therapy: Influence of Nonadherence as
Determined by Medication Possession

ABSTRACT
Background

Recent large trials have provided evidence that intensive

therapy for achieving tight glycemic control can reduce the risk of several
types of diabetic complications. Tight glucose control necessarily presumes
strict adherence to the prescribed hypoglycemic regimen . However,
adherence to prescribed drug therapy for chronic diseases is known to be suboptimal.

Objective

To determine if nonadherence, as determined by medication

possession , is associated with changes in hypoglycemic drug prescribing;
either as a change in medication strength or a change in type of hypoglycemic
medication dispensed .

Methods

.A retrospective cohort study examining retail pharmacy

dispensings of sulfonylureas and metformin. The medication possession ratio
(MPR) was used to assess adherence, with patients that did not receive a
sufficient quantity of medication to cover eight of ten days in the period (MPR
< 8: 10) classified as nonadherent. Outcomes assessed were change in

strength of hypoglycemic medication dispensed and change in type of
hypoglycemic medication dispensed . Multivariate logistic regression was used
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to estimate the influence of medication possession on these outcomes,
controlling for the potential confounding factors age, gender, insurance type,
and the total number of all pharmacy dispensings.

Results

For patients receiving dispensings only for a sulfonylurea , those

failing to possess medication for eight of ten days (MPR < 8: 10) were 41.7%
more likely to receive a dispensing for a different strength of medication in
subsequent months (OR 1.42, 95% Cl 1.02 - 1.96). Such patients were also
47.1 % more likely to receive a dispensing for a different strength or different
type of hypoglycemic medication (OR 1.47, 95% Cl 1.05 - 2.06). For the
smaller sub-population of users of only metformin (n

=166), a statistically

significant increase in the likelihood of either a change in strength or type of
hypoglycemic drug dispensed was not found for those having an MPR less
than 8: 10. However, for the combined sample of patients receiving either
monotherapy with a sulfonylurea or metformin , those having an MPR less than
8:10 were 36.4% more likely to receive a dispensing for a different strength of
medication (OR 1.36, 95% Cl 1.019 - 1.83), or for a different strength or type
of hypoglycemic medication (OR 1.39, 95% Cl 1.027 - 1.87).

Conclusions

Glycemic control would expectedly be poorer

among patients failing to possess prescribed hypoglycemic medication . In this
study, patients failing to refill prescriptions when due were more likely to
receive a dispensing for a different strength or type of hypoglycemic
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medication in subsequent months. This finding suggests that for patients that
do not tightly adhere to therapy, providers may respond to poor glucose
control by increasing the amount of medication prescribed . This response
may precipitate dangerous hypoglycemic reactions , and fails to address the
root cause of poor glycemic control for such patients, potentially resulting in
diabetic complications that could have been prevented.
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INTRODUCTION
Patients with diabetes are at risk for numerous adverse health outcomes .
Beyond consequences immediately related to blood glucose regulation, such
as hypoglycemia or ketoacidosis (1 ), diabetes increases risk for 'macro'
vascular diseases such as myocardial infarction and stroke (2). Diabetics are
also more likely to develop hypertension and dyslipidemia (3), which are risk
factors for developing these outcomes. In addition to macrovascular diseases,
diabetes also increases the risk of developing diseases resulting from damage
to the smaller blood vessels, such as retinopathy, neuropathy, and
nephropathy (4). The quality of life in patients with diabetes often diminishes
over time as diabetic complications become disabling (5).

Appropriate management of diabetes can reduce and delay the sequelae of
this disease. Therapeutic interventions have been proven effective in
controlling blood glucose levels (6) and in the longer-term, preventing some
types of diabetes complications (7-9). Dietary changes and routine exercise
are fundamental interventions. Often , however, normalization of blood glucose
control can only be achieved through drug treatment (10).

In addition to resolving blood glucose instability in many patients , drug therapy
has been demonstrated to confer the added benefit of preventing some types
of diabetes complications. Results from two large trials have provided
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evidence that drug therapy can reduce the incidence of micro-vascular
disease in patients that are aggressively managed .

Researchers in the Diabetes Control and Complications Trial (DCCT) (9)
compared standard care with intensive drug treatment and monitoring
regimens in 1,441 type 1 diabetics during a ten-year period . In this study, the
risk of developing retinopathy, nephropathy, and neuropathy was reduced by
76%, 50%, and 60% respectively among diabetics receiving the intense
treatment. This finding led researchers to conclude that intensive drug therapy
"delays the onset and slows the progression" of these diseases .

The United Kingdom Prospective Diabetes Study (UKPDS) (7) investigated
whether intensive drug therapy reduced the incidence of diabetic
complications in type 2 diabetes . In this study, 3867 patients with newly
diagnosed disease were followed during a 10-year period . As in the DCCT,
researchers attempted to determine if intense treatment and monitoring would
reduce the incidence of diabetic complications. The results of the UKPDS
provided compelling evidence that drug therapy can reduce the incidence of
certain types of complications in patients with type 2 disease. Compared with
patients treated with conventional care , the risk for developing microvascular
complications in patients receiving intensive therapy was reduced by 25%.
Further, the risk of developing retinopathy was reduced by 21 %, while the risk
of developing microalbuminurea was reduced by 34%. The incidence of
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myocardial infarction was also lesser in the group treated intensively, though
the 16% difference observed between groups failed to achieve statistical
significance (p

=0.052).

These two trials provided strong evidence that tight control of blood glucose
can prevent the microvascular complications in patients with diabetes, and
may reduce the risk for macrovascular complications such as myocardial
infarction. Since the publication of these trials, standards for the treatment of
diabetes have incorporated tight blood glucose control as an objective of
therapy. Thus, drug treatment is aimed at maintaining normal blood glucose
throughout the day to obtain the benefits described in these trials.

Patient adherence to prescribed drug regimens is implicit to a strategy of tight
blood glucose control. When medications are not taken according to
instructions, optimal control of blood glucose will clearly be compromised .
This may be the case for many diabetic patients. Patient adherence with
prescribed medication regimens for chronic diseases is known to be suboptimal (11-13) (14), and patients with diabetes in particular are known to have
difficulty adhering to prescribed dietary, exercise, and drug therapies (15, 16).
Further complicating matters is the progressive nature of diabetes, as patients
generally experience a worsening of glycemic contro l over time. Therefore,
not only is adherence important in reducing the risk of diabetic complications,
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it is a fundamental component of active participation in therapy that continually
requires assessment of medication needs for sustaining glucose control.

Thus, both disease progression and poor adherence can cause inadequate
blood glucose control, and it is important to distinguish between the two. The
patient who is poorly controlled because his disease has progressed
potentially requires a different intervention than the patient who is poorly
controlled due to poor adherence. Increasing the dose of medication for the
patient in the latter scenario may result in a dangerous hypoglycemic reaction .

Our working hypothesis was that patients that do not adhere to prescribed
drug regimens are more likely to be poorly controlled; and such poor control
will be manifested as a change in medication dose or a change in medication
prescribed . To investigate this hypothesis, we assessed adherence with
sulfonylurea or metformin therapy using pharmacy claims data. We
determined whether patients that were nonadherent to prescribed therapy
were more likely to receive a change in dose or change in hypoglycemic drug
dispensed during subsequent months.
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METHODS

Identification of the study samples

We conducted a retrospective cohort study using prescription dispensing
information. Consumer Value Stores, Inc (CVS) provided pharmacy utilization
data used in this study. The data included over one-quarter million
dispensings to 5056 diabetic patients between April 1997 and May 1999.
Most patients included in this population were enrollees of one of two area
health plans, and participants in a special managed care program in diabetes
through these plans. Patients were restricted to designated CVS pharmacies
for pharmacy services. The data provided represented pharmacy utilization by
patients enrolled in these two health plans from the designated pharmacies .
The restriction to designated pharmacies was an advantageous feature,
potentially resulting in a more complete representation of pharmacy utilization .

Of the patients included in the total population, we identified those that
received any hypoglycemic medication during a 12-month observation period.
From this population, we identified patients receiving mono-therapy with a
sulfonylurea or mono-therapy with metformin during the first four months of
this 12-month period . Patients who received two or more different types of
hypoglycemic medication during this four-month period were excluded. Thus,
two samples were created: patients receiving monotherapy with sulfonylurea
and patients receiving monotherapy with metformin .
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Patients who did not receive the same strength of medication and same
number of tablets per day for all dispensings during the four-month period
were excluded from study. Thus, the two samples represented patients
receiving dispensings for either only a sulfonylurea or only metformin at the
same dose during the four-month period, and receiving at least one dispensing
of a hypoglycemic medication during the following eight months.

Determining change in dose or medication regimen

We assessed the influence of adherence for two main outcomes: change in
dose of sulfonylurea or metformin ; or change in hypoglycemic drug dispensed .
To determine change in dose, we compared the initial strength of medication
with additional subsequent dispensings during the following eight months.
Also , we identified patients receiving an increased quantity of the same
strength of medication (e .g. two tablets daily instead of one). To identify such
patients, we compared the number of tablets in the daily dose for all
dispensings. By dividing the quantity supplied by the days supply of
medication received, we were able to determine the number of tables
prescribed per day. Patients who received a different strength of a same
medication, or who were prescribed a different number of tablets per day
during the eight months following the four-month period were classified as
havi ng a change in dose of sulfonylurea or metformin .
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In addition to change in medication dose, we identified patients who received
a dispensing for a different type of hypoglycemic drug in the months following
the initial four-month period . The two outcomes were also used to create a
combined outcome of receiving a dispensing for either a different strength or
type of hypoglycemic medication.

Calculating the medication possession ratio
We used the medication possession ratio (MPR) as the measure of adherence
with prescribed hypoglycemic drug therapy. The MPR describes the number
of days that a patient was in possession of medication (17). To calculate the
MPR, we determined the total days supply of medication received for all
dispensings preceding the last dispensing of the four-month period . A ratio
was created using the days supply of medication received and the number of
days between the first and last dispensing during the four-month period . For
example, the MPR for a patient that received three dispensings of 30 tablets
each (90 tablets) during a period of 113 days would be 90: 113, or roughly
8:10. For the purposes of this research , medication possession for at least
80% of days (MPR <::8:10) was considered to be adherent. Other researchers
have used this threshold in studies of adherence to therapies for other chronic
conditions, such as hormone-replacement therapy (18); hypertension (19 , 20);
and depression (21 ). Patients who received only one dispensing during the
four-month period but who received medication in following months were
classified as non-adherent.
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A limitation of the MPR as used to assess adherence is the potential for
misclassification , since a patient may possess but not consume a medication .
Possession of medication has however, been considered a useful 'first-order'
measure of adherence (22), since patients must first possess medication
before they can adhere to therapy

Potential confounding variables

We also examined the effect of four other factors on change in dose of
hypoglycemic medication or change in type of hypoglycemic medication
prescribed . One such factor, the number of medications prescribed , was
thought to potentially be an important influence on medication possession and
change in hypoglycemic therapy. To approximate the number of medications
prescribed , we identified the total number of dispensings for any class of
medication during the four-month period; including medications for conditions
other than diabetes. Three categories of this variable were created: less than
5 dispensings, 5-15 dispensings, or more than 15 dispensings. We also
assessed the effect of patient age, and categorized this variable using
categories of less than 50 years of age, 50-65 years , and greater than 65
years of age. Stratifications for the total number of prescriptions dispensed
and patient age were based upon assessment of parametric form , as
described in the following section .
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The type of insurance used for prescription reimbursement was also included
as a potential confounder. We categorized insurance type as health plan A,
health plan B, or a third category that included all other insurance types and
cash. We also included gender as an additional potential confounding
variable.

Based on the methodology for variable identification described above and as
presented in figure 2, we determined the relative risk of a change in
medication dose, change in class of hypoglycemic medication prescribed, or a
combined outcome of either for patients having a medication possession ratio
less than 8:10, as compared to those having an MPR

~8:10.

Additionally, we

assessed the influence of four other variables : the total number of
prescriptions dispensed, age category, insurance type, and gender; attempting
to control for the effect of these variables where necessary.

Statistical methods

Univariate statistics were used to describe the frequency and percent of
monotherapy with a sulfonylurea or metformin. For each of the two samples,
we categorized patients by gender, age, insurance type, and the total number
of prescriptions dispensed. These characteristics were also presented as
frequencies and percentages. We also determined the frequency and percent
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of subjects having an MPR greater than 8:10 and 9:10 . For all analyses
involving the MPR, we used the lower threshold of :?:8: 10.

We assessed the parametric form of the two continuous variables: age and
total number of prescriptions dispensed. This was accomplished by logistically
modeling quartiles of the frequency distribution to assess linearity. For each
independent variable, models were created for each quartile of the variable's
frequency distribution and each dependent variable. The resulting parameter
estimates were exponentiated and plotted to determine if a linear trend was
present. Non-linear relationships suggested the need for stratification of each
continuous variable for inclusion in multivariate logistic models.

Bivariate analyses were used to assess the relationship between the MPR and
other independent variables , and between independent and dependent
variables. Chi square analyses were used to assess the relation between the
medication possession ratio and the potential confounding variables. We also
used chi-square analyses to examine the relation between all independent
variables and the outcomes of change in dose and change in medication
dispensed . For each independent variable, bivariate logistic regression was
used to determine the relation between variable and change in dose and
change in medication dispensed. These results were presented as an odds
ratio with 95% confidence intervals.
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Multivariate statistics were used to identify the presence of collinearity
between independent variables, to determine the presence of interactions
between independent variables, and to assess the influence of the MPR on
outcome variables when other potential confounding variables were included.

Collinearity diagnostics were performed using the PROC REG procedure for
multiple regression as suggested by Allison (23). Collinearity was assessed
for all independent variables in separate models with dependent variables
change in dose, change in medication dispensed , and the combined outcome
of change in either. Presence of collinearity was determined using thresholds
for condition index and proportion of variance shared as described by
Tabachnick and Fidell (24).

Test for interaction between variables was performed using the chunk test for
multivariate logistic models as described by Kleinbaum (25). For this
procedure, we calculated the difference in the -21og statistic between full and
reduced models. Full models included all possible interaction and single
terms: Reduced models included single terms (variables) only. The difference
in -21og statistic between full and reduced models was tested for significance
using the Chi-square distribution , with degrees of freedom equal to the
difference in terms between the two models. A difference in -21og value that
was less than the X 2 statistic indicated that an interaction was not present.

65

Final multivariate logistic models contained only variables with significant
terms, or a significant strata . Initial models contained all independent
variables. Least significant terms were removed in order (backward
elimination), observing the effect of change in the parameter estimate beta
and confidence interval for each variable eliminated . Terms were excluded
from the model if they were non-significant contributors and if their removal
resulted in small or no change in the parameter estimate for the MPR. In
models where it was not a significant influence on the outcome variable, the
MPR variable was removed from the model , and the influence of other
significant terms was assessed .
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RESULTS

Table 1 presents the gender, age category, insurance type, and total number
of prescriptions dispensed for patients in the sulfonylurea and metformin
samples. Nearly six times as many patients received sulfonylurea
monotherapy than metformin monotherapy (967 versus 166). Also, a greater
percentage of males received sulfonylurea monotherapy, yet the percent of
males and females that received monotherapy with metformin was similar.
The age stratifications presented reflect the parametric form of this variable.
Nearly half of all patients in both samples were between 50-65 years of age.
A notable disparity was the higher percentage of patients in youngest age
strata among metformin users, as compared with subjects in the sulfonylurea
sample. Conversely, the sulfonylurea sample included a greater percentage
of patients 65 years of age or older as compared with the metformin sample.

In both the sulfonylurea and metformin samples , nearly 90% of patients were
covered by one of the two predominant insurance plans. The remainder of
patients used other insurance plans for prescription payment, or paid cash.
Percentages of categories of insurance type were similar for the sulfonylurea
and metformin samples.

More than half of patients were categorized as receiving a total of 5-15
prescriptions during the four-month period, a strata that represented the
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second and third quartiles of the distribution of this variable . We chose to
combine these quartiles due to a similar relationship between each quartile
and the outcome variables. However, the first and fourth quartile of the
frequency distribution of this variable differed from the second and third
quartile in relation to the dependent variables, necessitating the three levels
created .

Table 2 presents the results of univariate analysis of the medication
possession ratio. The percentage of patients possessing medication for at
least 80% of days during the time period was 77.2% and 71 .1% for the
sulfonylurea and metformin samples respectively. The percentage of patients
possessing medication for at least 90% of days was 66.8% for the sulfonylurea
monotherapy sample , and 56.6% for those dispensed only metformin . The
average percentage of days medication was possessed was similar (91 % for
patients receiving only sulfonylurea; 86.6% for patients receiving only
metformin). This percentage is highly skewed, with some patients receiving
quantities of medication that were greater than the quantity required to cover
100% of days between dispensings.

Table 3 presents the relation between the potential confound ing variables and
the medication possession ratio . The percentage of patients having an MPR <
8:10 did not differ significantly by gender or insurance type among patients
receiving either dispensings for a sulfonylurea or metformin . Among
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sulfonylurea users, patients in the youngest age category were more
frequently identified as having an MPR less than 8:10 (age under 50: 33.19%;
age 50-64 : 19.46%; Age 65+: 15.59%; p < 0.01 ). Similar percentage
distributions were observed for metformin users, though the ability to detect a
statistically significant difference was likely influenced by the smaller number
of patients in this sample. Patients receiving less than five total dispensings
during the first four months of the 12-month period were also more frequently
categorized as having an MPR less than 8:10. Subjects receiving greater than
15 dispensings were least frequently categorized as having an MPR < 8: 10.
These differences were statistically significant among patients in the
sulfonylurea sample (p < 0.01 ).

Tables 4a and 4b present the comparisons of proportions of patients having
an MPR < 8:1O and the potential confound ing variables with change of dose,
change in medication dispensed , or the combined outcome of either. More
than twice as many patients were identified as having a change in dose of
hypoglycemic medication as compared with a change in type of drug
dispensed (Sulfonylurea sample: change in dose : 58 .53%, change in regimen :
26.78%, Metformin sample: change in dose: 48.19%; change in drug
dispensed : 18.07%).

Males and females in the sulfonylurea group were roughly equally likely to
experience a change in dose or change in drug dispensed , though the
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percentage of metformin patients that experienced a change in drug was nonsignificantly higher among males (change in dose: sulfonylurea, males versus
females: 59.01 % v 59.35%; change in dose: metformin , males versus females:
53.75% v 48.84%. change in drug: sulfonylurea, males versus females:
25.70% v 28.35%; change in drug: metformin, males versus females: 22.35%
v 13.58%). In both the sulfonylurea and metformin samples, younger patients
were more frequently identified as having a change in dose or drug dispensed
(change in sulfonylurea dose, age less than 50 versus age 65 years or older:
65.94% v 52.36%; change in metformin dose, age less than 50 versus age 65
years or older: 54.55% v 40.00%; change in drug among sulfonylurea users,
age less than 50 versus age 65 years or older: 29.26% v 17.57%; change in
drug among metformin users, age less than 50 versus age 65 years or older:
23.64% v 20.00%). These differences were only statistically significant in the
sulfonylurea sample (p < 0.01 ). No statistically significant differences were
observed between changes in medication dose or regimen and health plan or
number of prescription dispensings. Patients in both samples having an MPR
of less than 8:10 experienced a dose change more frequently (sulfonylurea:
MPR < 8:10: 25.62%; MPR
MPR

~8 : 10:

MPR

~8:10

~8:10 :

18.70%, metformin: MPR < 8:10: 32.50%,

25.58%) This difference between values for MPR < 8:10 and
was nearly equal for both the sulfonylurea and metformin groups.

Howeve r, the difference between groups was only statistically significant in the
sulfonylurea group (p < 0.05), likely reflecting the fewer number of patients in
the metformin sample. The proportion of patients having an MPR < 8:10 did
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not differ significantly among those with a change in hypoglycemic drug
dispensed for each sample (sulfonylurea: MPR < 8:10: 23.55%; MPR
22.46%, metformin: MPR < 8:10: 30.00%, MPR

~8:10:

~8 : 10:

28.68).

Bivariate and multivariate logistic regression models were also used to
examine the relation between independent and dependent variables. These
results are presented for the sulfonylurea and metformin samples, in analyses
of the relation between each variable and the outcomes of change in
medication dose (tables 5a, 5b) or change in drug dispensed (tables 6a, 6b).
For the sulfonylurea sample, patients experiencing a change of dose were
50% more likely to be categorized as having an MPR < 8:10 (OR 1.50; 95% Cl
1.09- 2.05, p

=0.0118).

The MPR was not statistically significantly

associated with a change in medication dispensed among sulfonylurea users,
or with a change of dose or medication dispensed among metformin users.
Sulfonylurea patients 65 years of age and older were 43% less likely to
experience a dose change (OR 0.57 , 95% Cl 0.40 - 0.81, p =0.0018). Male
gender, insurance type, and the total number of dispensings were not found to
be significant influences on change in dose or of change in drug dispensed in
either sample.
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Multivariate results

We assessed the influence of the MPR on three outcomes: change in dose,
change in drug dispensed , and the combined outcome of change in dose or
drug dispensed. We examined the effect of MPR on these outcomes for three
populations: patients dispensed sulfonylureas , patients dispensed metformin ,
and a combined sample of patients dispensed either monotherapy with a
sulfonylurea or monotherapy with metformin . In sum, nine multivariate models
were created to assess these relationships .

For each of these nine models , we assessed collinearity and interaction
between variables. Collinearity between independent variables was not
detected at condition indices above the threshold of 30. However, collinearity
diagnostics indicated a high degree of shared variance between the number of
prescriptions dispensed and age. Interaction between the MPR and other
independent variables was assessed using the chunk test described by
Kleinbaum. We did not detect a significant interaction between any
combination of independent variables , as determined by comparing the
difference in -21og statistic between full and reduced models with a chi-square
value. These results are presented in table 7.

Tables 8a-c, 9a-c, and 1 Oa-c present the multivariate results of the nine
models . In these tables we have presented the resu lts of models that include
all independent variables in the logistic regression , followed by a final model
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containing only significant terms. For models having no significant terms, only
the model containing all independent variables is presented .

Tables 8a , 8b, and 8c present the multivariate results from the sulfonylurea
sample for outcomes of change in dose, change in medication dispensed , and
the combined outcome of change in dose, respectively . Table 8a presents the
results for the outcome of change in dose. In a model containing all
independent variables, the risk associated with a dose change was 42%
greater among those having an MPR < 8:10 . We removed from this model the
non-significant terms gender, insurance type, and total number of dispensings.
The resulting final model included only age and MPR < 8:10. Based on this
model, patients that were 65 years of age or older were significantly less likely
to experience a change in dose of sulfonylurea (OR 0.60; 95% Cl 0.41 - 0.85).
Age was also a significant influence in models for the outcome of change in
medication dispensed in the sulfonylurea sample. Patients 65 years of age or
older were less likely to be included among those with a change in type of
medication dispensed (OR 0.51; 95% Cl 0.34 - 0.78). Neither the MPR nor
any other independent variable was significantly associated with a change in
drug dispensed in the sulfonylurea sample.

Outcomes were combined to create a category of patients that included
patients having either a change in dose or change in medication dispensed.
For this combined outcome, the MPR and older age we re both associated with
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the risk of change in dose or medication dispensed; with MPR < 8:10
increasing the risk of this outcome by 50 % (OR 1.50; 95% Cl 1.08 - 2.08) and
an age of 65 years or greater decreasing the risk of this outcome by 38% (OR
0.62; 95% Cl 0.43 - 0.89).

Based upon the results of the multivariate logistic models for the metformin
sample (Tables 9a-c), none of the independent variables was a significant
influence of change in dose, change in medication dispensed, or the combined
outcome of either. The lack of significant predictors in the metformin sample
was potentially a result of sample size. We created a third sample of patients
by combining the sulfonylurea and metformin populations. As in the models
for the sulfonylurea sample, the MPR and age 65 years or older were
significant influences of change in medication dose in the sample of combined
patients (MPR < 8:10: OR 1.38; 95% Cl 1.04 - 1.84 , Age 65 or older OR 0.62 ,
95% Cl 0.45 - 0.87). The oldest age group was the only variable with
statistically significant influence in the model for change in medication
dispensed in the combined sample (OR 0.55; 95% Cl 0.38 - 0.81 ). Last,
using a population that included both the sulfonylurea and metformin samples,
the MPR and older age were significantly associated with the combined
outcome of change in dose or change in medication dispensed . The results of
models using the combined sample of patients are presented in tables 1Oa-c.
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DISCUSSION
Adherence to prescribed drug regimens is a common problem in patients with
chronic diseases. Adherence to prescribed drug regimens in patients with
diabetes is particularly important, since tight control of blood glucose has been
demonstrated to reduce the incidence of many types of diabetes
complications. Nevertheless, non-adherence to hypoglycemic therapy has
been identified as a major barrier to effective management of diabetes. Lack
of adherence with prescribed hypoglycemic medications has been correlated
with diminished blood glucose control (26-28), which in turn can result in
adverse health outcomes, both in the long and short-term.

Much research has been conducted investigating the cause for lack of
adherence to drug therapy. Immediate barriers to adherence include the cost
of medication, access to medication , and the complexity of the drug regimen .
Beyond these barriers, determinants of adherence are more complex, and
include physiologic, cognitive, behavioral , and environmental factors (29). For
example, the health belief model has been reported to predict adherence to
drug therapy (30).

According to the health belief model, adherence will be improved when
patients perceive their disease to pose a threat to their health, and believe that
prescribed medications will be effective in decreasing the risk of morbidity. In
one study, knowledge about hypoglycemic medications among diabetic
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patients in the UK was found to be poor, with only 35% of patients recalling
receiving any information about their hypoglycemic medication (31 ). One in
five patients surveyed in this study reported missing at least one dose of their
hypoglycemic medication per week. The lack of knowledge of hypoglycemic
drug therapy was perhaps a contributing factor resulting in the poor adherence
rates observed , according to the principles of the health belief model.

Other explanatory paradigms for predicting and understanding the behavior of
adherence include self-efficacy theory (32), the transtheoretical (stages of
change) model (33), and social learning theory (34). Each of these involves
patients taking active control of the disease management process, including
understanding the need for adherence to recommended therapies.

Lack of adherence to hypoglycemic medications is a recognized , though
perhaps under-appreciated problem. For example, Ward found that
physicians may tend to over-estimate patients' adherence to prescribed
medications (35). Yet the evidence continues to accumulate. Numerous
studies of various methodology have demonstrated that drug treatments for
chronic conditions are often not taken as prescribed (36, 37). Clearly this is an
area of pharmacotherapy that deserves heightened focus .

In this study, we attempted to demonstrate that lack of adherence to
prescribed hypoglycemic medication increases the likelihood that prescribed
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therapies will change. We assumed that a change in medication dosage or a
change drug type was an action in response to poor blood glucose control.
Appropriate interventions for patients who are non-adherent to therapy would
logically involve efforts intended to improve adherence. Increasing the
amount of medication prescribed to a non-adherent diabetic patient is a
potentially inappropriate intervention. Such a response may also be
dangerous, resulting in increased risk of hypoglycemia (38) and longer-term
complications resulting from continued poor glucose control.

In this study, the medication possession ratio was used to assess adherence.
Also included in analyses were four other factors that were considered to be
possibly associated with the MPR or related to the outcomes of change in
medication dose or change in type of hypoglycemic medication dispensed .
The age and gender of the patient were two of these factors. According to
various studies, the relation between adherence and these two factors is
unclear. For example, some studies have shown age and gender to be
influences on adherence (39-40), though others have not (41-42). In one
study of adherence with sulfonylurea therapy, age and gender were found to
be statistically significant influences on drug regimen adherence (43) . In our
study, we also included insurance type as a potential factor of influence.
Though we had no knowledge of details regarding co-payment structures or
formulary systems, we thought that attributes of the benefit design may have
had an impact on adherence or change in dose or type of drug dispensed . The
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total number of medications dispensed was the fourth of the other
independent variables included in our study. We included this factor based
upon research suggesting that adherence may be associated with the number
of medications prescribed.

As determined by the medication possession ratio, adherence to drug therapy
was poor among patients in both the sulfonylurea and metformin samples.
Only 77% of patients in the sulfonylurea sample possessed enough mediation
to cover at least 8 of 10 days during the four-month period . The percentage of
patients receiving enough of their sulfonylurea medication to cover 9 of 10
days in the period was 67%. In the metformin sample, a lower percentage of
patients possessed medication for each threshold. Of these patients, 71 %
received enough metformin to cover at least 8of10 days in the period, and
57% of patients possessed medication for 9 of 1O days. In summary, roughly
one in four patients dispensed sulfonylureas did not possess enough
medication to cover eighty percent of days during the four month period; and
approximately one in three did not receive enough medication for ninety
percent of days. Those receiving metformin monotherapy were less frequently
in possession of medication .

The finding that patients do not regularly obtain hypoglycemic medication is
not unexpected. In their investigation of compliance with sulfonylureas during
a two-year time period, Venturini et al (44) reported a mean compliance rate of
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83%: On average, patients did not possess medication for nearly one in five
days. In a study using Medicaid pharmacy data , Sclar et al (43) found
adherence with sulfonylurea therapy to be very low, with only 39% of patients
receiving at least a six-month supply of medication during a period of 12 or
more months.

Of the four potential confounding variables used in this study, only age and the
total number of dispensings were significantly associated with the MPR. The
percentage of patients having an MPR < 8:10 did not differ statistically
significantly by gender or insurance type. Patients 65 years of age and older
were more frequently in possession of medication for greater than 80% of
days; patients under 50 years of age were least frequently is possession of
medication for at least 80% of days. This difference was not statistically
significant in the metformin sample, though sample size may have affected the
ability to detect a significant difference. The finding that older patients were
more frequently categorized as adherent may perhaps be explained as a
greater concern among older patients for the protection of health, with a
corresponding adherence with prescribed medications.

It was interesting that a greater number of prescriptions dispensed was more
frequently associated with possession of medication for at least 80% of days.
This finding may also be related to concerns for maintaining heath . Patients
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receiving more medications are presumably less healthy, and perhaps more
likely to take medications as prescribed .

Multivariate analyses : Change in dose of hypoglycemic medication

A change in dose of sulfonylurea or metformin was more than twice as
frequently observed than a change in type of hypoglycemic medication
dispensed . Diabetes is a progressive disorder, and even patients that adhere
to therapy will require increased amounts of medication over time. In both the
sulfonylurea and metformin samples, the youngest of the three age groups
most frequently changed dose or type of drug dispensed , and the oldest age
group least frequently experienced a change dose or type of drug dispensed.
A possible explanation for the less frequent changes in drug dose among in
older patients is that perhaps these patients are receiving a maximum dose of
medication, a result of having diabetes for a longer duration . Betz-Brown et al.
found that prescribers may tend to continue sulfonylurea therapies despite
evidence that these agents are failing (45). The less frequent change in type of
drug prescribed among older patients may be the result of avoidance of newer
medications in older patients. For instance, troglitazone may have been
avoided in older patients due to concerns of increased risk of hepatic toxicity in
such patients . Another possible explanation for the more frequent changes in
dose or type of drug dispensed in younger diabetics is increased attention to
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achieving tight glucose control in younger patients, since these patients have a
greater number of yea rs in which to develop diabetic complications.

Both in bivariate and multivariate analyses that included other potential
confounding variables, an MPR < 8:10 was found to be an influence on the
outcomes of change of sulfonylurea dose. An MPR < 8: 1O increased the risk
of experiencing a change in dose by 50% in a bivariate model , and by 43%
when controlling for patient age. Of patients in the metformin sample, those
having an MPR < 8:10 were 40% more likely to experience a change in
medication dose. However, this finding was not statistically significant,
perhaps due to the smaller number of patients in this sample. Using a
population that included patients from both the sulfonylurea and metformin
samples, multivariate analyses demonstrated that an MPR < 8:10 was
associated with an increased risk for experiencing a change in medication
dose (OR 1.36; 95% Cl 1.02 - 1.83).

Of all patients included in this study, those who did not possess enough
medication to be adherent for at least 80% of days were 36% more likely to be
prescribed an increased amount of medication. This percentage increased to
43% in analyses that included only those prescribed sulfonylurea
monotherapy. The implications of this finding are uncertain. However, it is
likely that the prescribing of a greater amount of sulfonylurea drug may place
poorly adherent patients at an increased risk for hypog lycemic events.
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Perhaps most importantly, a change in dose of hypoglycemic medication
cannot be expected to induce an improvement in blood glucose control in
patients that are non-adherent. Such patients may likely continue to be poorly
controlled, and be at greater risk for diabetic complications.

Multivariate analyses: Change in type of hypoglycemic medication
dispensed

Among patients in the sulfonylurea sample, only age was found to be
significantly associated with experiencing a change in medication dispensed .
Patients 65 years of age and older were 48% less likely to receive a different
type of hypoglycemic medication than those under 50 years of age. In the
metformin sample, age was not a significant influence on experiencing a
change in type of drug dispensed . We examined the effect of age in a
population that included patients from both the sulfonylurea and metformin
samples. In this population , older age was again found to be an influence on
change in type of drug dispensed . Patients 65 years of age or older were 45%
less likely to experience a change in type of medication dispensed . The lesser
frequency of change in type of medication dispensed among older patients
may reflect an increased prevalence of co-morbidities within this age group.
For example, many patients experiencing secondary failure of sulfonylurea
therapy can regain blood glucose control through the addition of metformin .
However, metformin is contraindicated in patients with heart failure or renal
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disease. Additionally, patients with hepatic dysfunction would not be
appropriate candidates for troglitazone therapy; which was commonly
prescribed during the study period .

For the combined population that included those in the sulfonylurea and
metformin samples, we also conducted multivariate analyses assessing the
influence of the MPR on the combined outcome of either a change in dose or
change in type of medication dispensed . In these models, an MPR < 8:10 was
found to be of significant influence, increasing the risk of the combined
outcome by 41 % in a model that controlled for age. However, this result
should be interpreted with caution . Though an MPR < 8:10 increased risk for
a change in dose or change in type of drug dispensed, a direct influence of the
MPR on change in type of drug dispensed was not detected in separate
analyses. Thus, the influence of the MPR on the combined outcome appears
to be largely due to the relation between the MPR and the outcome of change
in dose.

We did not find gender, insurance type , or the total number of prescriptions
dispensed to be associated with change in dose, change in drug dispensed , or
a combined outcome of either change in dose or change in drug dispensed.
Thus, we did not include these factors in final multivariate logistic models.
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This study was conducted solely through the use of pharmacy claims data.
Such data is useful for assessing adherence with drug therapy (46), though
the use of multiple pharmacies may contribute to misclassification when
dispensings of medication are not captured. An advantageous feature of these
data was that patients were assigned to the pharmacies from which the data
was generated . Thus , misclassification of non-adherence may have been
minimized since patients were not reimbursed for prescriptions dispensed by
other pharmacies. The large number of records available for review is also a
strength of this study. We identified 967 patients receiving therapy with a
sulfonylurea which were eligible for inclusion for study. Though the number of
patients receiving metformin monotherapy was less, we felt it useful to include
this population for comparison with the sulfonylurea group, since this drug is
also frequently prescribed .

There were several important limitations to this study. Perhaps most
importantly, this study evaluated a small number of potential influences of a
change in dose or change in type of hypoglycemic medication dispensed . The
factor of interest was medication possession , which has been used by various
researchers to classify adherence. However, medication possession is only
one of several potential determinants of medication adherence. Patients may
possess medications yet take them incorrectly or sporadically. Certainly
howeve r, patients must possess medication in order to take them as
prescribed . Thus, the medication possession ratio represents a potentially

84

useful 'first order' measure of medication adherence . However, the impact of
various behavioral, clinical , social , and demographic factors on adherence was
not assessed .

The method used for determination of the medication possession ratio may
have also been a limitation . We chose to limit the sample to patients that had
received at least 12 months of hypoglycemic therapy. To allow sufficient time
to determine if a dose of medication changed or a new type of drug was
prescribed following a period of stability, we used only a four-month period to
calculate the MPR. It is possible that a longer period would have resulted in a
different percent of patients classified as having an MPR < 8:1O; and such
difference may have generated different results. Adherence assessments in
diabetes have used longer periods than we have used in this study (22, 43,
44). Additionally, a minimum MPR threshold of 8:10 may have been to low for
classifying adherence in this population. A higher threshold may have been
more appropriate in consideration of the degree of adherence necessary to
achieve tight glycemic control.

Also , we may have been incorrect in our assumption that a change in dose or
a change in type of medication dispensed reflected unstable glucose control.
For instance, some patients identified as experiencing a change in dose of
hypoglycemic medication may have been new diabetics being titrated to their
medication . Also, factors such as allergies or intolerances may have been a
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cause for change in medication type dispensed , and not necessarily poor
blood glucose control. However, it seems improbable that new diabetics
accounted for the majority of the 59% of patients in the sulfonylurea sample
and the 48% of patients in the metformin sample that were identified as having
a change in dose. Likewise, allergy or intolerance to a medication would
presumably not account for the majority of the 27% of sulfonylurea users that
were dispensed a different type of hypoglycemic medication, especially given
the high degree of tolerance ascribed to sulfonylureas (47). However,
metformin may cause side effects such as abdominal discomfort and diarrhea
in as many as 30% of patients (48). It is possible that a proportion of
metformin users who received a different type hypoglycemic medication were
intolerant of metformin, and not necessarily poorly controlled. However, the
number of such patients is likely to be small , since metformin intolerance
usually appears early in therapy. Study patients received at least four months
of therapy without a change in dose or drug.

The lack of availability of other data sources was also limiting. Medical data
would have been useful for categorizing disease severity and duration, and for
identifying relevant co-morbidities. For example, medical information would
have been of use in determining if duration of disease was a contributing
factor to the difference in frequency of dose change and change in type of
drug dispensed among age groups. Laboratory data would have been useful
in determining blood glucose control and its correlation with adherence to drug
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therapy. Such information could have been used to validate the conceptual
model presented in Figure 1. Last, information regarding prescription copayment would have been of use, given evidence that acquisition costs affect
medication purchase.

Despite these limitations, we feel that this study provides evidence to support
the hypothesis that poor adherence leads to greater instability; in this case
manifested as a change in medication dosage, or in the combined outcome of
change in medication dose or type of medication dispensed.

Lack of adherence to prescribed drug therapy is an acknowledged problem.
This problem can be complicated by a patient's lack of awareness of an
adherence problem, or a lack of truthfulness in describing medication-taking
behavior to the physician (49). The result of poor adherence with therapies for
controlling blood glucose can have adverse consequences. Prescribers that
increase the amount of medication prescribed to a poorly adherent diabetic
patient may cause great risk of inducing dangerous hypoglycemic reactions.
Further, the incidence of microvascular, and perhaps macrovascular
complications will be increased in patients with adherence problems and
corresponding poor glucose control.
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CONCLUSION

Non-adherence with prescribed sulfonylurea regimens , as measured by
possession of medication less than 80 percent of days, increases the
likelihood that prescribed hypoglycemic therapy will be changed by 43 to 50%.
Such change in therapy, presumably a response to poor blood glucose
control , fails to address the underlying cause of poor glucose control, and may
potentially cause dangerous hypoglycemic reactions. Increased awareness of
non-adherence with prescribed medications as a cause of inadequate blood
glucose control is necessary. Further, interventions aimed at improving
adherence should be increasingly examined as a potential effective means to
improve diabetes care.
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Figure 1. Conceptual Model : Non-adherence, Poor Glucose Control , and
Drug Therapy

Patient
poorly
adherent to
prescribed
medication s

-

MD concerned
about poor
blood glucose
control poor,
HbA1c above
goal

-

Patient
overestimates
adherence to
prescribed
medications or

non-truthful

-

Prescriber
increases
dose of
hypoglycemic
medication or

adds
additional
~nt

...

Outcomes
Increased risk for hypoglycemic events
Unrecognized adherence problems
Poor glucose control likely to continue;
increased risk for short and long term
complications
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Figure 2. Research Methodology: Identification of Users of Sulfonylurea
or Metformin Mono-therapy and Determination of Non-adherence

Data : 5056
patients receiving
hypoglycemic
drugs from retail
pharmacies

Did
patient receive
hypoglycemic medication
for at least a 12 month

Did
patient receive
only dispensings for
a sulfonylurea or metformin
during the first 120
days of the 12
-month period?

NO

NO

8
8

YES
Was
the dose
of sulfonylurea

NO

or metformin the same
during the first 120 days
of the 12-month
period?

8

YES
Patients in sample

Determine the number of days between the first and last dispensing of sulfonylurea
or metformin during the 120-day period (A).

Determine the days supply of medication received for all dispensings
preceding the last dispensing of the 120-day period (B)

Calculate the Medication Possession Ratio (MPR):
MPR= B: A

Research questions:
Is MPR < 8:10 associated with a dose change in the 8 months following first 120 days?
Is MPR < 8:10 associated with a medication change in the 8 months following first 120 days?
Is MPR < 8:10 associated with a dose change or a medication change in the 8 months following first 120
days?
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Table 1. Univariate Analyses: Patients Receiving Sulfonylurea or
Metformin Mono-Therapy

Sulfonylurea (N = 967)

Metformin (N = 166)

n

%

n

%

Gender
Male
Female

572
395

59.2
40.8

85
81

51.2
48 .8

Age
under50
50-64
65 or older

229
442
296

23 .7
45.7
30.6

55
81
30

33.1
48.8
18.1

Insurance
Plan A
Plan B
Other

315
527
125

32.6
54.5
12.9

53
95
18

32.0
57.2
10.8

Number of Rx
Dispensed
under5
5-15
over15

151
550
266

15.6
56.9
27 .5

31
95
40

18.7
57.2
24.1
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Table 2. Medication Possession Among Patients Dispensed Only a
Sulfonylurea or Only Metformin

Sulfonylurea (N

=967)

Metformin (N

=166)

n

%

n

%

747
646

77.2

118

66.8

94

71 .1
56 .6

Medication
Possession
Ratio (MPR)
~8:10
~9:10

Mean MPR

91.0

92

86.6

Table 3: Bivariate Analyses: Medication Possession Ratio (MPR) and
Gender, Age Category, Insurance Type, and Number of Prescriptions
Dispensed

MPR < 8:10
Sulfonylurea users
n =967
%

MPR < 8:10
Metformin users
n = 166
%

All subjects

22.75

28.92

Gender
Male
Female

22.72
22.78

29.41
28.40

33.19**
19.46**
19.59**

36.36
27.16
20.00

24.80
20.95
23.34

33.33
32.08
26.32

41 .72**
22.00··
13.53**

45.16
26.32
22.50

Age
Under 50
50-64
65 or older
Insurance
Plan A
Plan B
Other
Number of Rx dispensed
<5
5-15
> 15

.

p < 0.05,
•• p < 0.01,

x2
x,
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Table 4a. Bivariate Analyses of Proportions: Sulfonylurea Sample

Change of
Dose
%

Change of
Drug
%

Change of
Drug
or Dose
%

All subjects
(N =967)

58.53

26.78

62.67

Gender
Male
Female

59.01
59.35

25.70
28.35

62.59
62.78

65.94**
58 .82
52.36 ..

29.26 ..
31 .67 ..
17.57..

69.43*
62 .90
57.09*

Insurance
Plan A
Plan B
Other

62.40
55.87
59.20

24 .00
24 .13
29 .03

68 .00
59.05
63.57

Number of Rx
dispensed
<5
5-15
>15

64.24
56.36
59.77

29.80
25.27
28.20

69 .54
60.18
63.91

Medication
Possession
Ratio
< 8:10
< 9:10

25.62*
18.70*

23.55
22.46

70.45..
60 .37 ..

Age
Under 50
50-64
65 or older

.

p < 0.05
•• p < 0.01
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Table 4b. Bivariate Analyses of Proportions: Metformin

=166
Change of
Dose
%

Change of
Drug
%

Change
of Drug
or Dose
%

All subjects
(N = 166)

48.19

18.07

51 .81

Gender
Male
Female

53.75
48.84

22.35
13.58

55.29
48 .15

Age
Under 50
50-64
65 or older

54.55
46.91
40.00

23.64
13.58
20.00

58 .18
49.38
46.67

Insurance
Plan A
Plan B
Other

38.89
50.94
48.42

11 .11
18.87
18.95

38.89
56.60
51 .58

Number of Rx
dispensed
<5
5-15
>15

58.06
45.26
47.50

16.13
17.89
20.00

61.29
47 .37
55.00

Medication
Possession
Ratio
< 8:10
< 9:10

32 .50
25.58

30 .00
28.68

56 .25
50.00

n

No significant differences among proportions
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Table Sa. Bivariate Logistic Regression Analysis, Sulfonylurea Sample:
Dose Change

[),

OR

Cl low

Cl high

Pr > X2

MPR < 8:10

.404

1.497

1.094

2.049

.0118

Age
Under 50*
50-65
65 +

-.304
-.566

1.0
.738
.568

.529
.398

1.029
.811

.0733
.0018

Male gender

-.141

.986

.760

1.293

.9154

Number of
dispensings
<5
5-15
> 15

-.330
-.190

1.0
.719
.827

.495
.547

1.044
1.251

.8310
.3684

Insurance
Plan A
Plan B
Other insurance

.137
.271

1.0
1.146
1.314

.864
.857

1.520
2.004

.3436
.2119
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Table Sb. Bivariate Analyses of Metformin Sample: Change in Dose

r.,

OR

Cl low

Cl high

Pr > X 2

MPR< .80

.337

1.401

.714

2.747

.3268

Age
Under 50*
50-65
65 +

-.306
-.588

.736
.556

.370
.225

1.464
1.370

.3828
.2020

Male gender

.197

1.218

.662

2.240

.5271

Number of
Dispensings
<5
5-15
> 15

-.516
-.426

1.0
.597
.653

.263
.254

1.356
1.682

.2178
.3778

Insurance
Plan A
Plan B
Other insurance

-.101
-.490

1.0
.904
.6 13

.462
.206

1.771
1.823

.7686
.3785
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Table 6a. Bivariate Analyses of Sulfonylurea Sample: Change in Drug
Dispensed

I).

OR

Cl low

Cl high

Pr> X 2

MPR < 8:10

0.062

1.064

.759

1.490

.7192

Age
Under 50*
50-65
65 +

.114
-.663

1.0
1.121
.515

.791
.341

1.588
.779

.5206
.0017

Male gender

-.135

.874

.655

1.166

.3596

Number of
dispensings
<5
5-15
> 15

-.227
-.078

.797
.925

.535
.596

1.186
1.435

.2632
.7278

Insurance
Plan A
Plan B
Other insurance

.252
-.007

1.0
1.286
.993

.935
.612

1.771
1.613

.1221
.9776

98

Table 6b. Bivariate Analyses of Metformin Sample: Change in Drug
Dispensed

f),

OR

Cl low

Cl high

Pr >

MPR < 8:10

.064

1.066

.449

2.531

.8849

Age
Under 50*
50-65
65 +

-.678
-.2 14

1.0
.508
.808

.209
.272

1.236
2.401

.1352
.7009

Male gender

.605

1.832

.811

4.139

.1 455

Number of
dispensings
<5
5-15
> 15

.125
.262

1.0
1.133
1.300

.380
.379

3.376
4.454

.8222
.6762

Insurance
Plan A
Plan B
Other insurance

.005
-.622

1.0
1.005
0.538

.426
.106

2.372
2.724

.9906
.4534
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Table 7: Chunk Test for Interactions

-21og statistic
DV
Dose Change

SFU

Drug Change
Dose or
Drug Change
Dose Change

MET

Drug Change
Dose or
Drug Change
Dose Change

SFU

Drug Change

or
MET
Dose or

Drug Change

EV + V's•
v ·s•
EV + V's•
V's•
EV+ V's•
V's•
EV + V's•
v·s·
EV + V's•
V's•
EV + V's•
V's•
EV+ V's•
V's•
EV+ v·s·

1288.97
1293.35
1094.38
1099.1 0
1252.29
1256.71
213.28
223 .98
145.23
150.50
213.54
221.79
1520.58
1529.19
1260.95

v·s•
EV + V's•
V's only•

1267.154
1487.08
1494.36

-21og
difference

x2 dr=1:

4.38

NS

4.73

NS

14.07

4.42

NS

10.70

NS

5.27

NS

8.24

NS

8.62

NS

6.20

NS

7.28

NS

SFU = sulfonylurea sample
MET = metformin sample
• EV= Interaction terms; V =Lower order terms (independent variables)
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Table Ba. Multivariate Logistic Models of Sulfonylurea Sample: Change in
Dose
All Independent Variables
Beta

OR

se

Cl low

Cl High

Pr >X2

MPR < 8:10

0.3485

1.4169

0.1655

1.0244

1.9599

0.0353

Age
under50
50-64
65+

-0.2529
-0.5283

1.0
0.7765
0.5896

0.1735
0.1855

0.5527
0.4099

1.0911
0.8481

0.1449
0.0044

Male Gender

-0.0039

0.9961

0.1356

0.7636

1.2994

0.977

Insurance
Plan A
Plan B
Other

0.1121
0.2584

1.0
1.1186
1.2949

0.1457
0.2196

0.8407
0.8420

1.4884
1.9914

0.4416
0.2393

Total
Dispensings
0-4
5-15
16+

-0.2086
0.0055

1.0
0.8117
1.0056

0.1960
0.2214

0.5528
0.6516

1.1919
1.5519

0.2871
0.9801

Beta

OR

se

Cl low

Cl High

Pr>X2

MPR < 8:10

0.3569

1.4289

0.1622

1.0398

1.9637

0.0277

Age
under50
50-64
65+

-0 .2575
-0.5212

1.0
0.7730
0.5938

0.1713
0.1831

0.5525
0.4148

1.0814
0.8502

0.1328
0.0044

Final Model
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Table 8b. Multivariate Logistic Models of Sulfonylurea Sample: Change
in Drug Dispensed

All Independent Variables

Beta

OR

se

Cl low

Cl High

Pr> X2

0.0236

1.0239

0.1793

0.7205

1.4550

0.8953

50-64

0.1256

1.1 338

0.1821

-0.6453

0.5245

0.2148

0.7935
0.3443

1.6201
0.7991

0.4904

65+

-0.1077

0.8979

0.1507

0.6683

1.2064

0.4748

Plan B

0.2372

0.1653

0.9169

1.7528

0.1513

Other

0.0161

1.2677
1.0162

0.251

0.6214

1.6621

0.9489

5-15

-0.2264

1.0
0.7974

0.2101

0.5282

1.2037

0.2811

16+

-0.0562

0.9454

0.2377

0.5933

1.5064

0.8131

Beta

OR

se

Cl low

Cl High

Pr >X2

0.1776
0.2108

0.7914
0.3409

1.5876
0.7789

0.5206
0.0017

MPR < 8:10
Age
under50

Male Gender

1.0

Insurance
Plan A

0.0027

1.0

Dispensings
0-4

Final Model

Age
under50
50-64
65+

0.1141
-0.6631

1.0
1.1209
0.5153
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Table Sc. Multivariate Logistic Models of Sulfonylurea Sample: Change in
Dose or Change in Drug Dispensed

All Independent Variables
Beta

OR

se

Cl low

Cl High

Pr> X2

MPR < 8:10

0.3861

1.4712

0.171

1.0523

2.0570

0.0239

Age
under50
50-64
65+

-0.2256
-0.4852

1.0
0.7980
0.6156

0.1781
0.1896

0.5629
0.4245

1.1314
0.8926

0.2052
0.0105

Male Gender

0.0036

1.0035

0.1382

0.7654

1.3158

0.9796

Plan A
Plan B
Other

0.1694
0.3732

1.0
1.1846
1.4524

0.1478
0.2263

0.8867
0.9321

1.5826
2.2631

0.2516
0.0991

Dispensings
0-4
5-15
16+

-0 .2851
-0.0520

1.0
0.7520
0.9493

0.2028
0.2286

0.5054
0.6065

1.1191
1.4860

0.1598
0.8199

Beta

OR

se

Cl low

Cl High

Pr> X2

MPR

0.4046

1.4987

0.1674

1.0795

2.0807

Age
under50
50-64
65+

-0.2406
-0.4846

1.0
0.7862
0.6159

0.1757
0.187

0.5571
0.4269

1.1093
0.8886

Insurance

Fin al Model
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0.0157

0.171
0.0095

Table 9a. Multivariate Logistic Models of Metformin Sample: Change in
Dose

All Independent Variabl es

Beta

OR

se

Cl low

Cl High

Pr> X2

MPR < 8:10

0.2252

1.2526

0.3564

0.6229

2.5187

0.5274

Age
under50
50-64
65+

-0.3241
-0 .6631

1.0
0.7232
0.5153

0.3604
0.4976

0.3568
0.1943

1.4656
1.3664

0.3685
0.1827

Male Gender

0.1763

1.1928

0.3232

0.6331

2.2474

0.5853

Plan A
Plan B
Other

-0.0468
-0 .738

1.0
0.9543
0.4781

0.3593
0.5839

0.4719
0.1522

1.9298
1.5015

0.8964
0.2063

Dispensings
0-4
5-15
16+

-0 .6359
-0 .3006

1.0
0.5295
0.7404

0.4617
0.513

0.2142
0.2709

1.3087
2.0236

0.1684
0.5578

Insurance

No significant terms
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Table 9b. Multivariate Logistic Models of Metformin Sample: Change in Drug
Dispensed

All Independent Va riables

Beta

OR

se

Cl low

Cl High

Pr > X2

MPR < 8:10

0.0461

1 0471

0.46 19

0.4234

2.5891

0.9206

Age
under50
50-64
65+

-0.7268
-0.2083

1.0
0.4835
0.8120

0.4639
0.6069

0.1947
0.2471

1.2001
2.6677

0.1172
0.7314

Male Gender

0.6746

1.9632

0.4251

0.8533

4.5168

0. 1125

Dispensings
0-4
5-15
16+

0.2825
0.4662

1.0
1.3264
1.5939

0.5784
0.665

0.4269
0.4329

4.1213
5.8685

0.6252
0.4833

No significant terms
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Table 9c. Multivariate Logistic Models of Metformin Sample: Change in
Dose or Change in Drug Dispensed

All Independent Va riables
Beta

OR

se

Cl low

Cl High

Pr > X2

MPR < 8:10

0.1441

1.155

0.3608

0.5695

2.3426

0.6895

Age
under50
50-64
65+

-0.4277
-0.6356

1.0
0.652007
0.529618

0.3659
0.4999

0.3183
0.1988

1.3357
1.4109

0.2425
0.2036

Male Gender

0.3149

1.370122

0.3258

0.7235

2.5947

0.3336

Insurance
Plan A
Plan B
Other

-0.1544
-1.0509

1.0
0.856929
0.349623

0.3634
0.5875

0.4204
0.1105

1.7469
1.1058

0.6709
0.0737

Dispensings
0-4
5-15
16+

-0 .0706
-0 .1438

1.0
0.931835
0.866061

0.4704
0.5227

0.3706
0.3109

2.3429
2.4126

0.1326
0.7832

No significant terms
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Table 10a. Multivariate Logistic Models of Population of Combined
Sulfonylurea and Metformin Samples : Change in Dose

All Independent Va riables
Beta

OR

se

Cl low

Cl High Pr >X2

MPR < 8:10

0.3102

1.3637

0.1489

1.0185

1.8258

0.0372

Age
under50
50-64
65+

-0 .2368
-0.4821

1.0
0.7891
0.6175

0.1549
0.1697

0.5825
0.4428

1.0691
0.8611

0.1264
0.0045

Male Gender

0.0356

1.0362

0.1236

0.8133

1.3203

0.7736

Insurance
Plan A
Plan B
Other

0.0838
0.1523

1.0
1.0874
1.1645

0.134
0.2024

0.8362
0.7832

1.4140 0.5319
1.7315 0.4517

Dispensings
0-4
5-15
16+

-0.2505
-0.0311

1.0
0.7784
0.9694

0.1779
0.2017

0.5493
0.6528

1.1032 0.159 1
1.4394 0.8776

Beta

OR

se

Cl low

Cl High

Pr>X2

MPR < 8:10

0.3239

1.3825

0.146

1.0385

1.8405

0.0265

Age
under50
50-64
65+

-0.2421
-0.4717

1.0
0.7850
0.6239

0.1531
0.1672

0.5815
0.4496

1.0597
0.8659

0.1139
0.0048

Final Model
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Table 10b. Multivariate Logistic Models of Population of Combined
Sulfonylurea and Metformin Samples: Change in Drug Dispensed

All Independent Variables
Beta

OR

se

Cl low

Cl High

Pr> X2

MPR < 8:10

0.0077

1.0077

0.1654

0.7287

1.3936

0.9628

Age
under50
50-64
65+

0.0351
-0 .5959

1.0
1.0356
0.5511

0.1672
0.2001

0.7462
0.3723

1.4372
0.8157

0.8341
0.0029

Male Gender

-0 .0111

0.9890

0.1406

0.7508

1.3027

0.9373

Insurance
Plan A
Plan B
Other

0.2098
-0 .0385

1.0
1.2334
0.9622

0.154
0.238

0.9121
0.6035

1.6680
1.5342

0.1732
0.8714

Dispensings
0-4
5-15
16+

-0.1818
0.0279

1.0
0.8338
1.0283

0.1958
0.2216

0.5680
0.6660

1.2238
1.5876

0.3531
0.9001

Beta

OR

Cl low

Cl High

Pr> X2

0.1634 0.7514
0.1959 0.3759

1.4258
0.8101

Final Model

Age
under50
50-64
65+

0.0345
-0 .5945

se

1.0
1.0351
0.5518
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0.8329
0.0024

Table 10c. Multivariate Logistic Models of Population of Combined
Sulfonylurea and Metformin Samples : Change in Dose or Change in Drug
Dispensed

All Independent Variables
Beta

OR

se

Cl low

Cl High

Pr>X2

MPR < 8:10

0.3255

1.3847

0.1526

1.0268

1.8675

0.0329

Age
under50
50-64
65+

-0 .2277
-0.4374

1.0
0.7964
0.6457

0.1583
0.1727

0.5839
0.4603

1.0861
0.9058

0.1504
0.0113

Male Gender

0.0575

1.0592

0.1255

0.8282

1.3546

0.6468

Plan A
Plan B
Other

0.1185
0.2116

1.0
1.1258
1.2357

0.1357
0.2067

0.8629
0.8240

1.4688
1.8529

0.3829
0.3058

Dispens ings
0-4
5-15
16+

-0 .3211
-0 .0563

1.0
0.7254
0.9453

0.183
0.2072

0.5068
0.6298

1.0384
1.4188

0.0793
0.7858

Beta

OR

se

Cl low

Cl High

Pr> X2

Insurance

Final Model

MPR < 8:10
Age
under50
50-64
65+

0.3444

1.4111

0.1496

1.0525

1.8920

0.0213

-0.2377
-0.4275

1.0
0.7884
0.6521

0.1564
0.1701

0.5803
0.4672

1.0713
0.9102

0.1285
0.0120
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Adherence to Hypoglycemic Therapy Among Patients Prescribed
Monotherapy with a Sulfonylurea or Metformin, and Dual Therapy With
Both Agents

ABSTRACT
Background

Adherence to prescribed drug therapies for chronic

conditions is known to be poor. Lack of optimal adherence to drug therapies
for diabetes is particularly problematic, since poor glucose control has been
associated with an increased risk of certain types of diabetic complications.

Objective

To determine if diabetic patients prescribed dual therapy with

both a sulfonylurea and metformin as separate prescriptions are more likely to
be nonadherent than patients receiving monotherapy with either agent.

Methods

A cross-sectional study examining retail pharmacy dispensings

to diabetic patients receiving oral hypoglycemic therapy. Patients receiving
monotherapy with either a sulfonylurea or metformin and patients receiving
dual therapy with both drugs were identified. The medication possession ratio
(MPR) was used to assess adherence , as the days supply of all hypoglycemic
medication dispensed to the number of days between first and last
dispensings . The influence of the type of therapy prescribed (dual or
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monotherapy) on medication possession was assessed . Other factors
investigated as potential influences of medication possession included age,
gender, insurance plan associated with the dispensing, the total number of
dispensings, and dispensings for selected anti-depressant medications.
Multivariate logistic regression was used estimate the likelihood of
nonadherence among those receivi ng dual therapy, and controlling for
potential confounding variables.

Results

Overall, 71 % of patients possessed medication for at least 80%

of days during the assessment period, and 59% of patients possessed
medication for at least 90% of days. Patients who received only dispensings
for a sulfonylurea were most frequently in possession of medication (MPR ;;;::
8:10: 77%, MPR ;;::9:10: 67%). Patients who received dispensings only for
metformin were less frequently in possession of medication for at least 80%
and 90% of days (MPR ;;::8 :10: 71%, MPR ;;::9: 10: 67%). Medication
possession was lowest among patients receiving dispensings for both a
sulfonylurea and metformin, with 57% of such patients possessing medication
for at least 80% of days, and 43% of such patients possessing medication for
at least 90% of days. Using multivariate logistic models controlling for the
effects of age and the number of dispensings, we determined that patients
receiving dual therapy with a sulfonylurea and metformin were more than 3
times more likely to fail to possess medication for at least 80% of days (OR
3.14, 95% Cl 2.42 - 4.08) or 90% of days (OR 3.20, 95% Cl 2.49 - 4.11 ).
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Conclusions

As determined using the medication possession ratio ,

adherence to oral hypoglycemic drug therapies was frequently sub-optimal.
Patients that possessed medication for less than 80% of days were likely not
achieving tight control of blood glucose. Adherence was poorest among those
receiving the combination of a sulfonylurea plus metformin.

The success of intensive therapy in tightly controlling the blood glucose level is
contingent upon patient behavior. Though perhaps difficult to predict,
adherence can be assessed. Diabetes management strategies should include
the assessment of adherence with prescribed hypoglycemic drug regimens,
and the application of interventions designed to improve adherence.
Additionally, the complexity of the drug reg imen should be considered as a
potential barrier to optimal adherence.
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INTRODUCTION
Non-adherence to prescribed drug regimens is a primary cause of sub-optimal
health outcomes. Despite the efforts of prescribers and pharmacists, as
many as one-half of patients or more will not achieve the full benefit of
prescribed medications due to problems with adhering to therapy (1, 2).
Various types of interventions intended to improve adherence rates have been
studied. However, research has not uncovered any specific intervention that
effectively improves adherence to the degree where the full benefit of therapy
is realized (3-5). The utility of such interventions ultimately depends upon the
ability of health care providers to identify non-adherence with treatment
regimens and , most importantly, depends upon characteristics of individual
patients (6).

Further complicating the picture, despite greater than two decades of study
regarding adherence with prescribed therapies, researchers have been mostly
unable to consistently demonstrate associations between the behavior of
adherence and various potential predictive factors (7). For example , some
researchers have reported an association between adherence with prescribed
therapies and age (8, 9), gender (9, 10), and race (11, 12), though others have
not (13 , 14). Beyond such patient-specific factors , researchers have
attempted to understand and describe the underlying psychological
determinants of adherence. Models borrowed from the psychological sciences
have been used to characterize and predict the behavior of adherence with
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some success. For example, the health belief (15), self-efficacy (16), and
stages-of-change models (17) have all been shown to be useful in explaining
adherence to drug therapy.

Factors specific to the drug regimen prescribed have also been examined as
potential influences of adherence to therapy. Regimens having increased
complexity and greater behavioral demand have been shown to be associated
with decreased adherence (18, 19). The number of drugs prescribed and
number of required daily dosages have been shown to be associated with
adherence, with the probability of non-adherence increasing in patients
prescribed multiple medications and receiving divided daily doses (20, 21 ).
This phenomenon has been perhaps best demonstrated in studies of patients
treated for hypertension (22-24) and human immunodeficiency virus infection
(25). The cost of and access to medications may also be important barriers to
adherence for some patients.

Adherence to drug therapies prescribed for diabetes is particularly important.
Hypoglycemic therapy is essential for preventing acute complications resulting
from elevated blood glucose, such as the nonketotic hyperosmolar state.
Additionally, tight control of blood glucose has been demonstrated to reduce
the incidence of several types of chronic diabetic complications (26-28). For
the majority of diabetic patients, such tight control of blood sugar can only be
achieved through rigid adherence to the prescribed hypoglycemic drug
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regimen. Poor adherence to prescribed drug regimens would expectedly
result in sub-optimal blood glucose control, as demonstrated by Kavanagh et
al (29). In the longer term, patients that do not adhere to hypoglycemic drug
regimens are at increased risk for developing complications such as blindness,
neuropathy, and kidney disease.

In this study, we sought to determine if the complexity of the drug regimen was
an influence of adherence to therapy. Specifically, we hypothesized that
diabetic patients would be less likely to adhere to regimens that utilized two
drugs as compared with regimens consisting of a single hypoglycemic agent.
To test this hypothesis, we used pharmacy data to assess hypoglycemic drug
utilization among patients receiving dispensings for a sulfonylurea, metformin,
or both of these agents together but as separate tablets.

120

METHODS

Population

We conducted a cross-sectional study using data provided by Consumer
Value Stores, Inc (CVS). The data included over one-quarter million
dispensings to 5056 diabetic patients between April 1997 and May 1999.
Most patients included in this population were enrollees of one of two area
health plans, and were participants in a special managed care program in
diabetes. Patients were restricted to designated CVS pharmacies for their
pharmacy services, and all dispensings from these pharmacies were included
in the data provided for research . The restriction of patients to these
designated pharmacies was deemed an advantageous feature, potentially
resulting in a more complete representation of pharmacy utilization and thus
reducing the likelihood of misclassification of non-adherence.

From the population of all patients included in the sample provided, we
identified those that received a dispensing for any hypoglycemic medication
during a 12-month period. Patients that did not receive dispensings for any
class of hypoglycemic medication were not included in the sample. The
hypoglycemic medication dispensed did not need to be the same throughout
all 12 months. From those identified as receiving at least one hypoglycemic
drug during a 12-month period , we selected patients that received either a
sulfonylurea or metformin , or both during the first four months of this 12-month
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period. Patients who received a hypoglycemic drug other than a sulfonylurea
or metformin during this four-month period were excluded from the sample.
Thus, the final sample included only patients that received dispensings for a
sulfonylurea and/or metformin during a four-month period, and received some
type of hypoglycemic medication throughout a 12-month period. Patients were
classified by type of hypoglycemic drug regimen prescribed : either monotherapy with sulfonylurea or metformin, or dual therapy using both drugs.

Calculating the medication possession ratio

We used the medication possession ratio (MPR) as the measure of adherence
with prescribed hypoglycemic drug therapy, defined as the number of days
that a patient was in possession of medication. The use of the medication
possession ratio for assessing adherence is described by Fairman and
Motheral (30).

To calculate the MPR, we determined the total days supply of medication
received for all dispensings preceding the last dispensing of the four-month
period . A ratio was created using the days supply of medication received and
the number of days between the first and last dispensing during this fourmonth period . For example, the MPR for a patient that received three
dispensings of 30 tablets each (90 tablets) during a period of 113 days would
be 90: 113, or roughly 8: 10. Patients who received only one dispensing during
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the four-month period but who received medication in subsequent months
were classified as non-adherent. There were 19 such patients (1 .1%).

We assessed adherence using MPR thresholds of 8:10 and 9:10. Nonadherence was defined as failing to possess medication for at least 80% or
90% of days in the period . For example, the patient that received 90 tablets in
113 days would be classified as adherent using the 8:10 threshold , but
classified as non-adherent using the 9:10 threshold . Results based upon
these two MPR thresholds were presented separately. For patients dispensed
both sulfonylurea and metformin as dual therapy, non-adherence was defined
as failing to possess either medication for a number of days sufficient to cover
eight of ten or nine of ten days in the period . Thus, patients prescribed both
drugs must have adhered to both medications to be classified as adherent.

The MPR threshold of 8: 10 has been used in previous studies. Some
researchers have used a ratio of 8:10 , or 80% of days covered, in studies of
adherence to other chronic therapies such as hormone-replacement therapy
(31 ); hypertension (24, 32); and depression (33). Additionally, we also used
second MPR threshold of 9:10 to define adherence based on estimates of
what might be required to achieve tight glycemic control.
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Potential confounding variables

In addition to the type of hypoglycemic drug regimen prescribed , we assessed
the influence of five other potential confounding factors that were derivable
from the pharmacy data provided. Three of these variables , age, gender, and
insurance type, were obtainable from the patient profile. We stratified age into
three categories: < 50, 50-64, and 65 years of age or older; representing
younger, middle-aged , and senior patients. Insurance type was also
categorized into three types. Of all insurances associated with prescription
refills, two area health plans accounted for nearly 90% of all dispensings.
These two insurance types were classified as health plan A and health plan B.
A third category of insurance type included patients whose prescription
coverage was an insurance type other than health plan A or B, or patients that
paid cash for all dispensings. In cases where more than one insurance type
(or cash) was identified , the insurance type associated with the first non-cash
dispensing was used .

We also sought to examine the effect of the number of medications
prescribed , hypothesizing that a greater number of prescriptions would be
associated with a greater likelihood of non-adherence to therapy. For this
variable, we determined the total number of dispensings during the four-month
period , including medications for conditions other than diabetes.
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DiMatteo et al found depression to be a risk factor for non-adherence with
prescribed drug therapies (34). Thus, we also decided to include a fifth
potential confounding variable representing patients who had received an antidepressant medication. We decided not to include patients receiving an
tricyclic anti-depressant in our categorization method, since the popularity of
these agents for use in depression is declining (35, 36) and these agents are
used for conditions other than depression (37-41 ). Patients were considered
to have depression if they received at least one dispensing for a medication
presented in table1.

Statistical methods

Univariate statistics were used to determine the frequency and percentage of
patients that received dispensings for a sulfonylurea, metformin , or both. The
frequency and percentage of patients having a medication possession ratio
percentage of at least 8:10 and 9:10 was determined , overall and for each
type of regimen prescribed. The frequency and percentage of the potential
confounding variables described above was also determined for each of the
regimen types and overall.

For initial evaluation, the total number of dispensings was categorized into
three groups: less than 5 dispensings , 5-15 dispensings, and greater than 15
dispensings. These three groupings reflected quartiles of the frequency
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distribution for this variable, with the category of 5-15 dispensing representing
a combination of the inner quartiles.

For inclusion in logistic models, categories of the continuous variables age and
total number of prescriptions dispensed were based upon association with
medication possession, the dependent variable. Parametric form was
assessed by plotting quartiles of the frequency distribution for these
continuous variables with MPR thresholds of 8:10 and 9:10. The resulting
strata for age and the dichotomization of the total number of dispensings
reflect the results of this assessment.

Chi-square analyses were used to assess bivariate relationships between
proportions for all independent variables and the medication possession ratio.
Bivariate logistic models were also constructed, with separate models
assessed for each independent variable and the medication possession ratio.
For the dependent variable of medication possession , ratio thresholds of 8:10
and 9:10 were assessed . Multivariate statistics were used to identify the
presence of collinearity between independent variables, to determine the
presence of interactions between variables, and to assess the association
between type of reg imen prescribed and medication possession, controlling for
other potential confounding variables. Collinearity diagnostics were performed
using the PROC REG procedure for multiple regression as suggested by
Allison (42). Collinearity between independent variables was assessed
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separately for MPR thresholds of 8:10 and 9:10. The presence of collinearity
was determined using thresholds for condition index and proportion of shared
variance as described by Tabachnick and Fidell (43).

The likelihood ratio test was used to test for interaction between variables in
multivariate logistic models , using the chunk test as described by Kleinbaum
(44 ). For this procedure, we calculated the difference in the -21og statistic
between full and reduced models. Full models included all possible interaction
and single terms; reduced models included single terms only. The difference
in -21og statistic between full and reduced models was tested for significance
using the chi-square distribution with alpha .05, and with degrees of freedom
equal to the difference in terms between the two models. A difference in -21og
value that was less than the chi-square statistic was considered sufficient
evidence that the model could not be better fit by including interaction between
variables.

Various multivariate models were assessed. Initial models contained all
independent variables: non-significant terms were removed to create several
other models. When non-significant terms were removed from models, we
examined the magnitude of change in the parameter estimate beta and
confidence interval for the variable regimen type (dual or monotherapy). The
association between regimen type and medication possession is presented in
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a summary table that presents the parameter estimate, standard error, odds
ratio, and 95% confidence interval obtained for each model.
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RESULTS
A total of 1537 patients were identified as receiving dispensings for either a
sulfonylurea, metformin, or both. Of these three types of hypoglycem ic drug
regimens , a majority of patients were classified as users of sulfonylurea only
(n = 967; 63%). A total of 404 patients (26%) were determined to be users of
both sulfonylurea and metformin. A lesser number of patients were classified
as users of metformin only (n =166 ; 11 %).

Table 2 presents the frequency and percentage of several characteristics the
population, and within each regimen type. For all categories of drug therapy,
patients were most frequently male and between the ages of 50-64.
Approximately half of patients in each of the three regimen categories were
between the ages of 50 and 64. More than half of patients in each among
each regimen type were identified as having insurance plan B.

Insurance

types plan A and plan B accounted for 87-89% of all subjects.

Patients dispensed only sulfonylureas were least frequentl y dispensed a
medication for an anti-depressant (11 %), as compared to those receiving
monotherapy with metformin (13%) or dual therapy with sulfonylurea plus
metformin (16%). Of all patients studied , 13% received a dispensing for one
of the antidepressant medications presented in figure 1.
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The frequency and percent of patients possessing medication for at least 80%
and 90% of days is presented in Table 3. Patients receiving dispensings for
only a sulfonylurea were most frequently determined to have medication
possession ratios greater then 8: 10 and 9: 10 (77% and 69% respectively) .
Patients receiving dispensings for only metformin were less frequently
identified as having an MPR above 0.80 and 0.90 (71 % and 57%). Patients
dispensed both sulfonylurea and metformin were least frequently identified as
having an MPR greater than 8:10 (57%) or 9:10 (43%). Overall, 71 % of
patients possessed enough medication for 8 of 10 days, and 60% of patients
possessed a quantity of medication sufficient to be able to adhere to therapy
at least 90% of days .

The relationship between medication possession and other potential
confounding variables is presented in Tables 4a and 4b. For both users of
only sulfonylureas and among the total sample, patients under 50 years of age
were most frequently identified as having an MPR less than 8:10 or 9:10 (p <
0.01 ). Among those dispensed both a sulfonylurea and metformin, those
under 50 years of age were also more frequently categorized as having MPR
less than 8:10 or 9:10, though this result was statistically significant only for
the MPR threshold of less than 8:10 (p < 0.05). Subjects 65 years of age or
older were least frequently identified as having an MPR less than 8:10 or 9:10
(p < 0.01 ). The percentage of males and females having an MPR < 0.80 or
0.90 did not differ significantly for any of the regimen types or overall.
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Likewise, type of insurance did not differ significantly between groups for
either MPR threshold.

Patients receiving greater than 15 total dispensings were least frequently
categorized as having an MPR less than 8:10 or 9:10, and those dispensed
less than 5 prescriptions were most frequently categorized as not possessing
a sufficient quantity of medication using either MPR threshold. These
differences were statistically significant overall , and among the group of
patients receiving dispensings for sulfonylurea only (p < 0.01 for each). The
lesser number of patients in the metformin only and in the metformin plus
sulfonylurea regimen categories likely affected the ability to detect a statically
significant difference for these groups.

Among patients dispensed sulfonylureas, those who received a dispensing for
a medication for depression more frequently had an MPR less than 8:10 or
9:10 (p < 0.05). The percentage of patients who were prescribed an antidepressant did not differ in statistical significance for other regimen categories
or overall.

To determine the appropriate form for inclusion into logistic models , the
parametric form of the continuous variables age and number of dispensings
was assessed. Age was relatively linearly related to the MPR, with the
likelihood of being categorized as having an MPR less than 8:10 or 9:10
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decreasing with advancing age. Age categories used for analyses were based
upon the frequency distribution of ages and for ease in presentation and
interpretation. We did not find the presence of a strong linear trend between
the total number of dispensings and the MPR. However, patients receiving 12
or more dispensings were less likely to be classified as having an MPR less
than 8:10 or 9:10, while a total of less than 12 dispensings did not prove to be
associated with the MPR. Thus, for use in logistic models, we dichotomized
the total number of dispensings at 12 prescriptions.

Tables 5a and 5b present the results of bivariate logistic models for each
independent variable using MPR thresholds of 8:10 and 9:10. As compared
with patients receiving dispensings for either a sulfonylurea or metformin only,
those receiving dispensings for both drugs were more likely to be classified as
having and MPR less than 8:10 (OR 2.4; 95% Cl 1.9 - 3.1) or less than 9:10
(OR 2.49; 95% Cl 1.97 - 3.14 ). Age was also significantly associated with
medication possession. As compared with patients less than 50 years of age,
patients who were 50-65 years of age and 65 years or older were less likely to
be classified with an MPR less than 8:10 (age 50-65 OR 0.55: 95% Cl 0.42 0.71; age 65 or older OR 0.48: 95% Cl 0.35 - 0.65), and less likely to be
classified as having an MPR less than 9:10 (age 50-65 OR 0.60: 95% Cl 0.46
- 0.76; age 65 or older OR 0.58: 95% Cl 0.44 - 0.76). The total number of
dispensings was also associated with medication possession, as those
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receiving 12 or more dispensings were less likely to have an MPR less than
8:10 (OR 0.56: 95% Cl 0.45 - 0.71) or 9:10 (OR 0.57: 95% Cl 0.47 - 0.70).

Receiving a dispensing for an anti-depressant medication increased the
likelihood of being classified as having an MPR less than 8:10 or 9:10, though
the association was not statistically significant (MPR < 8:10 OR 1.27: 95% Cl
0.92 - 1.75; MPR < 9:10 OR 1.21 : 95% Cl 0.89 - 1.64). Gender and type of
insurance did not appear to influence the likelihood of being classified as
having an MPR less than 8:10 or 9:10 in bivariate logistic models.

Multivariate logistic analyses were performed to control for potential
confounding factors while assessing the association between type of regimen
(one drug or two) and medication possession. The results of a multivariate
model including all independent variables are presented in Table 7a (MPR
less than 8:10) and Table 7b (MPR less than 9:10). Compared to those
receiving dispensings for only a sulfonylurea or metformin , patients receiving
dispensings for both a sulfonylurea and metformin (dual therapy) were more
than three times as likely to be classified as having an MPR less than 8:10
(MPR < 8: 10: OR 3.12, 95% Cl 2.40 - 4.06; MPR < 9: 10 OR 3.20 , 95% Cl
2.49 - 4.12). In these models, age and more than 12 total dispensings were
also shown to be associated with medication possession . Receiving a
dispensing for an anti-depressant was a non-significant contributor to this
model (MPR < 8:10: OR 1.36, 95% Cl 0.96 - 1.92; MPR < 9:10: OR 1.31, 95%
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Cl 0.94 - 1.82). Gender and insurance type were not found to be associated
with medication possession using either the 8:10 or 9:10 thresholds.

Tables 8a and 8b present the results of multivariate models containing only
the significant terms: regimen type, age category and total number of
dispensings. Removing the non-significant variables (gender, insurance type,
and received anti-depressant medication) resulted in little change in the
likelihood of being categorized as having an MPR less than 8: 10 or 9:10
among those prescribed dual therapy. It this model , patients who received
dispensings for both a sulfonylurea and metformin remained more than 3
times more likely to be classified as having an MPR less than 8:10 or 9:10.
(MPR < 8:10: OR 3.14, 95% Cl 2.42 - 4.08; MPR < 9:10: OR 3.20, 95% Cl
2.49 - 4.11 ). To assess the influence of the total number of dispensings, we
included only the terms for regimen type and age category in another logistic
model (Tables 9a and 9b). Without controlling for the number of prescriptions
dispensed, patients receiving dispensings for both a sulfonylurea and
metformin remained less likely to possess medication , though the effect was
lessened as compared to models that included this factor (MPR < 8:10: OR
2.47, 95% Cl 1.93-3.14; MPR < 9:10 OR 2.51, 95% Cl 1.99-3.18). In the
models including only regimen type and age category, the effect of regimen
type on medication possession was similar to what was found for the bivariate
analyses presented in tables 5a and 5b. Parameter estimates (beta) for the
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(

regimen type and associated standard errors and 95% confidence intervals for
each of the models described above are presented in tables 1Oa and 1Ob.
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DISCUSSION

Medication possession was highest among patients that were dispensed only
sulfonylureas, with 77% and 67% of such patients possessing medication for
at least 80% and 90% of days, respectively. Medication possession was next
highest among patients dispensed only metformin , with 71 % of such patients
possessing medication for at least 8of10 days, and 57% of patients
possessing mediation for 9of10 days. Patients that received dispensings for
both drugs were less frequently in possession of medication. Only 57% of
such patients possessed enough medication to be adherence 80% of days,
and less than half of patients prescribed both drugs (43%) possessed enough
medication to cover 90% of days in the period . Overall , 71 % of all patients
possessed medication for at least 8of10 days , and only 60% of patients
possessed medication for 9of10 days. In all models, dual therapy with a
sulfonylurea plus metformin was associated with an increased likelihood of
non-adherence as defined as medication possession , as compared with
monotherapy with either a sulfonylurea or metformin.

These results provide evidence that the self-management of diabetes is far
from ideal for many patients. Clearly, patients who are not in possession of
medication cannot be achieving the 'tight control ' of blood glucose that has
been demonstrated to reduce the incidence of many types of diabetes
complications. Unfortunately, the finding that many diabetic patients do not
strictly adhere to prescribed hypoglycemic drug regimens is not unexpected .
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Other researchers have provided evidence that adherence to hypoglycemic
therapy is often sub-optimal. Venturini et al (45) reported a mean medication
possession percentage of 83% of days among HMO patients prescribed a
sulfonylurea . In a study using Medicaid claims data, Sclar et al (46) found that
only 39.4% of newly treated diabetics receiving a second-generation
sulfonylurea obtained at least 6 months supply of medication during a 12month period . In an assessment of hypoglycemic drug possession among
nearly 3,000 Scottish diabetics, Morris et al (47) found that roughly one-third of
patients prescribed sulfonylureas received enough medication to cover 90% of
days. Poor adherence to prescribed therapies among diabetic patients has
been described by several researchers (48-53).

The primary aim of this study was to determine if adherence to prescribed
drug regimens was poorer among patients prescribed dual therapy with a
sulfonylurea plus metformin as compared with patients receiving only one
medication as monotherapy. Indeed , patients prescribed the two
hypoglycemic drugs together were less likely to possess medication . In
addition , the difference in adherence was pronounced. As compared with
patients receiving dispensings for only a sulfonylurea or metformin , the
percentage of patients having a medication possession ratio less than 8:10 or
9:10 was significantly greater for patients receiving both drugs. Logistic
models provided an estimate of influence, with the odds of non-adherence as
measured in terms of medication possession ranging from 2.4 to 3.1 times
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greater for those prescribed both medications as compared with patients
receiving monotherapy, depending upon inclusion of other factors in the
model.

Morris et al (47) reported similar findings when comparing medication
possession rates among Scottish diabetics who received dispensings for
either sulfonylurea, metformin, or both . During a period of up to three-years,
only 31% of patients using a sulfonylurea, and 34% of patients using
metformin possessed enough medication to achieve adequate adherence,
defined as possessing medication for 90% of days during the period.

An influence of the number of medications prescribed on adherence has also
been described. Sellars and Hayes (54) note that in general the probability of
non-ad herence can be expected to increase with the number of medications
prescribed. Treatment complexity has been shown to be a barrier to
adherence in diabetic patients (55). In other health conditions, the number of
medications prescribed has been shown to be an influence of drug utilization .
For example, persistence with a single-pill combination of two antihypertensive agents was found to be superior to persistence rates when the
same agents were prescribed as separate pills (56). Additionally, treatment
complexity is a recognized feature of adherence to drug therapies for human
immunodeficiency virus (57, 58).
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The age of the patient was also found to be associated with medication
possession. In th is study, bivariate analyses revealed that patients 50 years of
age or older were less likely to be categorized as non-adherent. This finding is
consistent with research by Sclar, who also found older diabetic patients to be
more likely to obtain oral hypoglycemic medication regularly (46). This finding
is explainable using the health beliefs model as described by Becker (59).
According to this model , patients that perceive their disease to pose a threat to
health will be more likely to adhere to therapies that they perceive will lessen
the risk of illness. Thus, in this study, perhaps younger diabetic patients were
poorly adherent to drug therapy due to a lessened concern about poor longerterm outcomes resulting from persistent uncontrolled blood glucose.
Conversely, older patients may be more concerned about impending ill health,
and thus be more likely to adhere to therapy.

Patients receiving 12 or more dispensings were 55% percent less likely to be
non-adherent for MPR thresholds of 8:10 and 9:10 days. However, our
calculations of total dispensings do not equate to the total number of
medications prescribed, since non-adherence and differing days supply of
medications may be responsible for some portion of the difference in the
number of dispensings. Nevertheless, patients that received less than 12
dispensings were more likely to be identified as having an MPR below 8:10
and 9:10 days. A possible explanation for this finding is that patients receiving
less than 12 dispensings during the four-month period were less ill, and
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perhaps less adherent for reasons related to the health beliefs model as
previously described. Also, it is likely that patients receiving 12 or more
dispensings were afflicted with other co-morbid conditions and thus more
vigilant in their adherence to therapy in an effort to stave off ill health .

Removing the term for the total number of prescriptions from multivariate
models resulted in a decrease in the odds of non-adherence among patients
dispensed both a sulfonylurea and metformin. Thus, controlling for the
number of prescriptions dispensed resulted in an increase in the odds for nonadherence among those prescribed both drugs. Such effect was lacking for all
other independent variables except age. Gender and insurance type were not
found to be significant influences of medication possession .

Depression was identified as a risk factor for non-adherence by Di Matteo (34 ).
In an attempt to control for the presence of depression , we identified patients
that received a dispensing for one of several anti-depressant medications.
For such patients, the risk of nonadherence to drug therapy was greater.
However, the 95% confidence interval did not exclude the possibility that no
effect was present (MPR < 8:10: 95% Cl 0.92 - 1.75; MPR < 9:10: 95% Cl
0.89 - 1.64 ). Additionally, dispensing of an anti-depressant was not found to
be a significant influence of medication possession in multivariate models that
included all potential confounding variables. Thus, in this study, patients who
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received one or more selected antidepressant medications were not more
likely to be nonadherent to hypoglycemic drug therapy.

An important limitation of the study relates to the use of medication possession
as a measure of adherence. Certainly the possession of medication is only an
initial step in the process of adhering to prescribed therapy. Patients in
possession of medication may skip dosages when feeling well, or otherwise
consume medication in a manner that differs from the instructions of the
prescriber. Despite this limitation , possession of medication has been
considered a useful 'first-order' measure of adherence (60), since patients
must first possess medication before they can adhere to therapy.

Another limitation relates to the duration of time used to assess medication
possession. The four-month period used in this study is shorter than what was
used to assess adherence to hypoglycemic drug regimens for some other
studies. For example, Morris used a three-year period to investigate
hypoglycemic drug dispensings (47), while both Skaer at al (53) and Sclar at al
(46) assessed refill dispensings over a 12-month period. Beta-Brown et al
(61) investigated hypoglycemic drug use over a ten-year period. In our study,
use of a longer period of time for assessing adherence would have likely
resulted in a greater number of patients identified as non-adherent. It cannot
be assumed that such patients would have been similarly distributed in terms
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of regimen type and medication possession . Thus, a longer period of time
used to assess medication possession may have resulted in different findings .

Additionally, patients receiving dual therapy may have initially failed
monotherapy due to poor adherence . Thus, the group of patients using two
hypoglycemic medications may inherently be more likely to be nonadherent.

Importantly, this study did not include many important factors known to be
associated with adherence to prescribed drug regimens . Though we
assessed the influence of gender and age, other patient-related factors may
have been important to include. For example, race may have been an
influence on adherence with sulfonylurea treatment, as found by Sclar et al
(46). More notably, other complex behavioral factors may have been
responsible for the differences in medication possession observed . For
example, a patient's self-efficacy in adhering to prescribed regimens has been
associated with superior adherence (29). Add itionally, a patient's stage of
readiness to adhere to a prescribed regimen may prove explanatory (62 , 63).
In this study, the identification and incorporation of factors related to
perception and beliefs may have influenced the association between drug
regimen type and medication possession .

Additionally, important factors related to the characteristics of the disease
were not included in this analysis. It is possible , for example, that some
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patients classified as non-adherent in fact no longer required medication.
perhaps from adherence to recommended diet or exercise programs. Also , a
percentage of patients classified as non-adherent may have been hospitalized
during the assessment period. Additionally, the severity of disease may have
also been important to assess. as highly symptomatic patients may have been
more likely to adhere to therapy. Severity of disease may partly explain the
finding of increased medication possession among older patients.

Other potentially important confounding factors relate to obtaining medication.
Information related to prescription co-payment was not provided , thus the
influence of out-of-pocket expenditure on medication possession cannot be
assessed . Additionally, though patients were required to obtain prescriptions
at designated pharmacies for reimbursement. it is possible that some patients
filled prescriptions at other locations by using other insurances or by paying
cash. A last potentially important factor related to the drug regimen not
included in this analysis relates to the type of drug therapies studied. Though
sulfonylureas and metformin remain popular therapies in the treatment of type
2 diabetes. newer hypoglycemic agents have become increasingly utilized
during the past several years. Though dual therapy with a sulfonylurea plus
metformin was found to be associated with an increased likelihood of nonadherence. the association between other hypoglycemic drug combinations
and medication possession is uncertain . One must not assume that
adherence to therapy would also be lesser for combination therapies that
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include, for example, a thiazoladinedionne, meglitinde , or alpha glucosidase
inhibitor.

Finally, it is important to note that dose frequency was not included as an
influence on medication possession . Both metformin and sulfonylureas may
be prescribed as one or two daily doses; depending upon the agent prescribed
for the latter. (64 ). A sustained release preparation of metformin was not
available during the period of study.

Despite these limitations , we found that patients receiving dispensings for both
a sulfonylurea and metformin possessed medication for a lesser number of
days as compared with patients who were dispensed only a sulfonylurea or
metformin . This effect was strongest when controlling for the age of the
patients and the total number of prescription dispensings. In this model ,
patients who received dispensings for both drugs were 3.14 times more likely
to be non-adherent as defined as possessing medication for less than 8 of 10
days in the measurement period . Such patients were also 3.20 times more
likely to be non-adherent using an MPR threshold of 9 in 10 days . The
association between dual therapy with sulfonylurea plus metformin and an
MPR of less than 8:1O or 9: 1O was also significant in bivariate analyses.

Adherence with drug therapy was found to be sub-optimal among all patients,
regardless of regimen type. Greater than one in four of all patients did not
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possess a sufficient quantify of medication to adhere to prescribed therapy at
least 80% of days; and roughly two in five patients did not possess enough
medication to adhere to therapy at least 90% of days. Additionally, these
estimates likely underestimate the true rate of adherence, since possessing
medication is but one step in the process of adherence .

Despite the limitations described , this research should add to evidence
demonstrating that adherence to hypoglycemic drug therapy is a fundamental
problem , and potentially the greatest influence on the development of diabetic
complications. Accordingly, adherence to drug therapy for patients with
diabetes deserves at least as much attention as other components of diabetes
management, such as preventative exams and monitoring of blood pressure
and lipid levels.
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CONCLUSION

As compared with monotherapy with a sulfonylurea or metformin, dual therapy
with a sulfonylurea plus metformin is associated with a greater than three fold
increase in the likelihood of non-adherence, controlling for the age of the
patient and total number of medications dispensed. Patients receiving
monotherapy with sulfonylurea were most frequently adherent, with 77% of
patients possessing medication for at least 8of10 days in the study period ,
and 67% receiving at least enough medication to cover 9 of 10 days. Of those
receiving monotherapy with metformin , 77% possessed enough medication to
adhere 8 of 10 days , and 57% of patients possessed enough medication to
adhere 9 of 10 days. The lowest rate of adherence was among patients
receiving dispensings for a sulfonylurea and metformin. Among patients
receiving both drugs, 57% received enough medication to adhere 8 of 10
days , while only 43% of patients possessed at least enough medication for 9
of 10 days.

In this population many patients did not adhere to drug therapy to the extent
considered necessary to achieve tight glycemic control. Such patients can be
expected to be at increased risk for several types of diabetic complications.
Thus, components of diabetes management must include the assessment of
adherence with prescribed hypoglycemic drug regimens , and the application of
interventions known to be effective in improving adherence . Additionally, the
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complexity of the drug regimen should be considered as a potential barrier to
optimal adherence.
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Table 1. Medications Used to Identify Patients as Having Received an
Anti-Depressant Medication.

SSRI
Citalopram
Fluoxetine
Paroxetine
Sertraline

Other
Bupropion
Mirzatapine
Nefazodone
Trazodone
Venlafaxine
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Table 2. Characteristics of Patients Receiving Hypoglycemic Therapy
with a Sulfonylurea and/or Metformin
Sulfonylurea
(N =967 ;
62 .9%)
n
%

Metformin
(N = 166;
10.8%)
n
%

Sulfonylurea +
Metformin
=404; 26.3%)
n
%

(N

Total
Population
(N = 1537)
n
%

Gender
Male
Female

572
395

59.15
40 .85

85
81

51.20
48.80

215
189

53.22
46.78

872
665

56.73
43 .27

Age
under 50
50-64
65 +

229
442
296

23 .68
45.71
30.61

55
81
30

33 .13
48 .80
18.07

104
202
98

25.74
50.00
24.26

388
725
424

25.24
47 .17
27.59

Insurance
Plan A
Plan B
Other

315
527
125

32.57
54.50
12.93

53
95
18

31.93
57 .23
10.84

114
246
44

28.22
60.89
10.89

482
868
187

31.36
56.47
12.17

#of Dispensings
under 5
5-15
over 15

151
550
266

15.62
56.88
27.51

31
95
40

18.67
57.23
24.10

3
213
188

0.74
52.72
46.53

185
858
494

12.04
55.82
32 .14

Rx for
Depression

105

10.86

22

13.25

66

16.34

193

12.56
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Table 3. Medication Possession : Patients Receiving Dispensings for
Sulfonylurea and/or Metformin, and Total Population

Sulfonylurea
(n = 967)

Medication
Possession
Ratio (M PR)
>= 8:10
>= 9:10

Metformin
(n = 166)

n

%

n

%

747
646

77 .2
66 .8

118
94

71 .1
56 .6
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Sulfonylurea
+ Metformin
(n = 404)
%

230
174

56 .93
43.07

Total
Population
(N = 1537)
n
%

1095
914

71 .24
59.47

Table 4a: Bivariate Analyses: Medication Possession Ratio (MPR) and
Gender, Age Category, Insurance Type, Number of Prescriptions
Dispensed, and Rx for Depression
MPR < 8:10

All Subjects

Sulfonylurea n
= 967

Metformin
n = 166

%

Sulfonylurea plus
Metformin n =
404
%

Total
population
n = 1537
%

%

22.75

28.92

43.07

28 .76

Regimen type
sfu or Met
sfu +Met
Gender
Male
Female

23 .65 ..
43 .07 ..

22.72
22.78

29.41
28.40

44.65
41.27

28 .78
28 .72

33.19..
19.46..
19.59..

36.36
27.16
20.00

53.85.
40.59.
36.73.

39.18 ..
26 .21 ..
23.58 ..

24 .80
20 .95
23 .34

33.33
32 .08
26.32

40 .35
43.90
45.45

26 .76
29.49
30.48

#of Dispensings
<5
5-15
> 15

41 .72 ..
22 .00 ..
13.53..

45.16
26 .32
22 .50

53 .99
29 .79t

43.24 ..
30.42 ..
20.45 ..

Rx for
depression
Yes
No

30.48.
21 .81 ·

31 .82
28.47

37 .89
44.08

33.16
28.13

Age
Under 50
50-64
65 or older
Insurance

Plan A
Plan B
Other

• p < 0.05
•• p < 0.01
tNot reportable; one cell with less then 5 subjects
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Table 4b: Bivariate Analyses: Medication Possession Ratio (MPR) and
Gender, Age Category, Insurance Type, Number of Prescriptions
Dispensed, and Rx for Depression

MPR < 9:10
Total
population
n 1537
%

43.4

56.93

59.47

Metformin
n 166

%

33.2

=

All subjects

%

Sulfonylurea plus
Metformin n
404
%

Sulfonylurea n
967

=

=

Regimen type
sfu or Met
sfu +Met
Gender
Male
Female

=

34.69 ••
56.93 ..

33 .57
32.66

44.71
41 .98

59.07
54 .50

40.94
40.00

43 .23 ..
29 .19..
31.42..

52 .73
39.51
36.67

64.42
54.95
53.06

50.26 ..
37.52..
36 .79 ..

32 .06
32 .64
38.40

43.40
41 .05
55.56

54.39
56.50
65.91

38.59
40.32
46 .52

#of Dispensings
<5
5-15
> 15

54.97 ..
34.00 ..
19.17 ..

61.29
41 .05
35.00

67.61
44 .15t

56 .76 ..
43 .13 ..
29.96 ..

Rx for
depression
Yes
No

41.90.
32.13•

40 .91
43 .75

50.00
58 .28

44.56
39.96

Age
Under 50
50-64
65 or older
Insurance

Plan A
Plan B
Other

* p < 0.05
p < 0.01

tN ot reportable; one cell with less then 5 subjects
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Table Sa. Bivariate Logistic Regression Models: Independent Variables
and MPR < 8:10

r..

se

OR

95%
Cl low

95%
Cl high

0.8929

0.0699

2.442

1.921

3.104

Age
Under 50*
50-65
65 +

-0.5955
-0.7357

0.1340
0.1546

1.0
0.551
0.479

0.424
0.354

0.717
0.649

Male gender

0.0031

0.1138

1.003

0.810

1.254

Number of
dispensings
12 +

-0 .5731

0.1142

0.564

0.451

0.705

Insurance
Plan A
Plan B
Other insurance

0.1351
0.1822

0.1270
0.1893

1.0
1.145
1.2

0.892
0.828

1.468
1.739

Rx for anti-depressant

0.2374

0.1645

1.268

0.918

1.750

Dispensed
sulfonylurea plus
metformint

t versus monotherapy
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Table Sb. Bivariate Logistic Regression Models: Independent Variables
and MPR < 9:10

r..

se

OR

95%
Cl low

95%
Cl high

Dispensed sulfonylurea
plus metformint

0.9118

0.1183

2.489

1.974

3.138

Age
Under 50*
50-65
65 +

-0.5204
-0.5514

0.1273
0.1430

1.0
0.594
0.576

0.463
0.435

0.763
0.763

Male gender

0.0390

0.1049

1.040

0.847

1.277

Number of dispensings
12 +

-0.5562

0.1049

0.573

0.467

0.704

Insurance
Plan A
Plan B
Other insurance

0.0726
0.3254

0.1164
0.1739

1.0
1.075
1.385

0.856
0.985

1.351
1.947

Rx for anti-depressant

0.1888

0.1552

1.208

0.891

1.637

t versus monotherapy
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Table 6. Likelihood Ratio Test for 2-Way Interactions

DV
MPR < 8:10
MPR< 9:10

EV+ V's*
V's*
EV+ V's*
V's*

-21og
statistic
1693.107
1720.317
1912.485
1941.272

-21og
difference

x2 dt=2s:

27.21

NS

28.79

NS

*EV= Interaction terms; V =Single terms (independent variables)

155

40.11

Table 7a. Multivariate Logistic Model, All Independent Variables

MPR < 8:10

Beta

se

OR

95%
Cl low

95%
Cl High

Dispensed
sulfonylurea
plus metformint

1.1382

0.1 339

3.121

2.401

4.058

Age
under50
50-64
65+

-0 .5226
-0.5557

0.1398
0.1616

1.00
0.593
0.574

0.451
0.418

0.780
0.787

Male Gender

-0.0405

0.1205

0.960

0.758

1.216

Insurance
Plan A
Plan B
Other

0.0107
0.0759

0.1331
0.1970

1.00
1.011
1.079

0.779
0.733

1.312
1.587

#of Dispensings
12 +

-0 .8309

0.1297

0.436

0.338

0.562

Rx for Antidepressant

0.3040

0.1778

1.355

0.956

1.920

t versus monotherapy
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Table 7b. Multivariate Logistic Model, All Independent Variables
MPR < 9:10

Beta

se

OR

95%
Cl low

95%
Cl High

Dispensed
sulfonylurea
plus
metformint

1.1634

0.1284

3.201

2.489

4.117

Age
under50
50-64
65+

-0.4463
-0.3721

0.1331
0.1503

1.00
0.640
0.689

0.493
0.513

0.831
0.925

Male Gender

0.00125

0.1112

1.001

0.811

1.245

Insurance
Plan A
Plan B
Other

-0.0393
0.2328

0.1221
0.1813

1.00
0.962
1.262

0.757
0.885

1.222
1.801

#of Dispen sings
12 +

-0 .8108

0.1186

0.445

0.352

0.561

Rx for Antidepressant

0.2697

0.1674

1.310

0.943

1.818

t versus monotherapy
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Table Ba. Multivariate Logistic Model: Type of Drug Therapy, Age
Category, and Number of Dispensings

MPR < 8:10

t

Beta

se

OR

95%
Cl low

95%
Cl High

Dispensed
sulfonylurea
plus
metformint

1.1442

0.1334

3.140

2.417

4.078

Age
under50
50-64
65+

-0 .5392
-0.5679

0.1392
0.1609

1.000
0.583
0.567

0.444
0.413

0.766
0.777

#of Dispen sings
12 +

-0.7937

0.1266

0.452

0.353

0.580

versus monotherapy
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Table Sb.Multivariate Logistic Model: Type of Drug Therapy, Age
category, and Number of Dispensings

MPR < 9:10

Beta

se

OR

95%
Cl low

95%
Cl High

Dispensed
sulfonylurea
plus metformint

1.1621

0.1279

3.197

2.488

4.108

Age
under50
50-64
65+

-0.4586
-0.3743

0.1325
0.1496

1.000
0.632
0.688

0.488
0.513

0.820
0.922

#of Dispen sings
12 +

-0.7886

0.1159

0.454

0.362

0.570

t versus monotherapy
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Table 9a.Multivariate Logistic Model: Type of Drug Therapy and Age
Category

MPR < 8:10

Beta

se

OR

95%
Cl low

95%
Cl High

Dispensed
sulfonylurea
plus
metformint

9:1021

0.1239

2.465

1.933

3.142

Age
under50
50-64
65+

-0 .6293
-0 .7266

0.1369
0.1574

1.000
0.533
0.484

0.408
0.355

0.697
0.658

t versus monotherapy
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Table 9b.Multivariate Logistic Model: Type of Drug Therapy and Age
category

MPR < 9:10

Beta

se

OR

95%
Cl low

95%
Cl High

Dispensed
sulfonylurea
plus
metformint

0.9215

0.1193

2.513

1.989

3.175

Age
under50
50-64
65+

-0.5528
-0 .5383

0.1301
0.1458

1.000
0.575
0.584

0.446
0.439

0.742
0.777

t versus monotherapy
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Table 10a. Association Between Dual Therapy With a Sulfonylurea Plus
Metformint and Medication Possession: Comparison of Logistic Models

MPR < 8:10

Model

Beta

se

OR

95%
Cl low

95%
Cl High

1
2
3
4

1.1382
1.1442
9:1021
0.8929

0.1339
0.1334
0.1239
0.0699

3.121
3.140
2.465
2.442

2.104
2.417
1.933
1.921

4.058
4.078
3.142
3.104

Model
Model
Model
Model

1
2
3
4

Additional Variables
All independent variables (from Table 7a)
Age category and number of dispensings (from Table Ba)
Age category only (from Table 9a)
No additional variables: bivariate relationship (from Table 5a)

t versus monotherapy
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Table 10b. Association Between Dual Therapy With a Sulfonylurea Plus
Metformint and Medication Possession: Comparison of Logistic Models

MPR < 9:10

Model

Beta

se

OR

Cl low

Cl High

1
2
3
4

1.1634
1.1621
0.9215
0.9118

0.1284
0.1279
0.1193
0.1183

3.201
3.197
2.513
2.489

2.489
2.488
1.989
1.974

4.117
4.108
3.175
3.138

Model
Model
Model
Model

1
2
3
4

Additional Variables
All independent variables (from Table 7b)
Age category and number of dispensings (from Table 8b)
Age category only (from Table 9b)
Bivariate relationship (from Table 5b)

t versus monotherapy
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PART2

Part 2 includes the following appendices:

Appendix A. Background and Review of the Problem
Appendix B. Details of the Methods
Appendix C. Overview of Major Findings
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Appendix A.

Background and Review of the Problem

Diabetes is a major public health problem . According to data from the Third
National Health and Nutrition Examination Survey (NHANES Ill ), the
prevalence of diabetes in 1988-1994 was estimated to be slightly greater than
five percent for Americans 20 years of age or older (1 ). The prevalence of
diabetes was also found to be greater for certain races , with the condition
being increasingly prevalent among Mexican-Americans (5.6%) and nonHispanic blacks (6.9%). Additionally, applying criteria developed by the
American Diabetes Association to NHANES Ill data, another 2.7% of the U.S.
population have diabetes yet are undiagnosed (2).

The prevalence of diabetes has increased during the past three decades, and
this trend is projected to continue (3). Major factors contributing to the
increase in diabetes prevalence include the aging of the U.S. population and
an increased prevalence rate of diabetes among older Americans (4, 5).
Additionally, diabetes-related deaths have decreased during past several
decades, likely resulting from advances in knowledge and related
improvements in diabetes care (1 ). Poor diet and sedentary lifestyles have
also contributed to the increase in diabetes prevalence, with obesity and lack
of exercise often present as characteristics of the diabetic patient (6).
Diabetes will likely continue to be a significant epidemiologic problem in
coming years , as the number of older Americans continues to increase.
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Further, a growing number of Americans are obese (7), work environments
increasingly involve prolonged sedentary activity, and burdensome demands
associated with current lifestyles can make it difficult to incorporate healthy
nutrition and exercise into one's daily routine.

Though diabetes has emerged as an important public health problem, strides
in treatment have resulted in reduced morbidity. The Diabetes Control and
Complications Trial (DCCT) (8) demonstrated that intensive therapy in type 1
diabetes can reduce the incidence of retinopathy, neuropathy, and
nephropathy. In this trial, intensive therapy was defined as three or more daily
insulin injections guided by frequent blood glucose monitoring. The DCCT
demonstrated for the first time that aggressive management can reduce the
risk of some types of diabetic complications (9). Five years later, similar
results were reported from a large trial investigating the effect of intensive
glucose control among British patients with type 2 diabetes. The United
Kingdom Prospective Diabetes Study Group (10) assessed the effects of tight
control of blood glucose, using an intensive drug regimen aimed at achieving a
fasting plasma glucose concentration of a less than 6 mmol/L. As compared
to patients who received a regimen consisting of conventional care , those
receiving intensive therapy were 25% less likely to be diagnosed with a
microvascular complication , and 12% less likely to suffer any diabetes-related
endpoint. The DCCT and UKPDS studies were important in demonstrating
that several types of diabetic complications can be averted through tight
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control of blood glucose . Additional trials have since reported similar findings .
Examples include the Kumamoto Study in Japan (11) and the Veteran's Affairs
Cooperative Study on Glycemic Control and Complications (12), which both
reported reductions in risk for selected microvascular diseases among patients
receiving intensive therapy.

Intensive therapy has not been shown to significantly reduce the incidence of
macrovascular diseases such as myocardial infarction or stoke. Though a
trend for a reduction in these endpoints was observed among those receiving
intensive therapy in the UKPDS, the frequency of such events was
substantially greater than the frequency of microvascular complications (13).
Thus, though the UKPDS trial was sufficiently powered to detect a statistically
significant reduction in macrovascular complications, no such reduction was
observed . Additional information regarding the association between regimens
of tight control and macrovascular disease will be provided from the ongoing
Veteran 's Affairs Diabetes Trial (14), which is assessing the effect of intensive
blood glucose control on cardiovascular compl ications in patients with type 2
disease. Meanwhile, current evidence suggests that control of blood glucose
alone is not sufficient to significantly reduce the incidence of heart attack,
stroke, or diabetes-related death . Aggressive management of other
cardiovascular risk factors is essential , including reduction of LDL-C
cholesterol and blood pressure to below target levels (15).
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Strategies for achieving tight glycemic control include hypoglycemic drug
therapy, though no single class of oral hypoglycemic medication has
demonstrated superior ability in achieving tight control. In the UKPDS trial ,
patients assigned to intensive therapy with oral medication initially received
either a first or second-generation sulfonylurea. Patients failing sulfonylurea
monotherapy received insulin injections, or metformin if overweight (16). No
single agent or class of agents was associated with superior outcomes. All
hypoglycemic medications utilized were efficacious in reducing blood glucose,
yet the specific agent used to achieve this reduction was not of importance.
Current treatment guidelines of the American Diabetes Association describe
the goal HbA 1c to be achieved , yet do not recommend specific agents for
achieving this goal (17).

During the past several years, three new classes of oral hypoglycemic drugs
have become available for use. None of these newer classes of hypoglycemic
agents has been proven superior in reducing the incidence of microvascular or
macrovascular diabetic complications. However, the availability of newer
classes of hypoglycemic drugs has created a panoply of choices for achieving
euglycemia. Currently, prescribers can chose from over 25 different agents
representing five different classes of oral hypoglycemic drugs (18). Some of
these agents can be utilized as monotherapy (19, 20); most have been
approved for use in combination with other hypoglycemic medications (19-25).
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The first objective of this research project was to describe hypoglycemic drug
utilization in a diabetic population. In this descriptive study, we sought to
identify which mediations were utilized and how frequently they were
dispensed both alone and in combination. We also identified patients that
switched hypoglycemic regimens during a 12-month period, and identified to
which regimens patients were switching. We also compared utilization by age,
gender, and insurance type, including a comparison of the costs associated
with hypoglycemic drug utilization. This study will be of particular interest to
those seeking details of 'real-world ' patterns of hypoglycemic drug utilization,
and how drug utilization varies among sub-populations.

Recognizing the reductions in several types of diabetic complications
observed among patients receiving intensive therapy in the DCCT and UKPDS
trials, we also explored the relationship between adherence to prescribed
regimens and changes in drugs dispensed . Specifically, we hypothesized that
patients that did not consistently receive dispensings for prescribed
hypoglycemic medications would be more likely to receive a higher dose of
hypoglycemic medication or a dispensing for a different (new) hypoglycemic
medication in subsequent months. Thus, we attempted to demonstrate that in
patients who were nonadherent to prescribed regimens, prescribers might
have responded to resulting poor control of blood glucose by prescribing
additional medication. This action may potentially provoke dangerous
hypoglycemia. Further, it fails to address the behavior of nonadherence to
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prescribed hypoglycemic therapy, which may ultimately result in diabetic
complications that could have been avoided .

A third study involved assessing adherence with drug therapy among patients
prescribed monotherapy with a sulfonylurea or metformin , and among patients
prescribed dual therapy with both agents. We hypothesized that patients
prescribed dual therapy would be less adherent that those prescribed
monotherapy, and that adherence to hypoglycemic drug regimens would be
less than optimal overall. This hypothesis was based upon the findings of
other researchers who have reported poor adherence with therapies for
chronic diseases (26-31 ). Adherence with prescribed drug therapy in diabetes
is an acknowledged problem, and many have reported adherence rates that
would seem to fail to be consistent with requirements for tight control of blood
glucose (32-34). Morris et al (35) specifically examined the difference in
adherence between patients receiving monotherapy with a sulfonylurea or
metformin as compared with patients rece iving dual therapy with both agents.
In a presentation at the American Diabetes Association 's 601h Annual Scientific
Session , Morris reported that a significant difference in adherence was
observed among those prescribed both a sulfonylurea and metformin , and that
a far less than optimal rate of adherence existed among those receiving
hypoglycemic monotherapy. In third study presented here, we assessed
adherence among regimen types, focusing on the likelihood of nonadherence
among patients receiving dual therapy.
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Appendix B Details of the Methods

Data source

Data for research were provided by Consumer Value Stores (CVS), Inc to the
department of Applied Pharmaceutical Sciences at the University of Rhode
Island . The data cons isted of a population of enrollees in a comprehensive
management program for diabetic patients sponsored by either of two area
health insurance providers . The initial data set included 288,174 medication
dispensings to 5056 patients between April 27, 1997 and May 16, 1999. The
data included the following 16 variables:

ID: Patient Identification number; a unique integer from 1 to 5056.

BDATE : Patient date of birth; in mmldd/yyyy format.

GENDER: Male or Female, included as 'M' or 'F'.

AGENCYNM: Describes the type of payment associated with the medication

dispensing . For a majority of patients, this variable was one of two health
plans participating in the diabetes management program. Other insurance
types used for prescription reimbursement and cash payments were described
by this va riable.
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AGENCYJD: Numeric descriptor for above

RX_NBR: Unique number assigned by the dispensing pharmacy for each

new prescription dispensed and associated refills .

FILL_NBR: Identifies the refill number

NOC: National Drug Code identifier; a unique identification number used for

identifying the product dispensed .

LABELNM : Name of the product dispensed , including strength and dosage

from.

QTY: The quantity of medication dispensed

DAYSSUPP: The days supply of medication dispensed

AWPPRICE: The average wholesale price of the quantity of product

dispensed on the date of dispensing .

POSTXNDT: The date on which the medication was dispensed to the patient

or his/her agent
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AVAILFIL: The number of refills remaining on the prescription

STORENO: The store number, a unique identifier for the pharmacy

dispensing the medication

DEA: A unique identification number assigned to providers and institutions
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Data cleaning and preparation

Data was provided in comma-delimited form . From this file, a SAS data set
was created using SAS for microcomputers versions 6.2 and 8.01 . SAS
procedures such as PROC FREQ and PROC UNIVARIATE were used to
screen for missing and spurious data. Five duplicate records were deleted .
The resulting data set described 288, 171 medication dispensings. Missing
values for the date of dispensing (POSTXNDT) were present for 5470 of these
observations (1.9%), and were considered to represent prescriptions held 'onfile ' in the computer system . Such observations were deleted, further reducing
the number of dispensings to 282,701.

A next step was to create a date set that included only dispensings for
hypoglycemic medications. The PROC FREQ procedure was used to identify
all medications dispensed . Using this output, text strings describing
hypoglycemic products were identified and incorporated into a SAS program
that deleted dispensings for drugs not used for blood glucose control. A total
of 671 patients did not receive a dispensing for a hypoglycemic medication
(13 .3%): these patients were eliminated from the sample. The resulting data
set included only patients that received dispensings for a hypoglycemic
medication (N
medications (n

=4385), and included only dispensings for hypoglycemic
=78,960).
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The variable LABLENM was used to create two new variables for describing
categories of hypoglycemic medication dispensed. The first such variable,
RXCODE , consisted of the first four letters of the chemical name of the
product dispensed plus the medication strength. For example, a label name of
'GLYBURIDE 5MG TABLET' was converted to 'glyb5'. Similarly, a dispensing
for Dia beta® brand of glyburide 5mg was also coded as 'glyb5'. The use of
the RXCODE variable facilitated categorization of dispensings by therapeutic
class. The RXCODE drug categorization system was also useful in that a
change in manufacturer of a product dispensed would not be categorized as a
change in type of medication dispensed. Table 2 presents the description for
variable LABLENM for all hypoglycemic drugs identified, and associated
created variable RXCODE. A second variable, STRENGTH, was created to
describe the strength of medication dispensed. An additional variable BRAND
described the type of sulfonylurea dispensed as either brand or generic.
Variables RXCODE, STRENGTH, and BRAND were created using if-then
statements for each of 48 different descriptions of oral drugs described by
variable LABELNM. All insulin products were coded as RXCODE 'ins' and
STRENGTH '99999'.

Data was transposed to create a data set containing one record per patient,
using the PROC TRANSPOSE procedure. The resulting data set included
4385 observations (subjects) and 772 variables.
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To provide a standard for comparison , we included only patients that received
dispensings of hypoglycemic medication for at least a 12-month period . This
was accomplished by comparing the date of the first dispensing of
hypoglycemic medication with the last date of dispensing. Patients with at
least 365 days between first and last were included in the sample. The
resulting data set included 2901 patients, representing 57.4% of the original
5056 subjects.

Categorization of age, insurance type, and number of dispensings

Using the variable BDATE , we created three age categories: under 50 , 50-64,
and greater than 65 years of age. These categories were established to
compare drug utilization by younger, middle-aged , and senior diabetics. Such
patients represented 35.54%, 43.40%, and 22.06% of the population
respectively. Jn an effort to focus on patients with type 2 disease, we removed
patients under 40 years of age from some analyses (age under 40: n

=386,

13.62% of total population).

For most patients (87 .18%), the insurance type associated with hypoglycemic
drug dispensings was one of two health plans. Of the remaining patients,
8.62% received dispensings that were reimbursed by one of over 50 other
types of health insurance provider. Cash payment for dispensings was the
sole insurance type associated with dispensings for 4.2% of subjects. In
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comparisons of the drug regimen utilized, four categories of insurance type
were identified: health plan A, health plan B, other insurance, and cash. For
other bivariate and multivariate analyses, the insurance type categories of
'other insurance' and 'cash ' were combined into a single category, since we
were primarily interested in assessing differences between the two main
health plans.

The total number of dispensings was a factor that included dispensings for any
type of medication. The original data of all pharmacy dispensings was used to
obtain values of this variable. To derive this variable, we first identified the
earliest date of dispensing of a hypoglycemic medication . Next, we
determined the number of dispensings for which the dispensing date was later
than but no more than four months (122 days) following the first dispensing of
a hypoglycemic medication . Univariate analysis of this variable was
performed to obtain quartiles of the frequency distribution . The lowest,
highest, and inner quartiles of frequency distribution were used to create the
following three categories: under 5 dispensings; 5-15 dispensings, and greater
than 15 dispensings.

Creation of drug regimen categories

The frequency of dispensing of hypoglycemic medications was assessed
using the PROC FREQ procedure. Regimen categories were defined based
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on dispensing frequencies and with a priori awareness of regimens of interest;
such as users of sulfonylurea only and users of sulfonylurea plus metformin.
To minimize misclassification resulting from changes in regimen during the 12month period, we based drug regimen classification on the first three months
of the 12-month period . Using the regimen categories presented in Figure 1,
98.3% of patients were classified as receiving one of nine types of
hypoglycemic drugs regimen , with 1.72% of patients classified as receiving an
'other regimen' . The variable REGVAR was created , representing regimen
categories 1-10. To assess changes in drug regi men during the 12-month
period, we also categorized patients based upon the last th ree months of the
12-month period, using the same regimen classification strategy. The ten
levels of variable EN DVAR represented the regimen category utilized during
the last three months of the 12-month period .

Identifying changes in reg imen category and dose

Changes in drug regimen utilized between the first and last three months of
the 12-month period were identified by comparing val ues for variables
REGVAR and ENDVAR. We also determined which regimens patients were
switching to, presenting both the frequency and percentage of change.

We also identified changes in the dose of medication utilized. Two aspects of
dispensings were assessed to determine if a change in dose had occurred .
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First, a change in the variable RXCODE that did not result in a change in
regimen category was considered to represent a change in medication dose.
For example, a dispensing of glyburide 5mg tabs (RXCODE 'glyb5') was
considered to represent a change in dose if previous dispensings were for
glyburide 2.5mg tabs (RXCODE 'glyb2.5'). Second, we assessed the dose
dispensed by comparing the number of doses per day. This was
accomplished by dividing the quantity of medication dispensed by the days
supply received. For example, a dispensing of 60 tablets for a supply of 30
days would be identified as a daily dose of 2. A difference in this value
between dispensings of the same medication was considered to indicate a
dose change. For analyses involving medication possession , patients were
eliminated if either the drug dispensed or the daily dose differed during the first
four months of the 12-month period .

Determining the medication possession ratio

The assessment of medication possession was based upon the first four
months of the 12-month period . We calculated the total days supply of
medication received for all dispensings preceding the last dispensing during
the four-month period ; and determined the total number of days between the
first and last dispensing. The medication possession ratio (MPR) was defined
as the total days supply of medication received compared with the total
number of days between the first and last dispensing. Patients were
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considered to be nonadherent if the MPR was less than 8:10, or less than 9:10
for some analyses. Patients who received only one dispensing during the
four-month period but who received medication in subsequent months were
classified as non-adherent.

Analyses

All analyses were performed using the variables described above, and using
SAS for microcomputers version 8.01 . The coding of variables and description
of variable types is presented in Table 3. A summary of all analyses
performed is presented in Tables 4a (univariate), 4b {bivariate), and 4c
(multivariate).

Programming details were obtained from the SAS Procedures Guide (1) and
the SAS Language and Procedures usage manual (2) . Fundamentals of SAS
coding were learned using SAS Programming by Example by Cody and Pass
(3). Interpretation of statistical procedures was aided by Hatcher and
Stepanski's A Step-by-Step Approach to Using the SAS System for Univariate
and Multivariate Statistics (4) and Allison 's Logistic Regression Using the SAS
System (5).
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Table 1. Drug Regimen Categories

Re imen
1
2
3
4
5
6
7
8
9
10

Insulin only
Insulin + Troglitazone
Insulin + non-troglitazone agent
Sulfonylurea mono-therapy
Sulfonylurea + metformin
Sulfonylurea + non-metformin
Troglitazone mono-therapy
Glimepramide mono-therapy
Metformin mono-therapy
Other regimen not classified
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Table 2. Variable LABELNM and Derived Variable RXCODE
RX CODE

LABELNM

glim1
glim2
glim4
chlo100
glyb1 .2
glyb2 .5
glyb5
chlo100
chlo250
glip10
glip5
gluc100
gluc500
gluc850
glip10
glip5
glipxl1
glipxl5
glyb1 .2
glyb2 .5
glyb5
glyb1.5
glyb1 .5
glyb6
glyb1.5
glyb3
glyb6
migl25
migl50
ins
ins
ins
ins
ins
ins
ins
ins
ins
ins
ins
ins
ins
ins
ins
glyb1 .2
glyb2.5
glyb5

AMARYL 1MG TABLET
AMARYL 2MG TABLET
AMARYL 4MG TABLET
CHLORPROPAMIDE 100MG TABLET
DIABETA 1.25MG TABLET
DIABETA 2.5MG TABLET
DIABETA 5MG TABLET
DIABINESE 100MG TABLET
DIABINESE 250MG TABLET
GLIPIZIDE 10MG TABLET
GLIPIZIDE 5MG TABLET
GLUCOPHAGE 1000MG TABLET
GLUCOPHAGE 500MG TABLET
GLUCOPHAGE 850MG TABLET
GLUCOTROL 10MG TABLET
GLUCOTROL 5MG TABLET
GLUCOTROL XL 10MG TABLET SA
GLUCOTROL XL 5MG TABLET SA
GL YBURIDE 1.25MG TABLET
GL YBURIDE 2.5MG TABLET
GL YBURIDE 5MG TABLET
GL YBURIDE MICRO 1.5MG TAB
GL YBURIDE MICRO 3MG TABLET
GLYBURIDE MICRO 6MG TABLET
GLYNAS E 1.5MG PRESTAB
GL YNASE 3MG PRESTAB
GLYNAS E 6MG PRESTAB
GLYSET 25MG TABLET
GL YSET 50MG TABLET
HUMALOG 100U/ML CARTRIDGE
HUMALOG 100U/ML PEN
HUMALOG 100U/ML VIAL
HUMULIN 50/50 VIAL
HUMULIN 70/30 CARTRIDGE
HUMULIN 70/30 PEN
HUMULIN 70/30 VIAL
HUMULIN L 100U/ML VIAL
HU MULIN N 100U/ML CARTRIDGE
HU MULIN N 100U/ML PEN
HUMULIN N 100U/ML VIAL
HUMULIN R 100U/ML CARTRIDGE
HUMULIN R 100U/ML VIAL
HUMULIN R 500U/ML VIAL
HUMULIN U 100U/ML VIAL
MICRONASE 1.25MG TABLET
MICRONASE 2.5MG TABLET
MICRONASE 5MG TABLET
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Table 2 (continued). Variable LABLENM and Derived Variable RXCODE
LABLENM
NOVOLIN 70/30 100U/ML VIAL
NOVOLIN 70/30 150U/1.5ML PREFL
NOVOLIN 70/30 U100 CARTRIDG
NOVOLIN L 100U/ML VIAL
NOVOLIN N 100U/ML CARTRIDGE
NOVOLIN N 100U/ML SYRINGE
NOVOLIN N 100U/ML VIAL
NOVOLIN R 100U/ML CARTRIDGE
NOVOLIN R 100U/ML SYRINGE
NOVOLIN R 100U/ML VIAL
NOVOPEN 1.5 INSULIN DEVICE
NOVOPEN 3 INSULIN DEVICE
ORINASE 500MG TABLET
PRANDIN 0.5MG TABLET
PRANDIN 1MG TABLET
PRANDIN 2MG TABLET
PRECOSE 100MG TABLET
PRECOSE 25MG TABLET
PRECOSE 50MG TABLET
REZULIN 200MG TABLET
REZULIN 300MG TABLET
REZULIN 400MG TABLET
TOLAZAMIDE 100MG TABLET
TOLAZAMIDE 250MG TABLET
TOLAZAMIDE 500MG TABLET
TOLBUTAMIDE 500MG TABLET
TOLINASE 100MG TABLET
TOLINASE 250MG TABLET

RXCODE

ins
ins
ins
ins
ins
ins
ins

ins
ins
ins
ins
ins
tolb500
pran0 .5
pran1
pran2
prec100
prec25
prec50
rezu200
rezu300
rezu400
tola100
tola250
tola500
tolb500
tola100
tola250
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Table 3. Coding of Variables Used in Analyses
Variable

Description (codified as)

Variable type

AGECAT

Under 50 (1); 50-64 (2); 65 or older (3)

categorical

AGECAT1

Under 40 (1); 40-49 (2); 50-64 (3); 65 or older
(4)

categorical

AGENCYNM

Insurer name (char)

ANYCHANG E

dichotomous

BDATE

Change in medication or dose or drug
dispensed during the 12-month period (1 );
else (0)
The average wholesale price of the
medication dispensed minus ten percent
(num)
Date of birth as SAS date (num)

BRAN D

If brand product dispensed (1 ); generic (0)

dichotomous

CAS H

Cash payment (1); else (0)

dichotomous
(dummy)

COST12

The 12 month cost of all hypoglycemic
medication dispensed; calculated as AW P 10% (num)
The days supply of medication dispensed
(num)

AWP10

DAYSSUP

character
string

number

continuous

number

integer

DE PRES

Received Rx for antidepressant (1); else (0)

DOSE

The quantity dispensed divided by the days
supply (num)

number

DOSECHANG E

Change in dose of drug dispensed during the
12-month period (1); else (0)

dichotomous

ENDVAR

Category of drug regimen utilized (1-10) ,
based on the last three months of
dispensings; see Figure1, manuscript 1.

discrete
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dichotomous

(

FIRSTDT

Date of the earliest dispensing
hypoglycemic medication (num)

GEN1

First generation sulfonylurea (1 ); else (0)

dichotomous

GENDER

Male (M) or female (F)

dichotomous

INSCAT

Insurance category: planA (1 ); planB (2);
other insurance (3); cash (4)

LASTDT

Date of the latest dispensing
hypoglycemic medication (num)

MALE

Male (1 ); else (0)

dichotomous
(dummy)

MEDCHANGE

Change in medication during the 12-month
period (1 ); else (0)

dichotomous

MPR

Medication Possession Ratio; calculated by
dividing quantity of medication dispensed by
number of days between dispensings (num)

Continuous

MPR80

If MPR < 0.80 then (1 ); else (0).

dichotomous

MPR90

If MPR < 0.90 then (1); else (0).

dichotomous

OTHERINS

Other insurance (1); else (0)

dichotomous
{dummy)

OTHINSCA

Other insurance or cash (1); else (0)

dichotomous
{dummy)

OVER11

Greater than 11 dispensings during first four
months (1 ); else (0)

dichotomous
(dummy)

OVER15

Over 15 dispensings during first four months
(1); else (0)

dichotomous
(dummy)

OVER4LESS16

Between 5 and 15 dispensings during first
four months (1 ); else (0)

dichotomous
(dummy)

OVER50UNDER6 Age between 50-64 yea rs (1 ); else (0)

5
OVER65

Age 65 years or older (1 ); else (0)
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of

of

a

a

SAS date

categorical
SAS date

dichotomous
{dummy)
dichotomous
(dummy)

PLANA

Plan A (1); else (0)

dichotomous
(dummy)

PLANS

Plan B (1); else (0)

dichotomous
(dummy)

POSTXN DT

Date of dispensing (n um)

QTY

The quantity of medication dispensed (n um)

integer

REGVAR

Category of drug regimen utilized (1-10),
based on the first three months of
dispensings; see Figure1 . manuscript 1.

discrete

RX CODE

Used to identify class and strength of
hypoglycemic medication dispensed (cha r)

character
string

STRENGTH

Strength of medication dispensed; 9999 for
insulin products (num)

number

TOTALRX

Total number of dispensings during first four
months (num)

continuous
(i nteger)

TROGLIT

Troglitazone dispensed (1 ); else (0)

dichotomous

TXTYPE

Dual therapy with both a sulfonylurea and
metformin (1) or monotherapy with either
agent (0)
Less than 5 dispensings during first four
months (1); else (0)

dichotomous

Age under 50 years (1); else (0)

dichotomous
(dummy)

UNDER5
UNDER50
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SAS date

dichotomous
(d ummy)

Table 4a. Summary of Univariate Analyses Performed

=
=
=

IV Independent Variable
DV Depe ndent Variable
MPR Medication Possession Ratio

Table#;
Po~ulation

Descri~tion

Procedure

(ma nuscri~t

All patients
receiving
dispensing
s of hypoglycemic
drugs

Frequency and percent of patients
for each age category

PROC
FREQ

Table 1 (1)

Frequency and percent of patients
for gender

PROC
FREQ

Table 1 (1)

Frequency and percent of patients
for each category of insurance type

PROC
FREQ

Table 1 (1)

Frequency and percent of patients
receiving insulin or oral
hypoglycemic agents

PROC
FREQ

Table 1 (2)

Frequency and percent of patients
for each age category

PROC
FREQ

Table 1 (2)

Frequency and percent of patients
for gender

PROC
FREQ

Table 1 (2)

Frequency and percent of patients
for each category of insurance type

PROC
FREQ

Table 1 (2)

Frequency and percent of patients
for each category of number of
dispensings

PROC
FREQ

Table 1 (2)

Frequency and percent of patients
receiving an anti-depressant
medication

PROC
FREQ

Table 1 (3)

Mean medication possession ratio
(M PR) < 8:10, < 9:10

PROC
FREQ

Table 2 (2)

Frequency and percent of patients
having a medication possession ratio
(MPR) < 8:10 or< 9:10

PROC
FREQ

Table 2 (2)

Patients
receiving
sulfonylure
a only
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#)

Patients
receiving
metformin
only

Patients
recei ving
both
sulfonylurea
and
metformin

Patients
receiving
sulfonylurea
only or metformin only

Frequency and percent of patients for each
age category

PROC
FREQ

Table 1
(2)

Frequency and percent of patients for
gender

PROC
FREQ

Table 1
(2)

Frequency and percent of patients for each
category of insurance type

PROC
FREQ

Table 1
(2)

Frequency and percent of patients for each
category of number of dispensings

PROC
FREQ

Table 1
(2)

Frequency and percent of patients receiving
an anti-depressant medication

PROC
FREQ

Table 1
(3)

Mean medication possession ratio (MPR) <
8:10, < 9:10

PROC
FREQ

Table 2
(2)

Frequency and percent of patients having a
medication possession ratio (M PR) < 8:10
or< 9:10

PROC
FREQ

Table 2
(2)

Frequency and percent of patients for each
age category

PROC
FREQ

Table 1
(3)

Frequency and percent of patients for
gender

PROC
FREQ

Table 1
(3)

Frequency and percent of patients for each
category of insurance type

PROC
FREQ

Table 1
(3)

Frequency and percent of patients for each
category of number of dispensings

PROC
FREQ

Table 1
(3)

Frequency and percent of patients receiving
an anti-depressant medication

PROC
FREQ

Table 1
(3)

Frequency and percent of patients havi ng a
medication possession ratio (MPR) < 8:10
or<9:10

PROC
FREQ

Table 2
(2)
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All patients
receiving
sulfonylurea
only or
metformin
only, or
receiving
both drugs

Frequency and percent of patients for each
age category

PROC
FREQ

Table 1
(3)

Frequency and percent of patients for
gender

PROC
FREQ

Table 1
(3)

Frequency and percent of patients for each
category of insurance type

PROC
FREQ

Table 1
(3)

Frequency and percent of patients for each
category of number of dispensings

PROC
FREQ

Table 1
(3)

Frequency and percent of patients receiving
an anti-depressant medication

PROC
FREQ

Table 1
(3)

Frequency and percent of patients having a
medication possession ratio (MPR) < 8:10
Or< 9:10

PROC
FREQ

Table 2
(2)

Frequency and percent of patients having a
medication possession ratio (MPR) >= 8:10
Or>= 9:10

PROC
FREQ

Table 2
(3)
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Table 4b. Summary of Bi variate Analyses Performed

Table#;
Po~ulation

Descri~tion

Procedure

(manuscri~t

All patients
receiving
dispensings
of hypoglycemic
drugs
(N =
29,001)

Drug regimen and Gender

ChiSquare

Table 4 (1)

Drug regimen and age

Ch iSquare
ChiSquare

Table 5a (1)

Above , if
patient>=
40 years of
age

Patients
receiving
sulfonylurea
only

Drug regimen and insurance type

Table 6 (1)

Cost of medications dispensed and
Age

ANOVA,
Tu key's
test

Table 9 (1)

Cost of medications dispensed and
Gender

Student's
I-test

Table 9 (1)

Cost of medications dispensed and
Insurance type

ANOVA,
Tukey's
test

Table 9 (1)

Drug regimen and Age

ChiSquare
ChiSquare

Table 5b (1)

Brand name su lfonylurea and age

ChiSquare

Table 7 (1)

Brand name sulfonylurea and gender

ChiSquare

Table 7 (1)

Brand name sulfonylurea and
insurance type

ChiSqua re

Table 7 (1)

Medication possession ratio(< 8:10)
and age

ChiSquare

Table 3 (2)

Medication possession ratio(< 8:10)
and gender

ChiSquare

Table 3 (2)

Troglitazone dispensings and Age
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Table 8 (1)

#)

Medication possession ratio{< 8:10)
and insurance type

ChiSquare

Table 3 (2)

Medication possession ratio (< 8:10)
and number of dispensings

ChiSquare

Table 3 (2)

Medication possession ratio {< 8:10)
and dual drug therapy

ChiSquare

Table3a (3)

Medication possession ratio{< 8:10)
and Rx for depression

ChiSquare

Table3a (3)

Medication possession ratio{< 9:10)
and age

ChiSquare

Table 3b (3)

Medication possession ratio(< 9:10)
and gender

ChiSquare

Table 3b (3)

Medication possession ratio(< 9:10)
and insurance type

ChiSquare

Table 3b (3)

Medication possession ratio(< 9:10)
and number of dispensings

ChiSquare

Table 3b (3)

Medication possession ratio (< 9:10)
and dual drug therapy

ChiSquare

Table 3b (3)

Medication possession ratio(< 9:10)
and Rx for depression

ChiSquare

Table 3b (3)

Change in dose and Age

Table 4a (2)

Change in dose and Number of
Dispensings

ChiSquare
ChiSquare
ChiSquare
ChiSquare

Change in dose and Medication
Possession Ratio

ChiSquare

Table 4a (2)

Change in drug and Age

ChiSquare
ChiSquare
ChiSquare

Table 4a (2)

Change in dose and Gender
Change in dose and Insurance Type

Change in drug and Gender
Change in drug and Insuran ce Type
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Table 4a (2)
Table 4a (2)
Table 4a (2)

Table 4a (2)
Table 4a (2)

Change in drug and Number of
Dispensings

ChiSquare

Table 4a (2)

Change in drug and Medication
Possession Ratio

ChiSquare

Table 4a (2)

Change in dose or drug and Age

Table 4a (2)

Change in dose or drug Insurance
Type

ChiSquare
ChiSquare
ChiSquare

Change in dose or drug and Number
of Dispensings

ChiSquare

Table 4a (2)

Change in dose or drug and
Medication Possession Ratio

ChiSquare

Table 4a (2)

Medication possession and DV Dose
change

PROC
LOGISTIC

Table 5a (2)

Age and DV Dose change

PROC
LOGISTIC

Table 5a (2)

Gender and DV Dose change

PROC
LOGISTIC

Table 5a (2)

Number of dispensings and DV Dose
change

PROC
LOGISTIC

Table 5a (2)

Insurance type and DV Dose change

PROC
LOGISTIC

Table 5a (2)

Medication possession and DV
Change in drug dispensed

PROC
LOGISTIC

Table 6a (2)

Age and DV Change in drug
dispensed

PROC
LOGISTIC

Table 6a (2)

Gender and DV Change in drug
dispensed

PROC
LOGISTIC

Table 6a (2)

Number of dispensings and DV
Change in drug dispensed (DV)

PROC
LOGISTIC

Table 6a (2)

Change in dose or drug Gender
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Table 4a (2)
Table 4a (2)

Patients
receiving
metformin
only

Insurance type and DV Change in
drug dispensed

PROC
LOGISTIC

Table 6a (2)

Medication possession ratio(< 8:10)
and age

ChiSquare

Table 3 (2)

Medication possession ratio(< 8:10)
and gender

ChiSquare

Table 3 (2)

Medication possession ratio(< 8:10)
and insurance type

ChiSquare

Table 3 (2)

Medication possession ratio(< 8:10)
and number of dispensings

ChiSquare

Table 3 (2)

Medication possession ratio(< 8:10)
and dual drug therapy

ChiSquare

Table3a (3)

Medication possession ratio (< 8:10)
and Rx for depression

ChiSquare

Table3a (3)

Medication possession ratio(< 9:10)
and age

ChiSquare

Table 3b (3)

Medication possession ratio{< 9:10)
and gender

ChiSquare

Table 3b (3)

Medication possession ratio{< 9:10)
and insurance type

ChiSquare

Table 3b (3)

Medication possession ratio{< 9:10)
and number of dispensings

ChiSquare

Table 3b (3)

Medication possession ratio(< 9:10)
and dual drug therapy

ChiSquare

Table 3b (3)

Medication possession ratio(< 9:10)
and Rx for depression

ChiSquare

Table 3b (3)

Change in dose and Age

ChiSquare
ChiSquare
ChiSquare
ChiSquare

Table 4b (2)

Change in dose and Gender
Change in dose and Insurance Type
Change in dose and Number of
Dispensings
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Table 4b (2)
Table 4b (2)
Table 4b (2)

Change in dose and Medication
Possession Ratio

ChiSquare

Table 4b (2)

Change in drug and Age

Table 4b (2)

Change in drug and Number of
Dispensings

ChiSquare
ChiSquare
ChiSquare
ChiSquare

Change in drug and Medication
Possession Ratio

ChiSquare

Table 4b (2)

Change in dose or drug and Age

Table 4b (2)

Change in dose or drug Insurance
Type

ChiSquare
ChiSquare
ChiSquare

Change in dose or drug and Number
of Dispensings

ChiSquare

Table 4b (2)

Change in dose or drug and
Medication Possession Ratio

ChiSquare

Table 4b (2)

Medication possession and DV Dose
change (DV**)

PROC
LOGISTIC

Table 5b (2)

Age and DV Dose change

PROC
LOGISTIC

Table 5b (2)

Gender and DV Dose change

PROC
LOGISTIC

Table 5b (2)

Number of dispensings and DV Dose
change

PROC
LOGISTIC

Table 5b (2)

Insurance type and DV Dose change

PROC
LOGISTIC

Table 5b (2)

Medication possession and DV
Change in drug dispensed

PROC
LOGISTIC

Table 6b (2)

Change in drug and Gender
Change in drug and Insurance Type

Change in dose or drug Gender
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Table 4b (2)
Table 4b (2)
Table 4b (2)

Table 4b (2)
Table 4b (2)

Age and DV Change in drug
dispensed

PROC
LOGISTIC

Table 6b (2)

Gender and DV Change in drug
dispensed

PROC
LOGISTIC

Table 6b (2)

Number of dispensings and DV
Change in drug dispensed

PROC
LOGISTIC

Table 6b (2)

Insurance type and DV Change in
drug dispensed

PROC
LOGISTIC

Table 6b (2)

Medication possession and DV
Change in drug dispensed

PROC
LOGISTIC

Table 6b (2)

Age and DV Change in drug
dispensed

PROC
LOGISTIC

Table 6b (2)

Gender and DV Change in drug
dispensed

PROC
LOGISTIC

Table 6b (2)

Number of dispensings and DV
Change in drug dispensed

PROC
LOGISTIC

Table 6b (2)

Insurance type and DV Change in
drug dispensed

PROC
LOGISTIC

Table 6b (2)
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I

Patients
receiving
both
sulfonylurea
and
metformin

Patients
receiving
sulfonylurea
only,
metformin
only, or
both drugs

Medication possession ratio(< 8:10) and
age
Medication possession ratio{< 8:10) and
gender

ChiSquare

Table 3 (2)

Table 3 (2)

Medication possession ratio{< 8:10) and
insurance type

ChiSquare
ChiSquare

Medication possession ratio {< 8:10) and
number of dispensings

ChiSquare

Table 3 (2)

Medication possession ratio{< 8:10) and
dual drug therapy

ChiSquare

Table3a (3)

Medication possession ratio(< 8:10) and
Rx for depression

ChiSquare

Table3a (3)

Medication possession ratio(< 9:10) and
age

ChiSquare

Table 3b
(3)

Medication possession ratio{< 9:10) and
gender

ChiSquare

Table 3b
(3)

Medication possession ratio{< 9:10) and
insurance type

ChiSquare

Table 3b
(3)

Medication possession ratio(< 9:10) and
number of dispensings

ChiSquare

Table 3b
(3)

Medication possession ratio{< 9:10) and
dual drug therapy

ChiSquare

Table 3b
(3)

Medication possession ratio(< 9:10) and
Rx for depression

ChiSquare

Table 3b
(3)

ChiSquare

Table 3 (2)

Medication possession ratio{< 8:10) and
gender

ChiSquare

Table 3 (2)

Medication possession ratio{< 8:10) and
insurance type

ChiSquare

Table 3 (2)

Medication possession ratio(< 8:10) and
age
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Table 3 (2)

Medication possession ratio(< 8:10) and
number of dispensings

ChiSquare

Table 3 (2)

Medication possession ratio(< 8:10) and
dual drug therapy

ChiSquare

Table3a (3)

Medication possession ratio(< 8:10) and
Rx for depression

ChiSquare

Table3a (3)

Medication possession ratio(< 9:10) and
age

ChiSquare

Table 3b
(3)

Medication possession ratio(< 9:10) and
gender

ChiSquare

Table 3b
(3)

Medication possession ratio(< 9:10) and
insurance type

ChiSquare

Table 3b
(3)

Medication possession ratio(< 9:10) and
number of dispensings

ChiSquare

Table 3b
(3)

Medication possession ratio(< 9:10) and
dual drug therapy

ChiSquare

Table 3b
(3)

Medication possession ratio(< 9:10) and
Rx for depression

ChiSquare

Table 3b
(3)

Mono versus dual therapy and DV
Medication possession ratio(< 8:10)

PROC
LOGIS
TIC
PROC
LOGIS
TIC
PROC
LOGIS
TIC

Table 4a
(3)

PROC
LOGIS
TIC
PROC
LOGIS
TIC

Table 4a
(3)

Age category and DV Medication
possession ratio(< 8:10)
Gender and DV Medication possession
ratio
(< 8:10)
Number of dispensings and DV
Medication possession ratio(< 8:10)
Insurance type and DV Medication
possession
Ratio(< 8:10)
Rx for anti-depressant and DV
Medication possession ratio(< 8:10)
Mono versus dual therapy and DV
Medication possession ratio(< 9:10)
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PROC
LOGIS
TIC
PROC
LOGIS
TIC

Table 4a
(3)
Table 4a
(3)

Table 4a
(3)

Table 4a
(3)
Table 4b
(3)

Age category and DV Medication
possession ratio (< 9: 10)
Gender and DV Medication possession
ratio
(<9:10)
Number of dispensings and DV
Medication possession ratio(< 9:10)
Insurance type and DV Medication
possession
Ratio(< 9:10)
Rx for anti-depressant and DV
Medication possession ratio(< 9:10)
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PROC
LOGIS
TIC
PROC
LOGIS
TIC

Table 4b
(3)
Table 4b
(3)

PROC
LOGIS
TIC
PROC
LOGIS
TIC

Table 4b
(3)

PROC
LOGIS
TIC

Table 4b
(3)

Table 4b
(3)

Table 4c. Summary of Multivariate Analyses Performed
Table#;
(manuscri12t #)

Po12ulation

Descri12tion

Procedure

Patients
receiving
sulfonylurea
only

Assessment of Colinearity between
independent variables : DV = Dose
change

PROC
REG /
COLLIN

n/a

Assessment of Colinearity between
independent variables: DV = Drug
change

PROC
REG /
COLLIN

n/a

Assessment of Colinearity between
independent variables : DV = Dose or
Drug change

PROC
REG /
COLLIN

n/a

Likelihood ratio test for interactions
between independent variables (21og statistic):
DV = Dose change

PROC
LOGISTIC

Table 7 (2)

Likelihood ratio test for interactions
between independent variables (21og statistic):
DV = Drug change

PROC
LOGISTIC

Table 7 (2)

Likelihood ratio test for interactions
between independent variables (21og statistic):
DV = Dose or Drug change

PROC
LOGISTIC

Table 7 (2)

All independent variables and DV
Dose change

PROC
LOGISTIC

Table Ba (2)

lvs MPR and AGE category and DV
Dose change

PROC
LOGISTIC

Table Ba (2)

All independent variables and DV
Drug change

PROC
LOGISTIC

Table Bb (2)

IV AGE category and DV Drug
change

PROC
LOGISTIC

Table Bb (2)
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All independent variables and DV
Drug or Dose change

PROC
LOGISTIC

Table Be (2)

IV AGE category and DV Drug or
Dose change

PROC
LOGISTIC

Table Be (2)
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Patients
receiving
metformin
only

Patients
receiving
sulfonylurea
only or
metformin
only

Assessment of Colinearity between
independent variables : DV =Dose change

PROC
REG /
COLLIN

n/a

Assessment of Colinearity between
independent variables: DV = Drug change

PROC
REG /
COLLIN

n/a

Assessment of Colinearity between
independent variables: DV = Dose or Drug
change

PROC
REG /
COLLIN

n/a

Likelihood ratio test for interactions
between independent variables (-21og
statistic):
DV =Dose change
Likelihood ratio test for interactions
between independent variables (-21og
statistic):
DV = Drug change
Likelihood ratio test for interactions
between independent variables (-21og
statistic):
DV = Dose or Drug change

PROC
LOGISTIC

Table 7
(2)

PROC
LOGISTIC

Table 7
(2)

PROC
LOGISTIC

Table 7
(2)

Assessment of Colinearity between
independent variables : DV = Dose change

PROC
REG /
COLLIN

n/a

Assessment of Colinearity between
independent variables: DV = Drug change

PROC
REG /
COLLIN

n/a

Assessment of Colinearity between
independent variables : DV = Dose or Drug
change

PROC
REG /
COLLIN

n/a

Likelihood ratio test for interactions
between independent variables (-21og
statistic):
DV =Dose change

PROC
LOGISTIC

Table 7
(2)

Likelihood ratio test for interactions
between independent variables (-21og
statistic):
DV =Drug change

PROC
LOGISTIC

Table 7
(2)
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All patients
receiving
sulfonylurea,
metformin,
or both

Likelihood ratio test for interactions
between independent variables (-21og
statistic):
DV = Dose or Drug change

PROC
LOGISTIC

Table 7
(2)

All independent variables and DV Dose
change

PROC
LOGISTIC

Table 9a
(2)

All independent variables and DV Drug
change

PROC
LOGISTIC

Table 9b
(2)

All independent variables and DV Drug or
Dose change

PROC
LOGISTIC

Table 9c
(2)

All independent variables and DV Dose
change

PROC
LOGISTIC

Table
10a (2)

lvs MPR and AGE category and DV Dose
change

PROC
LOGISTIC

Table
10a (2)

All independent variables and DV Drug
change

PROC
LOGISTIC

Table
10b (2)

IV AGE category and DV Drug change

PROC
LOGISTIC

Table
10b (2)

All independent variables and DV Drug or
Dose change

PROC
LOGISTIC

Table
10c (2)

lvs MPR and AGE category and DV Drug
or Dose change

PROC
LOGISTIC

Table
10c (2)

Likelihood ratio test for interactions
between independent variables (-21og
statistic):
DV = MPR < 8:10
Likelihood ratio test for interactions
between independent variables (-21og
statistic) :
DV = MPR < 9:10
All independent variables and DV MPR <
8:10

PROC
REG /
COLLIN

Table 5
(3)

PROC
REG /
COLLIN

Table 5
(3)

PROC
LOGISTIC

Table 6a
(3)

All independent variables and DV MPR <
9:10

PROC
LOGISTIC

Table 6a
(3)
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lvs Mono versus dual therapy, Age
category, and Number of dispensings and
DV MPR < 8:10
lvs Mono versus dual therapy, Age
category, and Number of dispensings and
DV MPR < 9:10
lvs Mono versus dual therapy and Age
category and DV MPR < 8:10
lvs Mono versus dual therapy and Age
category DV MPR < 9:10

(

(
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PROC
LOGISTIC

Table 7a
(3)

PROC
LOGISTIC

Table 7b
(3)

PROC
LOGISTIC

Table 8a
(3)

PROC
LOGISTIC

Table 8b
(3)
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Appendix C.

Overview of Major Findings

The objective of the analyses described in manuscript 1 was to assess
hypoglycemic drug utilization; and specifically, to identify which hypoglycemic
agents were most frequently utilized and what differences in utilization and
direct costs may exist between age categories, genders, or insurance types.

Sulfonylureas were the most frequently prescribed class of hypoglycemic
medication . Greater than half of all patients (56.8%) and greater than threequarters of patients receiving oral therapy (75.7%) received a dispensing for a
sulfonylurea. Metformin was the next most frequently prescribed oral agent:
20.9% of all patients and 27.6% of patients receiving oral therapy received at
least one dispensing for metformin. Troglitazone was the third most frequently
utilized oral medication . During the 12-month period, 16.04% of all patients
received a dispensing for troglitazone. The use of this agent was most
frequent among younger diabetics: 20.3% of patients age 40 - 49 years
received a dispensing for troglitazone; only 10.2% of seniors received a
dispensing for this agent. Of the other newer hypoglycemic medications,
glimepramide, repaglinide , and acarbose were each dispensed to less than
5% of all patients.

During the 12-month period, patients frequently experienced a change in
hypoglycemic medication(s) dispensed. The most frequently observed change
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in drug regimen was for patients dispensed sulfonylurea only. The percentage
of patients categorized as receiving only a sulfonylurea decreased by 8.76% ,
the largest percent change for any drug regimen category. Changes in drug
regimen utilized were also frequent. Of patients categorized as receiving only
a sulfonylurea during the first 90 days of the 12-month period, 74% remained
using the same regimen during the last 90 days of the 12-month period . For
patients initially categorized as receiving both a sulfonylurea and metformin,
70% were similarly classified based upon dispensings during the last there
months. Thus, 26% and 30% of patients receiving sulfonylurea or sulfonylurea
plus metformin respectively changed regimen during the 12-month period .
Similar magnitude changes were observed for the other less frequently utilized
regimens, and ranged from a low of 18% for patients receiving insulin only to a
high of 70% among patients receiving insulin plus an oral agent other than
troglitazone. Based on these results , it was concluded that the diabetic
patients in this population frequently changed medication regimen, possibly as
a result of worsening glucose control, inconsistent refill patterns
(nonadherence), or desire to utilize new therapies.

Patients 65 years of age or older were less frequently dispensed troglitazone
or metformin as monotherapy, and more frequently received dispensings for
sulfonylureas. The less frequent use of troglitazone and metformin in older
patients may reflect an increased prevalence of contraindicating comorbidities. Increased duration of disease may be a potential explanation for
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the greater utilization of sulfonylureas in older patients. Such patients may
have been more likely to have initiated treatment in earlier years, when
sulfonylureas were the primary oral therapeutic option.

Differences in the 12-month cost of hypoglycemic medication utilized reflect
the differing patterns of drug use among age groups. Drug utilization costs
were lowest among older patients, who more frequently received dispensings
for lesser-cost sulfonylurea products. The total 12-month cost of medication
dispensed was not significantly different among patients under 50 years of age
and between 50 and 64 years of age.

The analyses described in manuscript 2 provided insight into the relationship
between adherence to therapy and changes in the drug regimen . It was
hypothesized poor glucose control would result from failure to possess a
sufficient quantity of medication necessary to be adherent. The proxy for poor
glucose control used in these analyses was a change in dose of hypoglycemic
medication dispensed or a change in the class of hypoglycemic drug
dispensed .

A change in dose of sulfonylurea or metformin was more than twice as
frequently observed than a change in type of hypoglycemic medication
dispensed for both users of sulfonylureas (change in dose: 58.53%, change in
drug 26.78%) and metformin (change in dose: 48.19%, change in drug
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18.07%). Among all patients dispensed either a sulfonylurea or metformin
only, 57% received medication at different dosages during the 12-month
period; 58.5% of patients receiving a su lfonylurea and 48.2% of patients
receiving metformin did not receive the same dose of medication throughout
the 12-month period.

In both bivariate and multivariate analyses of patients receiving dispensings
for sulfonylurea only, possession of medication for less than 8 of 10 days was
associated with an increased likelihood of a change in dose of medication
dispensed in subsequent months . A similar effect was observed among
patients in the combined sample of patients receiving a sulfonylurea or
metformin . Based upon the results of multivariate analyses, such patients
were 36% more likely to receive a dispensing for a different strength of drug
(OR 1.36, 95% Cl 1.02 - 1.83). A statistically significant association between
possession of metformin and change in dose dispensed was not observed,
possibly due to a lack of power to detect such an effect based on the lesser
number of such patients.

Among users of sulfonylureas, medication possession was associated with the
combined outcome of change in medication dose or change in type of
hypoglycemic medication dispensed. This association was also observed in
analyses based upon the combined sample of patients receiving dispensings
for sulfonylurea or metformin only. Such an association was not observed
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among patients receiving dispensings for metformin only. Additionally,
medication possession was not found to be associated with the sole outcome
of change of type of hypoglycemic medication dispensed for the sulfonylurea
only, metformin only, and combined samples.

Age was associated with medication possession. Patients under 50 years of
age were most frequently categorized as not possessing a quantity of
medication sufficient to cover eight of ten days in the assessment period . Th is
difference was only statistically significant for users of sulfonylurea
monotherapy. This sample included nearly six times as many patients as the
metformin sample (sulfonylurea: n

=967; metformin: n =166).

Age was also

found to be significant in multivariate analyses assessing the association
between medication possession and change in regimen utilized or dose
dispensed . As compared with younger patients, sulfonylurea users 65 years
of age or older were 43% less likely to receive a different dose of
hypoglycemic medication during the 12-month period (OR 0.57, 95% Cl 0.40 0.81 ). Such patients were also 48.5% less likely to receive a medication other
than a sulfonylurea during the 12 months (OR 0.52 , 95% Cl 0.34 - 0.78).
These relationships were not found to be significant for analyses based upon
the smaller sample of patients who received dispensings for metformin only.

Among patients dispensed either sulfonylureas or metformin , those dispensed
a greater number of prescriptions for any health condition were less frequently
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categorized as failing to possess medication for less than 80% of days. The
outcomes of change in dose or change in class of medication dispensed were
not found to be significantly influenced by differences in the medication
possession ratio.

The aims of the analyses described in manuscript 3 were to assess adherence
with hypoglycemic medication via the medication possession ratio and to
compare medication possession among patients dispensed either
monotherapy with sulfonylurea or metformin with patients receiving dual
therapy with both medications. Additionally, we examined the association
between medication possession and age, gender, insurance plan, the total
number of dispensings, and the dispensing of a medication typically used to
treat depression.

Based upon medication possession, adherence to any hypoglycemic drug
regimen was frequently sub-optimal. Greater than one in four of all patients
studied (28.8%) did not receive a quantity of medication sufficient to cover 8 of
10 days in th e period. Only 59.5% of all patients possessed medication at a
ratio equal to or exceeding 9: 10. Medication possession was highest among
patients who received dispensings for sulfonylureas only (MPR >= 8:10:
77.2%, MPR >= 9:10: 66.8%). Patients receiving dispensings for metformin
only were less adherent, with 71.1 % and 56.6% of patients possessing
medication for at least eight of ten or nine of ten days in the assessment
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period , respectively. The least adherent sub-population was patients receiving
dispensings for both metformin and sulfonylureas . Less than half of such
patients possessed medication for at least nine of ten days (43 .1%), while
56.9% of patients received at least enough medication to cover eight of ten
days.

In both bivariate and multivariate logistic models, dual therapy with a
sulfonylurea and metformin was associated with an increased likelihood of
failure to possess medication for at least eight of ten and nine of ten days. In
bivariate logistic analyses, patients were nearly 2.5 times more likely to be
classified as nonadherent if they received dispensings for both drugs (MPR <
8: 10: OR 2.44, 95% Cl 1.92 - 3.1 O; MPR < 9:10: OR 2.49, 95% Cl 1.97 3.14 ). Multivariate analyses controlling for the influence of age and the total
number of dispensings were also conducted . Based upon these analyses,
and as compared with a one drug regimen, the use of dual therapy was
associated with a greater than three-fold increase in the likelihood of being
classified as nonadherent for both the 8: 10 and 9: 10 MPR thresholds (MPR <
8: 10: OR 3.14, 95% Cl 2.42 - 4.08; MPR < 9:10: OR 3.20, 95% Cl 2.49 4.118).

Of the five potential confounding variables examined , only age and the total
number of dispensings were significant influences on medication possession.
Based upon bivariate logistic regression analyses, patents 65 years of age or
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older were 52.1 % less likely to be classified as nonadherent as compared with
patients of younger age, using an MPR threshold of less than 8:10 (OR 0.48,
95% Cl 0.35 - 0.65). Seniors were 42.4 % less likely to be classified as
nonadherent based upon the MPR threshold of less than 9:10 (OR 0.58, 95%
Cl 0.44 - 0.76). Patients receiving 12 or more dispensings for any type of
medication were 44.6% less likely to be classified as nonadherent based upon
the 8:10 MPR threshold (OR 0.56, 95% Cl 0.35 - 0.65), and 42.3% less likely
based upon the 9:10 MPR threshold (OR 0.57, 95% Cl 0.47 - 0.70). Three
other potential confounding variables were examined: gender, insurance type
and receiving a dispensing for an antidepressant. None of these variables
were found to be a significant influence on medication possession.

In sum, the hypoglycemic drug utilization patterns of diabetic patients and
various sub-populations can be characterized as frequently changing, and
differing substantially between age categories. Older patients in this
population more frequently received dispensings for sulfonylureas only, less
frequently received dispensings for troglitazone or metformin as monotherapy,
and more likely to refill prescriptions when due. Additionally, the 12-month
total cost of all hypoglycemic medication dispensed was lowest among
patients 65 years of age and older. Gender and insurance type were not
found to be significantly associated with medication possession, or with
change in medication dose or type of medication dispensed. Medication
possession was found to be associated with an increase in the likelihood of
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receiving a dispensing for a different strength of hypoglycemic medication
among sulfonylurea users, and among a combined sample of patients
receiving dispensings for with sulfonylurea or metformin only. Medication
possession was often sub-optimal for what would be deemed sufficient for
achieving tight glucose control. Patients were found to be least likely to
possess medication when both a sulfonylurea and metformin were used as
dual therapy, as compared with patients receiving either agent as
monotherapy.
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